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Abstract
Dementia causes an increasing social and economic burden worldwide, demand-
ing action regarding its diagnosis, treatment and everyday management. Recent
years have seen many advances in neurodegeneration research, but the search
for new truly disease modifying therapies for Alzheimer’s disease (AD) and fron-
totemporal dementia (FTD) has so far not been successful. This is mainly due to
a lack of understanding of the precise intracellular events that lead up to neuronal
dysfunction in early and in late stages of the disease.
This thesis describes the approaches taken to extend the current knowledge
about the intracellular effects of neuronal amyloid-β and the signalling pathways
causing neuronal death or disturbed synaptic function in dementia. Endophilin-1
(Ep-1), amyloid-binding alcohol dehydrogenase (ABAD), peroxiredoxin-2 (Prx-2)
and the EF-hand domain family, member D2 (EFHD2) have been found to be ele-
vated in the human brain with dementia and in mouse models for frontotemporal
lobar degeneration (FTLD) or AD. The expression of these proteins as well as the
expression of c-Jun N-terminal kinase (JNK), c-Jun and APP were analysed by
western blotting and real-time PCR in human brains affected by AD or FTLD as
well as in mouse models for AD. This provided a new insight into the regulation
of these proteins in relation to each other in the aging brain and uncovered a new
potential link between elevated levels of EFHD2, Prx-2 and APP in FTLD.
By studying the effects of the overexpression of Ep-1 in neurons, this research
has led to a better understanding of its role in JNK-activation. It furthermore
verified a protective role for Prx-2 against neurotoxicity and pointed towards a
new function for Prx-2 in the regulation of JNK-signalling. The analysis of the
i
effect of increased levels of EFhD2 uncovered for the first time its involvement in
the PI3K-signalling cascade in neuronal cells.
The current work has therefore contributed to the knowledge about the cel-
lular processes that are affected by Ep-1, Prx-2 and EFhD2 in different types of
dementia and will greatly benefit future research into their actions in the neuronal
network.
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CHAPTER 1. INTRODUCTION
1.1 Alzheimer’s disease and dementia
Dementia is the widespread impairment of higher cognitive functions beyond the
decline that would normally be expected during aging. It predominantly affects
elderly people over the age of 65 but can also occur in the younger population,
where it is referred to as early-onset or presenile dementia. Apart from memory
loss and partly because of it, dementia also includes symptoms such as confusion
and disorientation, mood changes and difficulties with communication and prob-
lem solving. The continuing decline of these brain functions in progressive types
of dementia eventually leads to the patients’ complete social dependence.
Alzheimer’s disease (AD) is the most common cause of dementia, underly-
ing about 60% of all cases, followed by vascular disease (30%), dementia with
Lewy bodies and frontotemporal dementia, which is the most prevalent form in
early-onset dementia (Luengo-Fernandez, 2010). AD is named after the German
neuropathologist Alois Alzheimer, who first presented its pathology in connec-
tion with early-onset dementia at a conference in 1906 (Alzheimer, 1906) and
then published the results in 1907 (Alzheimer, 1907). Despite the long time since
its discovery, the mechanism underlying this complex and multi-faceted disease
is still obscure and without a cure at hand, available treatments for AD focus on
the management of the symptoms of cognitive loss or emotional and behavioural
challenges.
It is estimated that around 35.6 million people, close to 0.5% of the population,
are suffering from dementia worldwide, causing an immense social and economic
burden, which amounted to $604 billion in 2010 (Abbott, 2011). A report on
dementia in the UK in the same year found that that about 820,000 people
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suffered from dementia, costing £23 billion per year, which is more than the costs
caused by cancer and heart disease combined (Luengo-Fernandez, 2010). These
figures, together with the social impact of this debilitating condition, illustrate
the importance of finding ways to diagnose and treat dementia and especially
Alzheimer’s disease.
1.1.1 Symptoms and diagnosis of Alzheimer’s disease
Patients suffering from Alzheimer’s disease typically present with some or all signs
of dementia and in the case of AD, this state is often preceded by a phase of mild
cognitive impairment (MCI) with less pronounced symptoms. Guidelines for the
clinical diagnosis of MCI and AD are provided by the National Institute of Neu-
rological and Communicative Disorders and Stroke and the Alzheimers Disease
and Related Disorders Association (NINCDS/ADRDA). Cognitive impairment is
usually assessed on the basis of the patient’s history and by mental status ex-
amination or more detailed neuropsychological testing. MCI is defined if at least
two of the following cognitive domains are impaired: episodic memory (acqui-
sition and recollection of new information), reasoning and handling of complex
tasks (understanding of safety risks, managing finances, planning), visiospatial
abilities (recognition of faces, finding or orienting objects), language functions
(speech, spelling and writing) and personality traits (McKhann et al., 2011). If
the symptoms appear gradually and are clearly worsening, a diagnosis of prob-
able AD is achieved and the patient’s status can be further defined as either an
amnestic (mainly involvement of episodic memory together with other deficits)
or a non-amnestic type (mainly involving either language, visiospatial abilities or
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executive functions together with other deficits) (McKhann et al., 2011).
In addition to these neuropsychological criteria, biomarkers are sometimes
used to corroborate the initial diagnosis of probable AD. Accepted biomarkers
include the detection of significant amyloid deposition in the brain by positron
emission tomography (PET) using Pittsburgh compound B (PiB) (see Figure 1.1,
top), which is accompanied by a decrease in soluble 42 amino acid long amyloid
peptide (Aβ42) detectable in the cerebrospinal fluid (CSF). In addition, the detec-
tion of markers for neurodegeneration can be used, which include elevated levels
of total and phosphorylated tau protein in the CSF, reduced glucose uptake by
the brain tissue measured by fluorodeoxyglucose positron emission tomography
(FDG-PET) (see Figure 1.1, bottom) as well as atrophy of the brain in the tem-
poral lobe and medial parietal cortex, which can be seen by magnetic resonance
imaging (MRI) (McKhann et al., 2011).
Figure 1.1: Diagnosis of AD by FDG-PET and detection of PiB. PET images from
a 67-year old healthy individual (left) and a 79-year old AD patient (right). Top:
Pittsburgh compound B (PiB) retention shown by yellow and red colours is high in the
frontal and temporal lobes of the AD patient. Bottom: 18F-FDG-labelling indicating a
marked reduction of glucose metabolism in the AD brain. Reproduced with permission
from Elsevier Ltd (Nordberg, 2004)
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Despite these clinical and biochemical tests, the definitive diagnosis of AD can
only be made post mortem by histological examination of the brain tissue. As
mentioned above, brains from Alzheimer patients typically show brain atrophy
caused by loss of neurons and synapses, which affects the cortex (temporal and
parietal lobes) as well as subcortical structures such as the hippocampus and
entorhinal cortex, the amygdala and the basal forebrain at different stages of
the disease (Zakzanis et al., 2003) (see Figure 1.3). It is in these brain regions
where the histological hallmarks of AD, senile plaques and neurofibrillary tangles
(NFTs), can be detected and are used to confirm the diagnosis. Senile plaques
(Figure 1.2a) are extracellular depositions in the brain parenchyma which mainly
contain the amyloid-β (Aβ) peptide, derived from the amyloid precursor protein
(APP) by enzymatic cleavage (see section 1.2.1). Their morphology is variable
and can be focal, diffuse or stellate in appearance after immunohistochemical
staining of the amyloid peptide. Focal deposits are also readily detected by
amyloid staining techniques using congo-red or thioflavin S or T (Duyckaerts
et al., 2009), which exploit the tendency of these aromatic dyes to bind to beta-
sheet rich proteinaceous material.
In contrast, neurofibrillary tangles (Figure 1.2b) are intracellular accumula-
tions of the hyperphosphorylated microtubule binding protein tau in axons and
dendrites of neurons (Kosik et al., 1986). Accordingly, the neurofibrillary pathol-
ogy typically progresses along anatomical tracts within the brain and its extent
corresponds to the stage of disease and atrophy of the brain (Duyckaerts et al.,
2009). Tau pathology however, unlike amyloid pathology, is not genetically linked
to AD (Crawford et al., 1999) and is not specific for AD as it can also be ob-
served in other neurodegenerative diseases such as progressive supranuclear palsy
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Figure 1.2: Histological hallmarks of AD. (a) A senile plaque visualised after staining
with anti-Aβ antibody with a focal deposit (arrowhead) surrounded by a halo and
corona (arrow) of lighter staining. (b) Neuritic crown of the plaque stained with AT8
anti-phosphorylated tau antibody. Tau-labelled tangle bearing processes (arrowhead),
surrounding the plaque core (arrow). Scale bar = 10 µm. Reproduced with permission
from Springer (Duyckaerts et al., 2009).
Figure 1.3: Staging of AD according to Braak et al. (Braak H, 1993). There are
3 stages distinguished from the analysis of the presence of amyloid in various brain
regions. Reproduced with permission from Elsevier (Nordberg, 2004).
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(PSP), corticobasal degeneration, Pick’s disease and frontotemporal dementia
with Parkinsonism linked to chromosome 17 (FTDP-17) (Goetz, 2001; LaFerla
and Oddo, 2005). Some researchers therefore regard the formation of neurofibril-
lary tangles as an event downstream of amyloid pathology in the development of
AD.
1.1.2 Causes and risk factors
Alzheimer’s disease results from the dysfunction and death of neurons but un-
derlying triggers for these events are still obscure. A subset of less than 1%
of patients are diagnosed with a genetically linked form referred to as familial
AD (FAD) and often suffer from dementia at a younger age (<65 years). These
patients have dominant mutations in the genes encoding the amyloid precursor
protein (APP) on chromosome 21 (Goate, 1991; Tanzi et al., 1988a), presenilin-1
(PSEN1) on chromosome 14 (Sherrington et al., 1995) or presenilin-2 (PSEN2)
on chromosome 1 (Rogaev et al., 1995) (a comprehensive database of these muta-
tions can be found at http://www.molgen.ua.ac.be/ADMutations), which mostly
lead to an increased amount of Aβ peptide being produced and it is thought that
processes affecting APP and Aβ also increase the risk for sporadic AD, as defined
in the amyloid hypothesis (Hardy and Selkoe, 2002). Another group of patients
who usually develop AD comparably early in life (between the age of 35 and
45) are patients with Down syndrome, who have a triplication of chromosome
21 (Lott and Head, 2005). However, the majority of cases are counted among
the sporadic late-onset form of AD, which is currently thought to be caused by a
complex set of genetic predisposition together with environmental and life-style
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factors (Lambert and Amouyel, 2011). Accordingly, a large number of studies
have established a link between medical conditions like head injury, hypertension,
stroke, obesity, diabetes and hypercholesterinemia and an increased risk of AD
(reviewed in Mayeux (2003); Hoelscher (2011)), however, the exact mechanisms
in AD are still elusive. For both FAD and sporadic AD, the strongest non-genetic
risk factor is age, which is signified by its incidence increasing dramatically after
the age of 65 (Hebert et al., 1995).
Genetic risk factors for the development of late-onset AD have also been iden-
tified. The strongest and best characterised one is a variant of the gene coding for
apolipoprotein E, APOE 4, which has been found to be 2.5 times more abundant
in late-onset AD patients than in the normal population (Saunders et al., 1993).
The gene product ApoE is a protein associated with lipoprotein particles in the
blood such as chylomicron remnants and very low, intermediate and low density
lipoproteins (VLDL/IDL/LDL). It targets these particles to special sites within
the body, especially in the brain and is essential for the delivery of triglycerides,
cholesterol and lipid soluble molecules to these locations. The ApoE 4 variant
however is less efficient at this compared to the more common ApoE 3 version
and therefore interferes with cerebral glucose metabolism, cholesterol synthesis,
signal transduction and APP processing in the brain (Lane and Farlow, 2005).
Single nucleotide polymorphisms (SNPs) of the SORL1 gene, which cause re-
duced expression of the SORL1 gene product in neurons have also been linked
to sporadic AD (Rogaeva et al., 2007). This gene encodes the membrane pro-
tein sortilin-1, which is involved in the sorting of other membrane proteins to
endocytic recycling vesicles and had previously been linked to the regulation of
APP processing (Andersen et al., 2005). Furthermore, reduced expression levels
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of sortilin-1 have been found in affected brain regions of AD patients (Zhao et al.,
2007) and have been linked to the development of AD pathology in mouse models
for the disease (Dodson et al., 2008). Genome wide association studies (GWAS)
have recently identified more genetic risk factors. SNPs in the genes encoding
clusterin (also known as ApoJ), Phosphatidylinositol binding clathrin assembly
protein (PICALM) (Harold et al., 2009) and complement receptor 1 (CR1) (Lam-
bert et al., 2009) have been associated with a small but significantly increased risk
of developing AD. Each of these proteins has been reported to play a role in the
transport and clearance of amyloid-β in the brain; clusterin by acting similarly
to ApoE and assisting clearance through the blood–brain barrier; CR-1, a com-
plement cell surface receptor, by mediating uptake of amyloid-β by immune cells;
and PICALM through its function in endocytosis, which could influence Aβ pro-
duction or its clearance through the endothelium of blood vessels (Lambert and
Amouyel, 2011; Olgiati, 2011). Other genes that have been linked to the incidence
of late-onset AD mostly affect proteins involved in cellular metabolism and the
production of free radicals. Such genes encode e.g. the transporter of the outer
mitochondria membrane (TOM40) (Bekris et al., 2009), nitric oxide synthase 3
(NOS3) (Dahiyat et al., 1999) and the insulin degrading enzyme (IDE) (Bjork
et al., 2007). Mitochondrial import processes involving the TOM40 protein are of
crucial importance for their function in cellular metabolism and are therefore also
central to neuronal function as described in sections 1.4.1 and 1.4.2.2. Further-
more, variations in the TOM40 gene might also be relevant for the intracellular
amyloid-pathology observed in AD as outlined in Section 1.4.2.2. IDE is an intra-
and extracellular metalloprotease belonging to the pitrilysin family of peptidases,
which is able to degrade Aβ (Falkevall et al., 2006). Inside cells, IDE is located in
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the cytosol and mitochondria, where it has been found to be responsible for the
degradation of cleaved mitochondrial targeting sequences (Leissring et al., 2004).
In addition to the genetic variations observed in AD patients (Bjork et al., 2007),
another study investigating late-onset AD cases linked to chromosome 10 (har-
bouring the IDE gene) found reduced systemic activity of IDE in these cases
compared to controls while its protein expression levels were not affected (Kim
et al., 2007), indicating that genuine malfunction of IDE might contribute to an
icreased risk for developing AD. Its relevance for AD pathology has been furhter
supported by the finding that IDE and Aβ can interact in vitro in a way that
results in a very stable complex resistant to denaturing conditions and such com-
plexes could also be extracted from rat and human AD-affected brains (Llovera
et al., 2008), suggesting a failure of Aβ-degradation in these cases. Of interest,
S-nitrosylation of essential cysteine residues has been reported to compromise its
enzyme activity (Cordes et al., 2009). This sort of post-translational modifica-
tion, described as nitrosative stress when it occurs in excess, has emerged as an
important factor in neurodegenerative processes in AD (Uehara et al., 2006; Cho
et al., 2009) and therefore variations in the gene encoding nitric oxide synthase
might play a role in the increased levels of nitrosative stress observed (Dahiyat
et al., 1999). Additionally, IDE protein levels are positively regulated by the PI3-
kinase/Akt signalling pathway, which is defective in the AD brain (Zhao et al.,
2004; Ryder et al., 2004) (see also Section 1.2.3.2). It is therefore conceivable that
oxidative and nitrosative stress brought about by Aβ itself or other age related
processes together with genetic risk factors, can affect IDE and contribute to a
build-up of Aβ inside the cytosol and mitochondria.
A summary of the current understanding of the interplay between causes and
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risk factors in AD is given in Figure 1.4.
Figure 1.4: Causes and risk factors and the amyloid hypothesis in AD.
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Figure 1.4: Causes and risk factors and the amyloid hypothesis in AD (continued).
The sequence of events leading to dementia according to the amyloid hypothesis defined
by Hardy and Selkoe (Hardy and Selkoe, 2002) and its involvement with risk factors for
famial AD (FAD) and late-onset AD (LOAD). Modified with permission from Nature
publishing group (Citron, 2004; Lambert and Amouyel, 2011).
1.1.3 Treatment of AD
A cure for AD does not currently exist and so the available treatment options
are confined to the management of symptoms and do not halt the progression of
the disease (Hogan et al., 2008; Herrmann and Gauthier, 2008). It is therefore
generally recommended to approach treatment of symptoms as well as poten-
tial risk factors (hypertension, lack of physical and cognitive exercise, hyperc-
holesterinemia) by pharmacological and non-pharmacological means (NCCMH,
2006-2011). Neuropsychological symptoms of dementia like depression, agitation
and psychosis can also be treated pharmacologically in order to assist the disease
management, although non-pharmacological approaches are recommended here
first because of the treatment-associated risks for stroke and death (Herrmann
and Gauthier, 2008).
One class of available medicines specifically targeting AD focuses on correct-
ing imbalances between neurotransmitters in the brain which are caused by the
death of neurons (Figure 1.5). For mild to moderate AD these are the acetyl-
cholinesterase inhibitors Aricept, Exelon and Reminyl, which are designed to
inhibit the breakdown of acetylcholine and therefore increase the concentration
of available neurotransmitter and maintain synaptic transmission essential for
cognitive function (Hogan et al., 2008) (Figure 1.5(a)).
In cases of severe AD, these can be combined with the other class of medicine,
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which is the NMDA-receptor (NMDA-R) antagonist Memantine. NMDA-R over-
stimulation is a feature of AD can be result of the built-up of glutamate in the
synaptic cleft due to its imparied recycling by the exitatory amino acid trans-
porter into glia cells (Chen et al., 2011) or be caused by the binding of Aβ
peptides (see Section 1.2.1) to the NMDA-receptor itself, causing its activation
(Pellistri et al., 2008). In agreement with a failure of the glutamaterigic system
in the brain is also that mRNA and protein levels of the vesicular glutamate
transporter 1 (VGLUT1), which is responsible for the loading of glutamate into
pre-synaptic vesicles in the cerebral cortex and hippocampus, are significantly
decreased in the post mortem prefrontal (Kashani et al., 2008; Chen et al., 2011)
and parietal/occipital (Kirvell et al., 2010) cortices of AD patients. This corre-
lates not only with disease duration and severity but also with a reduction of
the synaptic vesicle marker synaptophysin (Chen and Yan, 2010; Kashani et al.,
2008), indicating that loss of VGLUT1 expressing synapses as a whole may be
the underlying cause of this reduction. Memantine is designed to protect gluta-
matergic synapses by reversibly blocking NMDA-receptors in a similar way to its
natural inhibitor Mg2+ (Herrmann and Gauthier, 2008) (Figure 1.5(b)).
It is important to note however, that neither of these drugs are able to stop
the underlying pathological mechanisms and that their efficacy therefore decreases
with disease progression.
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(a)
Figure 1.5: Mechanism of available AD drugs. (a) acetylcholinesterase-inhibitors
increase the amount of the neurotransmitter acetylcholine (ACh, blue circles), thereby
strengthening synaptic transmission between cholinergic neurons. Following page: (b)
Aβ (yellow/red) inhibits glutamate recycling through glia cells (grey) and causes excess
NMDA-R (dark blue) activation, thereby disturbing the transmission of new glutamate
signals. Memantine (light green ovals) acts as non-competitive NMDA-R antagonist,
reducing the effect of excess glutamate (green circles).
15
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(b)
Figure 1.5: Mechanism of available AD drugs (continued).
1.2 The neuropathology of AD
There have been several major hypotheses proposed to explain aspects of the
molecular mechanisms leading to the deterioration of the brain in AD. First, it
has been noted that the anatomical structures of the brain affected in AD are re-
gions occupied mainly by cholinergic neurons and their projections (Breese et al.,
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1997; Perry et al., 1992) and that cholinergic neurons are specifically affected
in the disease progress (Herholz et al., 2008). In line with this cholinergic hy-
pothesis, it has been found that cholinergic neurons are specifically vulnerable
in current in vitro models for AD because of an interaction between Aβ and the
nicotinic acetylcholine receptor (Wang et al., 2000; Nagele et al., 2002). These
findings have led to the introduction of cholinesterase-inhibitors for the treatment
of AD, as mentioned before. Substantial research efforts have also focused on the
two specific proteins related to histological hallmarks found in AD brains. This
gave rise to the other main theories, which are the amyloid cascade-hypothesis
(Hardy and Selkoe, 2002) and the tau-hypothesis, that regard either senile amy-
loid plaques or neurofibrillary tangles, respectively, as the factors initiating AD.
Recently, more interactions between Aβ and tau-pathologies have been found
and lead to an increasing awareness of their reciprocal effects on the neuropathol-
ogy of AD (LaFerla and Oddo, 2005; Ittner and Gotz, 2011). Of note is that a
link between normal aging, the specific effects of the neurotrophic factors nerve
growth factor (NGF) and brain-derived neurotrophic factor (BDNF) on cholin-
ergic neurons and the amyloid and tau-pathologies has recently been suggested
(Schindowski et al., 2008; Costantini et al., 2005, 2006), adding to the complexity
of the processes that are believed to occur in the brain during AD.
1.2.1 APP processing
The amyloid precursor protein (APP) is a type-I transmembrane protein belong-
ing to the APP family, which also comprises two amyloid precursor-like proteins
(APLP1/2), but the Aβ domain is unique to APP. All proteins belonging to this
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family have been associated with synaptic function, cell adhesion and neuronal
development (Coulson et al., 2000; Thinakaran and Koo, 2008). APP exists in
several isoforms, with the three main isoforms containing 695, 751 or 770 amino
acids, respectively (Kang and Mueller-Hill, 1990). APP695 was first identified in
1987 (Kang et al., 1987) and is the most abundant isoform in the brain (Kang and
Mueller-Hill, 1990). The longer isoforms are also expressed in peripheral tissues
as well and unlike APP695, contain a Kunitz protease inhibitor (KIP) domain
within their large extracellular domain (Tanzi et al., 1988b). Some reports have
suggested that there is a relative increase in the production of the longer isoforms
in AD, possibly leading to a shift towards the production of more pathological
amyloid-β peptides (Matsui et al., 2007) (reviewed in Zhang et al. (2011)). It is
also noteworthy that a study on human brains affected by head injury found in-
creases in APP and Aβ immunohistochemical staining (Gentleman et al., 1993),
indicating that APP or its cleavage products might play a physiological role in
the neuronal response to cell or metabolic stress. This also points towards the
increased risk for AD associated with those insults, which might be explained
by the associated cellular/metabloic stress or the increased production of the
amyloid peptides as a results of higher APP levels (see section 1.4).
APP mRNA is translated at the endoplasmic reticulum (ER) and transported
through the Golgi complex to the trans-Golgi network (TGN), where most of the
cellular APP can be detected (Vetrivel and Thinakaran, 2006; Zhang et al., 2011).
APP can then be transported to the plasma membrane, where it is quickly inter-
nalised again due to its YENPTY internalisation motif (Selkoe et al., 1996; Haass
et al., 1992). The cleavage of APP can be achieved in two ways (amyloidogenic or
non-amyloidogenic) by consecutive action of different proteases (secretases) in-
18
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and outside of the membrane and it is a disturbed balance between these two
cleavage pathways which is believed to initiate the amyloid-cascade (Hardy and
Selkoe, 2002) (Figure 1.6).
Figure 1.6: APP-processing. Full length APP (middle) can be processed in a non-
amyloidogenic cleavage pathway by α- and γ-secretases (top) or in a amyloidogenic
pathway by β- and γ-secretases. See text for detailed description and function of the
fragments produced. Adapted with permission from Korean Society for Biochemistry
and Molecular Biology (Chang and Suh, 2010).
1.2.1.1 Non-amyloidogenic pathway
If APP is first cleaved by the α-secretase, shedding the extracellular domain of
the protein (sAPPα), it leaves the α-C-terminal fragment (αCTF) in the plasma
membrane and precludes the production of Aβ, which has been cut between Lys16
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and Leu17 of its sequence. The α-secretase cleavage can be achieved by different
proteins at the plasma membrane including the zinc metalloproteases A disinte-
grin and metalloproteinase domain-containing protein 17 (ADAM17; also: tumor
necrosis factor-α converting enzyme, TACE), ADAM9, ADAM10 and metallopro-
tease disintegrin 9 (MDC9) as well as the aspartyl-protease beta APP cleaving
enzyme 2 (BACE2) (Allinson et al., 2003). Recently, ADAM10 has been put for-
ward as the physiologically relevant α-secretase in the brain (Kuhn et al., 2010).
It has been found that the sAPPα fragment released from the N-terminus of APP
has protective and growth promoting effects on both neuronal and non-neuronal
cells and that release of this fragment might underlie the reported trophic func-
tions of APP itself (reviewed in Chasseigneaux and Allinquant (2012)). Of note,
fragments corresponding to this type of APP processing have been detected in
various brain regions and throughout life and also inside neurons without any
pathological implication (Wegiel et al., 2007).
α-Secretase in AD treatment: Following from these observations, stimu-
lation of α-secretase activity has been considered as a therapeutic option for AD
(Allinson et al., 2003). For example, it has been demonstrated that pharmaco-
logical activation of muscarinic acetylcholine receptors can activate α-secretase
cleavage and have protective effects in a triple transgenic mouse model for AD
(Caccamo et al., 2006). Similarly, activation of the purinergic receptor P2X7 can
also induce α-secretase activity in a MAP-kinase dependent manner and could
therefore be a therapeutic target in AD (Delarasse et al., 2011). It is important
to note, however, that a possible caveat against the use of α-secretase activat-
ing agents could be the growth promoting and inflammatory effects of sAPPα,
which could lead to tumorigenesis and promote neurotoxic inflammation (Chas-
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seigneaux and Allinquant, 2012).
1.2.1.2 Amyloidogenic pathway
Production of the Aβ peptide requires its C-terminal end to be produced by β-
secretase cleavage of APP at either Asp1 (β-site) or Glu11 (β’-site) of the Aβ
sequence. This cleavage releases an extracellular sAPPβ fragment, which is 16
amino acids shorter than the corresponding sAPPα and does not possess all of
its neuroprotective properties (Chasseigneaux and Allinquant, 2012). Instead,
some reports have rather pointed towards a cytotoxic function of this fragment
by binding to death receptor 6 (DR6) (Nikolaev et al., 2009). β-Site cleavage also
leaves the β-CTF of APP inside the membrane, which is then processed by the
γ-secretase complex (see below).
Several lines of evidence have indicated that an increase in β-secretase ac-
tivity might be associated with the initiation of Aβ pathology. The function
of this secretase is fulfilled by the beta APP cleaving enzyme 1 (BACE1), an
aspartyl-protease. BACE1 is predominantly present in the Golgi complex/TGN
and early endosomes (Zhang et al., 2011), where it is located in cholesterol-rich
microdomains (lipid rafts) and its enzymatic activity requires the presence of
cholesterol (Kaether and Haass, 2004). BACE1 expression is elevated in AD af-
fected brain (Matsui et al., 2007; Fukumoto et al., 2002) but it has emerged that
BACE1 could also be affected by normal aging. Experimental evidence exists
from mouse models that production of ceramide, which is an important compo-
nent of lipid rafts and stabilises BACE1 activity, increases with age as a result
of enhanced p75NTR signalling and can lead to a concomitant increase in the
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production of Aβ with age (Costantini et al., 2005, 2006).
APP can reach BACE1 in lipid rafts as a result of cell signalling events, es-
pecially involving calpain, which can accordingly promote the production of Aβ
(Saito et al., 1993; Mathews et al., 2002; Andersen et al., 2005; Liang et al.,
2010). Furthermore, it has been revealed APP targeting can be influenced by
phosphorylation of the APP intracellular domain at Thr668 (Selkoe et al., 1996;
Lee et al., 2003) which probably acts as a sorting signal to these domains. Phos-
phorylation at this site can be mediated by the stress kinase c-Jun N-terminal
kinase (JNK), which is therefore thought to be an important regulator of Aβ
production in response to stress signals (Colombo et al., 2009). In addition, a
stretch in amino acids 680-689 including the YENPTY motif of APP can interact
with the scaffold protein JNK interacting protein 1b (JIP-1b) and enhance APP
Thr668 phosphorylation (Taru et al., 2002; Matsuda et al., 2001; Scheinfeld et al.,
2002). In agreement with this, reduced energy metabolism (Gabuzda et al., 1994;
Velliquette et al., 2005) as well as oxidative stress (Tamagno et al., 2005, 2008)
(an inducer of JNK activity) have been identified previously as factors increasing
amyloid production and are both associated with the aging brain (Beal, 1995; Lin
and Beal, 2006).
β-Secretase in AD treatment: Evidence suggests an essential role for β-
secretase in Aβ production and causing neurodegeneration during AD as well as
in normal aging. It follows that β-secretase inhibition as a potential therapeu-
tic approach for AD has come into focus. Promising results were obtained from
BACE1 knock out animals, which were protected against amyloid build up in the
brain and no detrimental side effects caused by the deficiency could be detected.
However, development of a BACE1 specific aspartyl-protease inhibitor as a drug
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molecule has so far been challenging (Citron, 2004). Due to their negative effect
on the levels of cholesterol in the blood and potentially the brain tissue, which
is necessary for BACE1 function as mentioned above, lipid-lowering agents such
as statins have been suggested to have a beneficial effect on the progression of
AD. However, rigorous assessment of the different types of lipid-lowering agents
currently available, considering their mechanism of action, blood-brain barrier
permeability, effects on other apsects of cellular metabolism and efficacy at dif-
ferent stages of AD pathology is still outstanding (Shepardson et al., 2011).
1.2.1.3 The γ-secretase step
The shedding of the extracellular domain by either α- or β-secretase prepares APP
for cleavage by γ-secretase. γ-Secretase is a multiprotein complex, consisting of
presenilin-1 or presenilin-2, Aph-1 (anterior pharynx defective 1), PEN-2 (prese-
nilin enhancer 2) and nicastrin, where the presenilins act as the catalytic subunits
(Haass and Steiner, 2002). The enzyme and its activity have been detected in
several compartments of the cell, including the ER, Golgi complex, TGN, plas-
mamembrane and endosomes (Thinakaran and Koo, 2008) and have also been
found in association with mitochondria (Hansson et al., 2004; Area-Gomez et al.,
2009). Cleavage of the remaining APP-CTF membrane stub occurs within its
α-helical domain inside the membrane (Wolfe et al., 1999; Haass and Steiner,
2002) at different sites, producing, Aβ49 (-site), Aβ46 (δ-site) and Aβ40 or 42
(γ-sites) respectively following β-secretase cleavage or a p3 fragment (γ-site) fol-
lowing α-secretase cleavage. Some evidence has pointed towards a consecutive
cleavage model, where δ- and -site fragments only exist as intermediates towards
the production of Aβ40/42 (Zhao et al., 2007; Zhang et al., 2011). It has also been
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proposed that changes in the membrane environment, e.g. by endocytosis, could
affect the specificity of the γ-secretase cleavage at least at the -site (Fukumori
et al., 2006).
Full proteolysis by the γ-secretase produces the more abundant Aβ40 and the
Aβ42 peptides, which are released into the extracellular/lumenal space and are
able to cause neurodegeneration. At the same time, Aβ peptides have been
attributed contrasting functions under different conditions. It has been sug-
gested early on that low concentrations of Aβ peptides, probably representing
monomers, could act as neurotrophic factors (Yankner et al., 1990). This view
has been supported by a more recent study, finding that picomolar concentrations
of Aβ positively affect synaptic plasticity in hippocampal neurons (Puzzo et al.,
2008). Interestingly, the study also revealed that the effect was mediated by the
α7-containing nicotinic acetylcholine receptor (Puzzo et al., 2008), a previously
identified binding site for Aβ42 peptides, which caused cytotoxicity at the higher
Aβ concentrations (Wang et al., 2000). In contrast, the p3 fragment produced
by non-amyloidogenic cleavage is believed to be degraded rapidly and have no
further function (Zhang et al., 2011).
Cleavage of the CTF at the -site close to the cytosolic face of the membrane
also results in the release of the APP intracellular domain (AICD). The AICD
interacts with other proteins via its YENPTY motif, carries post-translational
modifications (Figure 1.7) and its activity and turnover can be regulated by
caspase cleavage and degradation by the insulin-degrading enzyme (IDE). A range
of functions have therefore been proposed for the AICD. The most accepted model
is that a complex comprising AICD, the adaptor protein Fe65 and the histone
acetyl-transferase Tip60 acts as a transcriptional regulator which plays a role
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in the induction of apoptosis and cytoskeletal re-arrangements involved during
neuronal development and synaptic plasticity (Keita et al., 2009; Scheinfeld et al.,
2002; Zhang et al., 2007; Mueller et al., 2008).
Figure 1.7: The APP intracellular domain (AICD). Motifs and binding partners are
depicted. Phosphorylation sites in the sequence from APP695 are indicated above. Re-
produced with permission from Korean Society for Biochemistry and Molecular Biology
(Chang and Suh, 2010).
γ-Secretase in AD-treatment: Because of its pivotal role in generating
the toxic Aβ peptides, much work has been done towards the development of
γsecretase inhibitors. A problematic aspect of this approach is that APP is not
the only γ-secretase substrate. The enzyme is also responsible for the release of
intracellular domains from a number of other membrane proteins after they have
undergone ectodomain shedding in response to ligand binding or stimuli activat-
ing second-messengers (Kopan and Ilagan, 2004). Amongst these are important
molecules for neuronal development and function like the cell surface receptor
Notch and its ligands Delta and Jagged, N-cadherin and the neurotrophin co-
receptor p75NTR and release of their intracellular domains is a crucial part of their
signalling function (Kopan and Ilagan, 2004). Failure of clinical phase studies on
γ-secretase inhibitors, most prominently Elly Lilli’s semagacestat, are probably
down to effects on these molecules (Gravitz, 2011; Imbimbo and Giardina, 2011).
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The focus has therefore now shifted towards achieving more subtle changes in
γ-secretase activity, which would affect Aβ-production but not the processing of
other substrates. Non-steroidal anti-inflammatory drugs (NSAIDs) are able to
act as such modulators of γ-secretase cleavage and shift it towards the produc-
tion of the less toxic Aβ38 peptide (reviewed in Selkoe and Wolfe (2007); Zhang
et al. (2007)). So far, use of NSAIDs for clinical use has not been recommended
because of the lack of proof of efficacy (NCCMH, 2006-2011; Imbimbo and Gi-
ardina, 2011), but it is conceivable that small molecule inhibitors with similar
properties could be developed (Selkoe and Wolfe, 2007).
1.2.2 Amyloid production in AD
1.2.2.1 FAD mutations cause increased Aβ production
The mutation causing a substitution of Val717 to Ile in the APP gene, which is
associated with familial AD had been identified long before its processing and
the identity of the secretases had been elucidated (Goate, 1991). Many other
mutations in APP have since been found, which are all clustered around the
cleavage sites for the different secretases and favour either entry into the amy-
loidogenic cleavage pathway or the production of more Aβ42 compared to Aβ40
(Suzuki et al., 1994; Citron et al., 1992; De Jonghe et al., 2001; Haass et al., 1995).
Some of this data also indicates that the production of Aβ from APP is shifted
from endosomes towards the secretory pathway (TGN) by the Swedish mutation
(APPK595N/M596L) (Haass et al., 1995; Martin et al., 1995). Similarly, mutations
in the genes encoding the presenilins also lead to an increased production of
toxic Aβ42 (Borchelt et al., 1996) but effects of some PSEN mutations which
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are independent from Aβ production, as no amyloid-pathology can be observed,
have also been suggested in rare cases. They relate to defects in processing other
γ-secretase substrates (Van Broeck et al., 2007).
1.2.2.2 Aβ oligomers, fibrils and plaques
The general hypothesis supported by experimental data is that under physio-
logical conditions, Aβ aggregation is an ordered process of polymerisation with
distinct steps (Figure 1.8) but is an unspecific aggregation at supranatural con-
centrations. The Aβ sequence is amphipathic with a hydrophilic N-terminus and
a hydrophobic C-terminal segment, which can adopt an α-helical or a random coil
structure depending on its environment. In contrast to the shorter Aβ variants,
the monomeric Aβ42 version more rapidly adopts a β-sheet conformation in aque-
ous solutions at a physiological pH, which can then aggregate further. Residues
17–21 seem to be essential for further aggregation to happen and formation of
a β-turn in segment 24–28 has been reported to help this process (reviewed in
Finder and Glockshuber (2007)).
Small oligomers of Aβ consist of 3–50 subunits, while Aβ42 is thought to
form intermediate unstructured paranuclei comprising 5–6 monomers, followed
by 60 kDa Aβ24-globulomers which can also be found in vivo. Aβ derived
diffusible ligands (ADDLs), which range in size from 17–42 kDa, can also
be counted amongst them. These early aggregation species are believed to be
the most cytotoxic forms of Aβ (Bucciantini et al., 2002; Walsh et al., 2002b;
Stine et al., 2003). Their toxicity towards neurons has been established in a
large number of studies and the detection of these soluble species has also been
correlated with disease severity (Hoelscher et al., 2007; Klein, 2002; Walsh et al.,
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Figure 1.8: Aβ aggregation. Beginning with Aβ taking on a β-sheet conformation,
different species with varying toxic properties (see text) are formed during the process of
plaque formation. Most of these can also be detected in vivo. Adapted with permission
from Karger (Finder and Glockshuber, 2007).
2002a; Klein, 2006; McLean et al., 1999).
Some data has indicated that Aβ can also disrupt calcium homeostasis of
cells by inducing Ca2+ fluxes (Mattson et al., 1992) and disrupting membranes
(Friedrich et al., 2010; Yang et al., 1998; Arispe et al., 1993). The formation of
annular pore-like structures by Aβ has therefore been suggested but could not
be demonstrated in vivo (Mueller et al., 2001; Arispe et al., 1993; Finder and
Glockshuber, 2007).
Protofibrils are rod-like β-sheet containing structures made of arrays of Aβ-
monomers, which can dissociate into oligomers or elongate depending on Aβ
concentration, temperature, pH and ionic strength of the environment. They
have been reported to quickly aggregate into various shapes of fibrils (Finder and
Glockshuber, 2007), which are highly ordered assemblies of β-strands involving
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the C-terminal part of Aβ. These can then aggregate into extracellular plaques
(Finder and Glockshuber, 2007; Duyckaerts et al., 2009).
A recent study has shed some light on the process of Aβ-aggregation under
physiological conditions. The results demonstrated that Aβ plaque formation
in cell culture depends on living cells capable of endocytosis or phagocytosis
(Friedrich et al., 2010), suggesting that all these species could be found inside
cells and that the acidic endosomal pH facilitates their production. They also
showed that the presence of pre-formed fibrils can have a strong seeding-effect
(Friedrich et al., 2010). Immunohistochemical studies on human brain material
from AD sufferers and patients with Down syndrome have also supported the view
that intracellular assembly of Aβ aggregates precedes the formation of plaques
(Gyure et al., 2001; Gouras et al., 2000) and this sequence has also been observed
in AD animal models (Oddo et al., 2006).
1.2.3 Tau and neurofibrillary tangles
1.2.3.1 Tau structure and function
Tau belongs to the family of structural microtubule associated proteins (MAPs)
type II and like the other group member MAP2, is mainly expressed in neurons
(Dehmelt and Halpain, 2004). In humans there are 6 isoforms of tau which are
built of an N-terminal projection domain of varying length (N), followed by two
proline-rich domains, 3–4 microtubule binding repeats (R) and a C-terminal tail
(Figure 1.9) (Kar et al., 2005; Morris et al., 2011; Mandelkow et al., 1995).
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Figure 1.9: Human tau isoforms. The 6 most common isoforms A-F generated
by alternative splicing are depicted. Isoform F with 441 amino acids corresponds to
”htau40”, the 4R isoform commonly used in the generation of transgenic animal mod-
els. Protein domains are indicated: Microtubule binding domains (blue), the proline
rich domain (grey), N-terminal inserts (green). The alternatively spliced exon 10, in-
cluded in 4R tau isoforms is shaded in gray. Corresponding exons in the tau gene are
indicated below. Modified with permission from Lippincott Williams & Wilkins (Kar
et al., 2005).
While there is only one 4R isoform in the adult mouse brain, human brain
contains a 1:1 ratio of 3R to 4R tau proteins through alternative splicing of exon
10 and the balance between them seems to be crucial for neuronal function (Kar
et al., 2005). Binding of tau along the microtubules has been thought to sta-
bilise them by influencing the dynamics between shortening and lengthening of
the tubulin rods, which occurs more efficiently by the 4R isoforms (Dehmelt and
Halpain, 2004). Recently though, this view has been challenged in favour of mi-
crotubule based transport related functions of tau (Morris et al., 2011). In vivo
experiments have demonstrated that it can influence axonal transport in cells
and the detachment of motor proteins from their microtubule tracks (Dehmelt
and Halpain, 2004; Morris et al., 2011). Tau carries a large number of post-
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translational modifications, suggesting a high level of regulation of its function
(Morris et al., 2011). Phosphorylation at sites within its microtubule binding do-
mains regulates its ability to bind microtubules and is widely believed to play a
part in NFT pathology (Mandelkow et al., 1995; Hanger and Wray, 2010) (see sec-
tion 1.2.3.2). Addition of N -actetylglucosamine (GlcNAc) to serine and threonine
residues has been found to inhibit its phosphorylation, thereby possibly stabilising
its function at microtubules (Liu et al., 2004). In agreement with the important
function of the microtubule network for neuronal development and function, tau
is strongly expressed and phosphorylated at physiological sites in axons, cell bod-
ies and dendrites of developing neurons (Brion et al., 1994) but is concentrated in
axons at later stages of development (Dehmelt and Halpain, 2004). Furthermore,
interaction of tau with actin filaments has also been reported, possibly pointing
towards a function of tau in connecting actin with microtubule networks (Morris
et al., 2011).
Functions of tau that are not directly mediated by its microtubule binding
repeats but rather by interactions of its proline-rich domain with SH3-domain
containing proteins have been identified. In neuronal cell lines, the src-kinase
fyn has been shown to interact with and phosphorylate N-terminal Tyr residues
in tau which is required for NGF-induced neurite outgrowth (Lee et al., 1998)
and similar functions have also been allocated to tau in oligodendrocytes (Klein
et al., 2002). In non-neuronal cells and neuronal cell lines, tau has been found
to activate src and fyn kinases as well and play a role in growth factor induced
actin remodelling independent from microtubule binding (Yu, 2006; Sharma et al.,
2007). It has now emerged that tau also interacts with fyn during pathological
NMDA-receptor signalling (Ittner et al., 2010). Other signalling related functions
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of tau include possible activation of PLCγ and the cellular response to heat shock
in neurons (Morris et al., 2011).
1.2.3.2 Hyperphosphorylated tau and tauopathy
Although phosphorylation of tau at some sites seems to be part of its normal
function, hyperphosphorylation of tau has been observed in a number of mod-
els for metabolic and oxidative stress in animals and cell cultures, such as acute
treatment with Aβ oligomers, hypoxia, glucose deprivation and heat shock (Zem-
pel et al., 2010; Melov et al., 2007; Blurton-Jones and Laferla, 2006; Morris et al.,
2011). In addition, the presence of hyperphosphorylated tau and neurofibrillary
tangles has been detected in human brains after head injury (Omalu et al., 2011).
Co-localisation of hyperphosphorylated tau with NFTs and in vitro bind-
ing experiments have long suggested that hyperphosphorylated tau disengages
from its interaction partners, most importantly the cytoskeleton, and eventually
polymerises into paired helical filaments (PHF) which assemble into sarkosyl-
insoluble aggregates, detectable with thioflavin dyes (Morris et al., 2011; Iqbal
et al., 2010). Evidence for this proposed sequence of events stems from the find-
ing that hyperphosphorylated tau can be detected before NFTs occur in human
AD brain (Bancher et al., 1989). Phosphorylation of tau in vitro by GSK3β and
CDK5 is also sufficient for its aggregation into filaments, while dephosphorylated
tau disaggregates (reviewed in Iqbal et al. (2010)). Of note, phosphorylation of
already assembled tau filaments by GSK3β can promote their aggregation into
tangles in vitro (Rankin et al., 2008), suggesting that phosphorylation at certain
epitopes can have effects at multiple stages of the aggregation process. The β
sheet forming elements in tau are located in the microtubule-binding repeats R2
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and R3 and phosphorylation at sites adjacent to these repeats appears to pro-
mote fibrillisation (Iqbal et al., 2010). Known phosphorylation sites in tau and
the kinases able to phosphorylate these sites in vivo are listed in Table 1.1.
Site Foetal tau Adult tau PHF Kinases
Ser46 + ERK2
Thr175 + ERK2, p38, JNK, GSK3β
Thr188 + + ERK2
Ser184/185 + p38
Ser198 + + ?
Ser199 + + ERK2, GSK3β
Ser202 + + + ERK2, p38, JNK, CDK5
Thr205 + Erk2, p38, JNK
Ser208 + ?
Ser210 + ?
Thr212 + ERK2, p38, JNK, GSK3β
Ser214 + PKA, PKC
Thr217 + + ERK2, p38, JNK, GSK3β
Thr231 + + + ERk2, p38, JNK, GSK3β, CDK5
Ser235 + + ERK2, p38, JNK, GSK3β, CDK5
Ser237 + PK
Ser238 + ?
Thr245 + p38
Ser262 + + GSK3β, PKA, PKC, MARK1, PK
Ser305 p38
Ser356 + GSK3β, PKA, MARK1
Ser396 + + ERK2, p38, JNK, GSK3β
Ser400 + + GSK3β
Thr403 + ?
Ser404 + + + ERK2, p38, GSK3β, CDK5
Ser409 + + PKA
Ser412 + ?
Ser413 + + GSK3β
Ser422 + ERK2
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Table 1.1: Tau-phosphorylation sites detected in foetal rat, adult rat brain and in PHF
of human AD. Sites and in vitro phosphorylation by kinases of those sites found in vivo
were identified in studies by Hanger et al. (1998), Morishima-Kawashima et al. (1995)
and Reynolds et al. (2000) and references therein. ERK2: extracellular signal regulated
kinase 2 (also p42-MAPK), JNK: c-Jun N-terminal kinase; p38: p38 mitogen activated
kinase (p38-MAPK), GSK3β: glycogen-synthase kinase 3β, CDK5: cyclin dependent
kinase 5, PKC: protein kinase C, PKA: protein kinase A, MARK1: microtubule affinity
regulating kinase (formerly p110MARK)
The significance of these phosphorylation sites has been demonstrated re-
cently in an in vitro study, which investigated their effect on aggregation and
microtubule binding in different tau isoforms (3R and 4R). Introduction of mu-
tations mimicking 7 of these phosphorylation events (Ser199, Ser202, Ser205, Ser31,
Ser235, Ser396 and Ser404) enhanced the polymerisation of the 4R isoforms but
inversely affected the 3R isoforms. At the same time the mutations interfered
with microtubule stabilisation more in 3R isoforms than in 4R isoforms (Combs
et al., 2011). This further highlights how phosphorylation of the different iso-
forms present in the human adult brain (but not the rodent brain) might lead to
tauopathy.
Some research has suggested that not only phosphorylation but also pro-
teolytic events have an impact on tangle formation, either by inducing direct
conformational changes or by facilitating tau phosphorylation. Amongst the pro-
teases involved in this cleavage are caspases 3, 6 and 7, calpain, cathepsin D and
thrombin (Hanger and Wray, 2010). In a mouse model for tauopathy expressing
the regulatable P301L tau mutant, activation of caspases precedes the formation
of tangles following transgene expression but the authors found that both events
do not lead to immediate cell death (de Calignon et al., 2010). The presence of
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caspase cleaved tau has been confirmed in NFT in AD brain and cleavage of tau
by calpain and caspases is also induced by exposure of cell cultures to Aβ (Morris
et al., 2011; Hanger and Wray, 2010).
Some experimental results imply that tau species other than insoluble fila-
ments are responsible for neurodegeneration (Morris et al., 2011; Iqbal et al.,
2010). Comparing wild-type, soluble R406W mutant tau and P301L mutant
tau revealed that wild-type and R406W mutant tau but not the more aggrega-
tion prone P301L mutant can promote Aβ toxicity in hippocampal slice cultures
(Tackenberg and Brandt, 2009). Interestingly, dementia caused by the R406W
tau mutation in tau has clinically been defined as a rare Alzheimer-mimicking
type of frontotemporal dementia (Tolboom et al., 2010). This indicates that
soluble tau is of particular importance in AD pathology and that the processes
leading to frontotemporal dementia, e.g. caused by the P301L mutation, are not
identical to those leading to tauopathy in AD.
Soluble tau was found to act in pathways of amyloid toxicity involving the
NMDA-R, GSK3β and calcineurin in the mouse brain (Tackenberg and Brandt,
2009; Shipton et al., 2011). Phosphorylation and redistribution of endogenous
tau from its normal location in axons to dendrites (rather than aggregation)
has also been detected in primary hippocampal neurons exposed to oligomeric
Aβ, which caused defects in spine morphology and microtubule assembly (Zhang
et al., 2011). In dendrites, tau has been found to act together with the src
kinase fyn, which had previously been associated with neurite outgrowth (Lee
et al., 1998; Sharma et al., 2007; Klein, 2002; Ittner et al., 2010). It has been
shown that tau can localise fyn to post-synaptic sites containing PSD95 and the
NMDA-R in response to Aβ, thereby causing neurotoxicity (Ittner et al., 2010).
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More information about the fyn–tau interactions comes from the JNPL3 mouse
model for tauopathy (FTLD), expressing the human 4R P301L tau mutant. A
strong interaction between tau and fyn and fyn-mediated Tyr18 phosphoryla-
tion of tau have been found in the JNPL3 mouse model just before the onset
of pathology (Bhaskar et al., 2005). Importantly, the same study also showed
that the 3R isoform of tau interacts stronger with fyn than the 4R isoform but
that the interaction between fyn and 4R tau can be increased by disease related
tau-phosphorylation (Bhaskar et al., 2005). This suggests that hyperphosphory-
lation of tau can lead to an increased interaction between 4R tau and fyn and
possibly the re-distribution of fyn and tau, which is not seen under physiological
conditions. More similarities between other tauopathies and human AD were
revealed by studying the distribution of mitochondria. In human AD brain and
a mouse model reversibly expressing the P301L tau mutant, disruption of mito-
chondrial trafficking has been found in neurons bearing tau pathology. However,
this was reversed as soon as the expression of the tau mutant was stopped in
the mice, which reduced soluble tau species but not NFT pathology (Kopeikina
et al., 2011).
1.2.3.3 Tauopathy in AD
Mechanisms causing tauopathy which might be at play specifically in AD have
been described by numerous studies, although evidence for their presence in the
human brain in vivo has not been presented for all of them.
As pointed out, tau cleavage can promote its aggregation but whether or not
this is actually toxic to neurons or a protective side effect leading to disposal of
toxic soluble tau remains to be seen. Even though activation of caspases follow-
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ing exposure to Aβ has been well documented (Umeda et al., 2011; D’Amelio
et al., 2011), it is not clear if this happens as a result of Aβ mediated tau-
phosphorylation causing toxicity or if Aβ activates caspases via other routes.
The ability of Aβ exposure to activate caspases in models of tau deficiency has
not been tested so far. Calpain, a calcium-activated protease which is able to
cleave tau, has also been linked to AD, as its activation has been detected in
human AD brain samples (Saito et al., 1993) and in cell cultures overexpressing
APP (Kuwako et al., 2002). Similarly, the lysosomal protease cathepsin D can
cleave tau and is also affected by AD pathology, as it leaks from defective lyso-
somes accumulating Aβ42 (Yang et al., 1998; Umeda et al., 2011). A point to
consider is that phosphorylation of tau around the respective cleavage sites inter-
feres with proteolysis and these phosphorylation events have also been detected
in brains affected by AD (Hanger and Wray, 2010). This leads to the idea that
increasing phosphorylation of tau might be able to overcome a possibly protective
tau cleavage and thereby initiate pathology.
Most of the kinases involved in normal and pathological phosphorylation of
tau have been found to be altered in AD and so it is conceivable that the delicate
balance of tau-phosphorylation will be disturbed, contributing to tauopathy. Ev-
idence for the involvement of the signal transduction pathways involving each of
these kinases is summarised below.
• There is an increased expression of pERK1/2, p38 and JNK in AD and
Down syndrome compared to control brains and higher expression of the
CDK5 activator p25 in AD (Swatton et al., 2004). Fittingly, increases
in tau-phosphorylation at sites that have been reported as target sites for
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MAPKs and CDK5 have also been detected (Reynolds et al., 2000; Swatton
et al., 2004).
• CDK5 also accumulates in neurons with early tangle pathology in AD brains
(Pei et al., 1998).
• Phosphorylated (activated) JNK)(Lagalwar et al., 2006; Zhu et al., 2001)
and its substrate, the transcription factor c-Jun (MacGibbon et al., 1997;
Thakur et al., 2007; Pearson et al., 2006) are associated with tangles in
AD brains. Also, Aβ treatment of cell cultures results in the activation of
JNK in cell lines (Troy et al., 2001; Marques et al., 2003) and in neurons
(Minogue et al., 2003; Morishima et al., 2001).
• The scaffolding protein p66shc is a target of JNK. p66shc is involved in
the regulation of cellular oxidative stress and aging related dysfunction of
organelles such as the mitochondria and its activation has, too, been found
following Aβ exposure (Smith et al., 2005).
• Activated transcription factor NF-κB, which is a target of the MAPK sig-
nalling cascade, has been detected in neurons exposed to Aβ and in AD
brain in affected regions. However, this activation is dependent on the pro-
duction of reactive oxygen species (ROS) in response to Aβ (Kaltschmidt
et al., 1997) and might therefore be secondary to the activation of other
signalling molecules such as JNK and p66Shc.
• The Ser/Thr kinase Akt (PKB), which regulates GSK3β activity, is down-
regulated in response to Aβ in cell cultures and also diminished in affected
AD brain regions, which co-localise with areas of increased GSK3β activity
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(Ryder et al., 2004). Accordingly, Akt isolated from Aβ expressing cells is
deficient in its kinase activity towards GSK3β in vitro (Lee et al., 2009).
In line with this, Aβ-exposure on neurons leads to GKS3β activation and
inhibiting GSK3β blocks Aβ toxicity (Koh et al., 2008), as does the over-
expression of Akt in cell lines (Martin et al., 2001).
• GSK3 and CDK5 not only phosphorylate tau but also cause hyperphospho-
rylation of the collapsin response mediator protein 2 (CRMP2), disturbing
its function in the assembly of microtubules. This hyperphosphorylation is
also present in AD mouse models and human AD brains but not in a mouse
model lacking amyloid pathology (Cole et al., 2007).
• N -acetylglucosamine (GlcNAc) modifications on phosphorylation sites,
which negatively regulate phosphorylation, are reduced in AD brains, which
could contribute to the observed hyperphosphorylation of tau in these tis-
sues(Liu et al., 2004).
Additionally, studies in transgenic mouse AD models confirmed the pro-
posed cascade of events (Aβ pathology causing tau-pathology). They revealed
an aggravation of tauopathy in APP/tau double transgenic animals compared
to single transgenic mice (LaFerla, 2010; LaFerla and Oddo, 2005). Finally,
clearance of intra- and extracellular Aβ in a triple transgenic mouse model
APPSwe/PSEN1M146V /tauP301L by an immunotherapy approach led to the reduc-
tion of hyperphosphorylated tau and NFTs as well as Aβ-pathology and upon
removal of the therapeutic antibody, NFTs only reappeared after Aβ accumula-
tion (LaFerla, 2010).
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1.2.4 Prospective disease-modifying treatments for AD
1.2.4.1 Targeting amyloid-β
Research into the development of inhibitors of Aβ production has so far not re-
sulted in a breakthrough in AD therapy. Other avenues such as the enhancement
of Aβ clearance from the brain and interference with toxic Aβ aggregation are
therefore being explored as therapies which could be used in place of or in com-
bination with other potential therapeutics.
Inhibition of Aβ aggregation: A large amount of evidence is pointing
towards Aβ aggregates as the culprits in amyloid-mediated neurotoxicity, so it
is only logical to think of ways to stop this aggregation as a therapeutic ap-
proach. Still, Aβ aggregation is a complex and non-linear process, which leads
to the production of not only one species of aggregate but many with entirely
different properties. As mentioned, it is Aβ oligomers, rather than large aggre-
gates and fibrils, which are believed to induce neurotoxicity (Walsh and Selkoe,
2007; McLean et al., 1999) and so it is of crucial importance to be aware of the
dynamics of Aβ aggregation and how a potential inhibitor might affect relative
levels of individual Aβ species. Meanwhile, some compounds have been tested for
their therapeutic potential and for example, cyclohexanehexol inhibitors seemed
to have beneficial effects in an AD mouse model (Van Broeck et al., 2007). Like-
wise, zinc-chelators and glycosaminoglycan mimetics have been tested for their
potential to reduce Aβ aggregation in clinical trials but no significant improve-
ment has been reported (reviewed in Citron (2004)). Interestingly, a differential
effect of zinc-chelators on plasma Aβ levels (reduction only in less severe cases)
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and cognition (improvement only in more severe AD cases) was noted during
these studies (Citron, 2004), adding weight to the view that inhibition of aggre-
gation can have opposing effects under different conditions.
Enhancement of Aβ clearance: One approach to increase the clearance
of Aβ peptides from the brain is based on the ability of the endogenous pepti-
dases insulin-degrading enzyme (IDE) and neprilysin to degrade Aβ (Qiu et al.,
1998; Shirotani et al., 2001). An increased expression of both enzymes has been
demonstrated in AD brains, possibly as a response to higher Aβ levels (Vep-
salainen et al., 2008). Furthermore, systemically reduced levels of neprilysin in
mice have been shown to affect Aβ degradation and build-up in brain regions
typically affected by AD (Iwata et al., 2001) and variations in the IDE gene on
chromosome 10 have also been associated with genetically linked cases of late-
onset AD (Bjork et al., 2007; Kim et al., 2007; Vepsalainen et al., 2007). Ways to
increase the activity levels of these enzymes as potential therapies are therefore
being explored but have not reached the level of clinical trials yet (Miners et al.,
2011).
More advanced studies have investigated the use of immunotherapy in AD.
Trials using active vaccination based on aggregated Aβ preparations have proven
very successful in AD mouse models, where reduction of amyloid load and cog-
nitive improvement could be demonstrated (reviewed in Brody and Holtzman
(2008)). Disappointingly, phase II clinical trials with patients suffering from mild
to moderate AD had to be halted because of cases of meningoencephalitis and
antibody titers were usually much lower than expected from the studies in an-
imals. Even analysis of ”responders” (with reasonable antibody-titers) without
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encephalitis did not demonstrate any improvement in vaccinated patients, al-
though autopsies revealed a specific reduction in amyloid pathology (Brody and
Holtzman, 2008). Much hope has now been directed towards studies into the use
of passive immunisation with monoclonal antibodies. Notably, results in mouse
models have revealed that vaccination can improve behavioural deficits but also
that there is no correlation with amyloid plaque clearance in those animals, sim-
ilar to the observations made in human trials (Brody and Holtzman, 2008). This
shows that the mechanism of amyloid directed immunotherapy has so far not
been understood. Several mechanisms have been proposed, which in fact might
work in concert (Brody and Holtzman, 2008; Citron, 2004). For example:
• phagocytosis of plaques by immune cells
• disruption of Aβ aggregates favouring their clearance
• capture and clearance of soluble Aβ species
• action as a peripheral sink by binding of Aβ and transport away from the
brain
• stimulation of non-immunogenic cell mediated effects (phagocytosis)
1.2.4.2 Targeting tau-pathology
It appears that tau-pathology is a more downstream event in AD, probably
brought about by processes involving Aβ together with other factors. Irrespec-
tive of the order of events leading to AD, there is little doubt that hyperphos-
phorylation and disengagement of tau from its interaction partners can cause
neurotoxicity (Goetz, 2001) and as such it would be worthwhile preventing.
A modified version of methylene blue (TauRx) has been claimed to inhibit
tau-aggregation and have a positive effect on AD progression but the results and
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methodology of the phase II clinical study are controversial (Ballard et al., 2011;
Gravitz, 2011). Other tested therapeutics targeting tau-tangles are inhibitors of
the important tau-kinase GSK3β. Lithium has been reported to act as such an
inhibitor and is being tested in clinical trials (Leroy et al., 2010; Gravitz, 2011),
as well as other new inhibitors of GSK3 (Gravitz, 2011; Palmer, 2011). The
stabilisation of microtubules alongside reduction of tau-phosphorylation is the
proposed effect of another class of reagents tested in AD treatment (NAP and
AL-108) but with unknown results so far (Morris et al., 2011).
1.3 Frontotemporal dementia and AD
As mentioned, mutations in the tau gene, leading to its aberrant processing and
mostly increasing the amount of 4R tau (Hanger and Wray, 2010) are not char-
acteristic of AD but more of frontotemporal dementia. However, tau-mutations
and its aggregation are not defining for all cases of FTLD either as reviewed by
Goedert et al. (2012). Instead, they characterise 5% of all FTLD cases which are
together described as frontotemporal dementia and parkinsonism linked to chro-
mosome 17 (FTDP-17) and manifest clinically as either dementia-dominant or
parkinsonism-dominant types with different levels of atrophy in the frontotem-
poroparietal part or basal ganglia of the brain. Tau-inlusions are a feature of
about 40 % of FTLD cases while only a small minority of them additionally
bear amyloid pathology and then also present with AD-like neuropsychological
symptoms (logopenic non-fluent aphasia). In those cases, the distribution of tau-
pathology throughout the brain has also been linked to the specific clinical symp-
toms, as is has been described for AD (Goedert et al., 2012; Duyckaerts et al.,
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2009). However, whereas tau-inlcusions in FTLD have mainly been described to
contain the 4R tau-isoform, inclusions in AD have been described to contain a
mixture of 4R and 3R tau aggregated in neurofibrillary tangels (Goedert et al.,
2012; Duyckaerts et al., 2009; Goetz, 2001).
Most of the remaining cases of FTLD without tau-inclusions and cases of
FTD presenting with motor neuron disease symptoms (FTD-MND) contain pro-
teinous inclusions which stain positive for the transactive response-DNA binding
protein-43 (TDP-43), encoded by the TARDBP gene, which is linked to some
cases of FTLD and to MND. TDP-43 is a heterogenous nuclear ribonucleoprotein
(hnRNP) which (when not aggregated in the cytoplasm) acts as a transcriptional
repressor and splicing modulator (Goedert et al., 2012). Some other cases of tau-
negative FLTD contain inclusions of another protein which has been genetically
linked to familial amyotrophic lateral sclerosis (ALS), called fused in sarcoma
(FUS), which also is a DNA/RNA binding protein invovled in transcriptional
regulation. Genetically, FTLD cases not caused by mutations in the tau gene
are sometimes associated with loss of function mutations in the gene encoding
progranulin (PGRN), a secreted glycoprotein, which can act as a growth factor ac-
tivating cytokine-type signalling pathways in neurons and immune cells. PGRN
dysfunction has also been linked to the formation TDP-43 inclusions (Ahmed
et al., 2007; Muynck and Damme, 2011). Other genes linked to FTLD include
valosin-containing protein (VCP) which is involved in autophagosome formation
and the charged multivesicular body protein 2B (CHMP2B), which is also part
of the cellular response against aged/unfolded endocytic proteins by acting in
the endosomal-sorting complex required for transport-III (ESCRT-III) (Goedert
et al., 2012). In summary, while some overlap exists between FTLD and AD
44
CHAPTER 1. INTRODUCTION
in terms of tau-pathology and clinical and anatomical manifestation, different
pathological mechanisms underlie most of the pathological features of both dis-
eases. Figure 1.10 summarises the different variants of frontotemporal dementia
and classifies them according to knowm mutations and protein inclusions.
Figure 1.10: Types of frontotemporal dementia. There are four subtypes of FLTD
(FTLD-Tau, FTLD-TDP, FTLD-FUS, and FTLD-UPS), based on the major compo-
nents of the pathological deposits that can be detected (tau, TDP-43, FUS and un-
known protein only identified by markers of the ubiquitin-proteasome system (UPS)).
FTLD-Tau and FTLD-TDP are more common than FTLD-FUS and FTLD-UPS. Tau
deposits are made of either 3R, 4R or all six (3/4R) isoforms of tau. Together, FTLD-
TDP, FTLD-FUS, and FTLD-UPS make up FTLD-U, which is characterized by the
presence of tau-negative, ubiquitin-positive inclusions. Abbreviations: PSP = progres-
sive supranuclear palsy, CBD = corticobasal degeneration, MSTD = multiple system
tauopathy with presenile dementia, AGD = argyrophilic grain disease, GGI = globular
glial inclusion, NIFID = neuronal intermediate filament inclusion disease, BIBD = ba-
sophilic inclusion body disease. Reproduced with permission from Cold Spring Harbor
Laboratory Press (Goedert et al., 2012).
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1.4 Signalling processes in AD
The activation and inactivation of various intracellular signalling pathways by Aβ
has been outlined above. Activation of JNK stress kinase signalling in particular
appears to start a self-activating cycle. JNK phosphorylation and activity is en-
hanced in AD brains (Thakur et al., 2007; Zhu et al., 2001) and can be induced
by Aβ in cell culture (Smith et al., 2005; Morishima et al., 2001; Minogue et al.,
2003). At the same time, phosphorylation of APP at Thr668 by JNK, which is
facilitated by JIP1b (Taru et al., 2002; Matsuda et al., 2001; Scheinfeld et al.,
2002; Colombo et al., 2009) can enhance cleavage of APP by BACE1 (Lee et al.,
2003; Colombo et al., 2009; Selkoe et al., 1996). Interestingly, a signalling com-
plex containing APP, the MAP3K ASK1, JIP1 and JNK1 has been identified in
neuronal cell cultures undergoing a metabolic stress response and in an mAPP
transgenic mouse model (Galvan et al., 2007). It is not surprising then that the
presence of phosphorylated JNK in the brains of AD patients correlates with the
detection of intraneuronal Aβ accumulation (Shoji et al., 2000).
An important observation is also that many of the molecules activated or de-
fective in AD (PDK, Akt, GSK3) are involved in insulin/insulin-like growth factor
(IGF) signalling and are critical for the normal network function and survival of
neurons. This feeds in with type II diabetes being one of the strongest risk factors
for AD (Leibson et al., 1997; Cole et al., 2007). In fact, the IGF-receptor itself and
its adaptor molecules insulin-receptor substrate (IRS) 1 and 2 have been found to
be affected in late-onset AD and AD patients also tend to have aberrant insulin
levels in CSF and plasma, pointing towards a potential insulin-insensitivity (re-
viewed in Hoelscher (2011); Cole et al. (2007)). The underlying reasons for these
46
CHAPTER 1. INTRODUCTION
changes are not yet known, but attempts to translate diabetes treatments into
approaches for managing AD have been made. Stimulation of insulin signalling,
for example by using troglitazones, ω-3 fatty acids, exercise and caloric restriction
(Cole et al., 2007) has been suggested. Similarly, direct modulation of cell survival
signalling via glucagon-like peptide (GLP) and glucose-dependent insulinotropic
polypeptide (GIP), which is also used for diabetes treatment (Hoelscher, 2011),
have been considered as options for AD treatment and such stimulation has al-
ready been shown to protect cell cultures from Aβ toxicity (Wei et al., 2002).
Notably, signalling downstream from the IGF-1 receptor has also been associ-
ated with a switch from the NGF-receptor TrkA towards its co-receptor p75NTR,
which is observed in mouse models during aging and controls levels of Aβ produc-
tion via BACE1. Experiments have shown that IRS2, PI3K/Akt and ceramide
production were involved in the signalling cascade and interestingly, caloric re-
striction could prevent these age-related changes, which further validates the role
of insulin-signalling in these processes (Costantini et al., 2006, 2005). It is not
yet clear how these findings relate to the situation in the aging human brain and
to the potential insulin-insensitivity in AD sufferers.
1.4.1 Dysregulation of calcium mediated processes in AD
Ca2+ is the most important second messenger in the cell, controlling a large
number of processes via calcium-binding proteins (such as calmodulin, calbindin,
calcineurin, calpain) and a resting concentration of 100 nM is therefore usually
maintained. It is known that calcium levels in the cell have a reciprocal rela-
tionship with amyloid pathology, which can lead to a positive feedback of an
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increasingly disturbed calcium-homeostasis and amyloid production (Berridge,
2010). Aβ can lead to pathological increases in the intracellular calcium con-
centration by affecting the internal stores the mitochondria (see below) and the
ER (at InsP3 and ryanodine receptors, reviewed in Berridge (2010)) or via cell
surface receptor calcium channels, such as the NMDA-R (Verdier et al., 2004;
Pellistri et al., 2008; Zempel et al., 2010; Mattson et al., 1992). Decreased levels
of the calcium buffer protein calbindin and elevated levels of the calcium de-
pendent serine-phosphatase calcineurin and the kinase calpain, possibly due to
AICD modulated gene expression in AD brain and AD animal models, have also
been reported (Berridge, 2010). On the other hand, calcium signals influencing
calpain can also regulate Aβ production through BACE1 as mentioned before
(Liang et al., 2010).
An important player in mitochondrial dysfunction and calcium-homeostasis
is the mitochondrial permeability transition pore (mPTP) (Figure 1.11). The
mPTP is a non-specific pore consisting of proteins in the inner and outer mito-
chondrial membranes and plays a central role in neuronal cell death in response
to oxidative and other cellular stresses (Halestrap, 2009; Leung and Halestrap,
2008). Opening of this pore collapses the membrane potential due to the uncou-
pled release of H+ and influx of water from the cytosol causing mitochondrial
swelling. This also facilitates the leakage of ROS from the electron-transport
chain and can amplify apoptotic mechanisms by releasing Ca2+ as well as pro-
apoptotic proteins from the intermembrane space (Halestrap, 2005). Opening
of the mPTP is also thought to be behind very transient superoxide flashes in
single mitochondria throughout the cell, which can be observed at a higher fre-
quency during hypoxia and might therefore be an indicator of cellular stress
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(Wang et al., 2008). The mPTP is believed to comprise of, at least, the adenine
nucleotide translocase (ANT) and possibly the mitochondrial phosphate carrier
(Basso et al., 2008) in the inner mitochondrial membrane, the voltage dependent
anion channel in the outer membrane, as well as cyclophilin D (CypD) in the
mitochondrial matrix (Leung and Halestrap, 2008; Halestrap, 2005) (see Figure
1.11). It is interesting to note that there is data suggesting a higher suscepti-
bility towards mPTP formation in mitochondria from brain regions which are a
more vulnerable during ischemia (hippocampus > cortex > cerebellum) and that
this correlates with a lower adenine nucleotide content in these regions (Friberg
et al., 1999). Higher vulnerability was also detected in synaptic mitochondria
in comparison to mitochondria from other compartments of the cell (Du et al.,
2010) and this could serve as an explanation for the selective damage of synapses
in the hippocampus and cortex of the brain during aging and cellular stress. An
important link between the mPTP and AD in particular is that CypD acts as a
binding site for Aβ in mitochondria (see Section 1.4.4).
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Figure 1.11: The mitochondrial permeability transition pore (mPTP). The formation
of the pore containing the adenine nucleotide transporter (ANT) and the mitochondrial
phosphate carrier (PiC) in the inner mitochondrial membrane (IMM) and the voltage
dependent anion channel (VDAC) in the outer mitochondrial membrane (OMM) is
promoted by high levels of calcium (Ca2+) and dependent on the presence of cyclophilin
D (CypD). mPTP formation causes the release of calcium and disturbs the membrane
potential due to the eﬄux of protons (H+) from mitochondria, which can cause necrosis.
Mitochondrial swelling happens due to influx of water (H2O) and results in the release
of apoptotic proteins from the intermembrane space. Reproduced with permission from
Portland Press (Muirhead et al., 2010)
1.4.2 The location and species of intracellular amyloid
In agreement with the proposed location of the β-secretase which initiates the
amyloidogenic processing, the secretory and the endosomal compartments have
been found to be the main sites of Aβ production within the cell (Selkoe et al.,
1996; Khvotchev and Sudhof, 2004). Some familial forms of AD associated with
mutations in APP such as the Swedish mutation APPK595N/M596L, have been
found to cause an increase of Aβ production in the secretory pathway (Martin
et al., 1995; Haass et al., 1995). Likewise, Aβ produced in cells during over-
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expression of wild-type APP is produced in the secretory pathway (Khvotchev
and Sudhof, 2004), while cleavage of endogenous APP does not seem to take
place there under normal conditions (Selkoe et al., 1996). This means that any
pathological mechanism leading towards a strong increase in APP translation or
modification of APP can shift Aβ production towards the Golgi or TGN. However,
this might not be what is happening in all cases of AD, especially not late-onset
AD, where e.g. targeting of APP to lipid rafts at the cell surface or BACE1
expression/activity itself could be affected first. The decrease of of sortilin-1 ex-
pression, which has been associated as a risk factor for late-onset AD (Rogaeva
et al., 2007; Zhao et al., 2007; Dodson et al., 2008) also points towards a role of
the endosomal compartment in these cases. Missorting of APP to the endosomal
pathway, rather than its recycling by sortilin-1 could facilitate its accumulation
and processing there (Andersen et al., 2005). Figure 1.12 summarises the various
sites inside the cell where APP and Aβ can be found and the consequences of
Aβ accumulation in these compartments, which will be described in more detail
in the remainder of this section. It also highlights the best studied interaction
partners of Aβ inside the cell.
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Figure 1.12: Intracellular amyloid and its effects. APP is synthesised in the ER and
transported to the Golgi complex and TGN, where secretases are present and can pro-
cess APP in the TGN to produce Aβ (1). Excess secreted Aβ contributes to plaque
formation (2) and can also be taken up by the cell by endocytosis (3) and be found in
endosomes, lysosomes and multivesicular bodies (MVB). Unprocessed APP travels to
the plasmamembrane and can also be endocytosed and processed by β- and γ-secretase
in the endosomal compartment (3). Endosomal Aβ (4) is important for plaque forma-
tion and causes disturbance of protein recycling and degradation. It can also impair
vesicle integrity and cause cell stress through the leakage of “aged” proteins, lysosomal
enzymes as well as Aβ itself. Cytosolic Aβ (5) can interact with other proteins and dis-
turb ROS turnover and cell signalling processes. APP with its dual targeting sequence
can reach the mitochondria and interfere with the mitochondrial import machinery (6).
Cytosolic or locally produced Aβ can be imported into mitochondria and interact with
parts of the electron transport chain (7), causing ROS production and disturbing ATP
synthesis. In the matrix, Aβ can bind to ABAD (8) and interfere with its function.
It can also bind to CypD (9), cause its translocation to the inner membrane and the
opening of the mPTP. MAM: mitochondria associated membranes.
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1.4.2.1 Aβ in endosomes and lysosomes
A large amount of evidence points towards the endosomal/lysosomal compart-
ment as an important pathological site in late-onset AD, either by way of amy-
loid production or endocytosis. Experiments have demonstrated recently that
in vitro plaque formation induced by the addition of exogenous Aβ requires the
presence of cells capable of endocytosis and is accompanied by the leakage of
fibrillar amyloid from multivesicular bodies (MVBs) (Friedrich et al., 2010). Up-
take of Aβ added to the culture medium by receptor mediated endocytosis had
been previously demonstrated, where it competed with ApoE for its LDL recep-
tor with the help of cell surface glycoproteins (Winkler et al., 1999). Another
Aβ binding receptor, which like the LDL-R is involved in transport processes
through the blood–brain barrier is the receptor for advanced glycation end prod-
ucts (RAGE) (Deane et al., 2003, 2004). Finally, the α7 containing nicotinic
acetylcholine receptor (α7-AChR) has been shown to help its receptor mediated
endocytosis (Nagele et al., 2002; Wang et al., 2000). Once in endosomes, Aβ is
believed to be able to damage them causing leakage from endosomes and lyso-
somes (Umeda et al., 2011; Zhang et al., 2002; Yang et al., 1998). MVBs are
derived form early endosomes by membrane-invagination and acidification of the
lumen. They are critical structures for the ubiquitin dependent recycling and
degradation of membrane proteins and the silencing and recycling of cell surface
receptors. The presence of Aβ in MVB has been implicated in the inhibition of
the ubiquitin-proteasome system, disturbing the activity of membrane receptors
and leading to the accumulation of ”aged” proteins (Almeida et al., 2006). Aβ
has also been found to accumulate in MVBs in transgenic animals and in the
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human AD brain, especially in the post-synaptic compartment (Takahashi et al.,
2002). The ability to impair the integrity of vesicular membranes can explain the
presence of Aβ in the cytosol and interaction with cytosolic proteins (see below).
1.4.2.2 Mitochondrial Aβ
Another site of intracellular Aβ accumulation is the mitochondria. This location
of Aβ was first described by Lustbader et al. (2004), who confirmed the interaction
of Aβ with amyloid binding alcohol dehydrogenase (ABAD) and demonstrated
their co-localisation inside the mitochondrial matrix in the human AD brain by
immunoelectron microscopy. These findings were confirmed by other groups,
for example Caspersen et al. (2005), who detected Aβ accumulation in the mi-
tochondria of mAPP transgenic mice and brains from AD patients, which was
more pronounced than in non-transgenic mice and brains from non-demented
subjects. In agreement with previous studies, they found Aβ40 and Aβ42 co-
localising with the mitochondrial matrix chaperone Hsp60 by immunoelectron
microscopy and western blot analysis, although Aβ42 appeared to be the more
abundant form (Caspersen et al., 2005). There has however been some contro-
versy regarding these findings as Hansson Petersen et al. (2008) found Aβ only
associated with the inner mitochondrial membrane but not the soluble (matrix)
fraction in mitoplasts produced by osmotic shock (to remove the outer mitchon-
drial membrane and contaminating microsomal membranes) (Hansson Petersen
et al., 2008). Whatever the submitochondrial location, most evidence has so far
pointed towards a solely pathological role of the accumulation of Aβ within the
mitochondria. A recent comparison of mitochondria from different brain regions
in mAPP transgenic animals revealed that synaptic mitochondria are affected
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by Aβ accumulation and impaired function earlier than mitochondria from other
parts of the cell and before the onset of extracellular Aβ accumulation (Du et al.,
2010). The synaptic pool of mitochondria also exhibited a lower threshold for
mPTP formation, more oxidative stress and a more pronounced decline in res-
piratory function (Du et al., 2010), which could underlie a selective failure in
synaptic transmission during the early stages of AD pathology. As descibed in
Section 1.4.4, recent findings support the idea that specific interactions of Aβ
with the mitochondrial proteins ABAD (amyloid-binding alcohol dehydrogenase)
and CypD (cycolphilin D) could be important for Aβ induced mitochondrial dys-
function.
The origin of mitochondrial Aβ: There is experimental evidence for the
local production as well as the import of Aβ from the cytosol as possible expla-
nations for its occurrence in mitochondria. As outlined below, it is likely that
both mechanisms are taking place.
APP can be targeted to mitochondria in cell culture systems and in the hu-
man brain due to its chimeric N-terminal targeting sequence, which causes the
protein to translocate to the ER or the mitochondria (Anandatheerthavarada
et al., 2003; Devi et al., 2006). This dual-targeting mechanism has previously
been observed for other proteins (Anandatheerthavarada et al., 1999), however
in the case of APP, co-staining, immunoblot and immunoprecipitation experi-
ments only detected APP in a transmembrane-arrested form in contact with the
mitochondrial translocases in an N-in C-out orientation (Anandatheerthavarada
et al., 2003). Accordingly, this was associated with mitochondrial dysfunction
(Devi et al., 2006) and interestingly, a correlation was noticed in AD patients be-
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tween the amount of transmembrane arrested APP and the presence of the ApoE
4 allele (Devi et al., 2006). The reason for this is unknown, but no physiological
function of APP in mitochondria has so far been described, indicating that its
presence there might be due to a missorting event, where altered cholestrol levels
influencing membrane composition might play a role as well. This would be diffi-
cult to correct as mitochondria do not take part in normal antero- and retrograde
vesicular traffic in the cell.
In support of the concept of local production of Aβ is the detection of all
the components of the γ-secretase complex in mitochondria by immunoelectron
microscopy (Hansson et al., 2004). However, a full explanation of the mechanism
of mitochondrial cleavage of APP is still outstanding. β-Secretase, which is also
crucial for Aβ production, has not been found in association with mitochondria.
In addition, the topology of APP detected in mitochondria with the Aβ region
located in the intermembrane space as reported by Anandatheerthavarada et al.
(2003), would not be suitable for cleavage by the γ-secretase complex, which is
an intramembrane cleaving protease.
One possibility around this topological problem would be the cleavage of APP
by both secretases in mitochondria associated membranes (MAMs). These mem-
brane compartments represent close contact points between the ER and mito-
chondria (Rusinol et al., 1994), where lipids and membrane proteins are thought
to be exchanged directly between the organelles (Stone et al., 2009). Of note,
presenilin 1 and 2 have been detected in this compartment (Area-Gomez et al.,
2009) and the presence of active β-secretases in the secretory pathway (and hence
also the ER) has been previously demonstrated (Khvotchev and Sudhof, 2004;
LaFerla et al., 2007). Notably, dynamin like protein 1 (DLP1; also known as
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Drp1) and mitofusin 1 and 2 (Mfn1/2), which are normally involved in mitochon-
drial fission and fusion processes, and are thought to modulate MAMs (Giorgi
et al., 2009), have been reported to be down-regulated in AD (Wang et al., 2009).
This could affect MAMs and cause changes in the way lipids and proteins, includ-
ing APP, are distributed between the ER and mitochondria. The current data
therefore supports two possible pathways. Firstly, APP might be fully cleaved
while residing in the ER membrane and Aβ would subsequently be transported
into mitochondria from the cytosol. Secondly, β-cleaved APP from the ER could
transported to the mitochondrial outer membrane alongside other proteins and
lipids in MAMs and then be cleaved by the γ-secretase in the mitochondrial
membrane, thereby releasing Aβ directly into mitochondria.
In keeping with the first possibility, direct import of Aβ from outside the
cell through the cytosol into mitochondria via the translocase system has been
demonstrated (Hansson Petersen et al., 2008). Aβ has consequently been found
within the mitochondrial cristae associated with the inner mitochondrial mem-
brane and import of Aβ was independent of the mitochondrial membrane poten-
tial and involved the transporters of the outer membrane TOM20, TOM40 and
TOM70 (Hansson Petersen et al., 2008). It is significant that this study found
Aβ in mitochondrial preparations from in vivo human brain biopsies from non-
demented patients, although it was present at lower levels compared to samples
from demented patients (Hansson Petersen et al., 2008). Genetic studies have
also produced evidence for a link between the mitochondrial import machinery
and AD (Bekris et al., 2009; Yu et al., 2007). A single nucleotide polymorphism
(SNP) in the TOM40 gene on chromosome 19 directly next to the APOE gene is
linked to an increased risk for AD. However, the effect of this SNP on the TOM40
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protein has not been explained so far.
Aβ degradation in mitochondria: Unlike in other compartments, there
is evidence that Aβ can be rapidly degraded inside mitochondria, which could
explain why it has been challenging to detect it in this location before. PreP is a
thiol-sensitive metalloprotease located in the mitochondrial matrix, which is able
to rapidly degrade Aβ (Falkevall et al., 2006). Another Aβ-degrading enzyme,
the insulin degrading enzyme (IDE), has also been genetically linked to late-onset
AD (Vepsalainen et al., 2008; Qiu et al., 1998) (see Section 1.1.2).
1.4.3 Mitochondrial dysfunction and dementia
Mitochondria take centre stage in the cellular metabolism. They contain the en-
zymes responsible for the β-oxidation of fatty acids as well as those making up the
tricarboxylic acid (TCA) cycle and the electron transport chain for ATP produc-
tion; they regulate the cellular Ca2+ homeostasis with the help of their powerful
membrane potential, are involved in free radical (ROS) production and play an
important role in the execution of apoptosis. For neurons, which are highly po-
larised cells with a high energy demand and rely on the efficient regulation of local
currents and Ca2+ signals, mitochondria are vital. They play a key role together
with the ER in the buffering of local calcium signals produced, for example at
the NMDA and AMPA receptor ion channels during synaptic transmission. A
link between the dysfunction of mitochondria and neurodegenerative conditions
such as AD has therefore been recognised (Beal, 1995; Bowling and Beal, 1995).
Bioenergetic deficits which can be measured in dementia patients using FDG-PET
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(Foster et al., 1983; Duara et al., 1986) are also an indicator of problems involv-
ing mitochondria. Due to the proximity of mitochondrial DNA to ROS naturally
produced in the electron transport chain, their DNA is prone to accumulation
of mutations over time, which can cause increasing mitochondrial dysfunction
and higher production of ROS with age (Richter et al., 1988; Liu et al., 2002).
Accordingly, levels of the mitochondrial manganese-dependent isoform of super-
oxide disumutase (Mn-SOD), which is an important enzyme for the control of
mitochondrial oxidative stress, have been linked to levels of amyloid-pathology
and memory deficits in AD mouse models (Li et al., 2004; Dumont et al., 2009).
Data demonstrating the impairment of specific mitochondrial enzymes in AD has
also been produced. Parker et al. found reduced cytochrome C oxidase (COX)
activity in platelets (Parker et al., 1994a) and the brains (Parker et al., 1994b)
of AD patients and these findings were later confirmed by Cottrell et al. (2001).
Diminished activity of the α-ketoglutarate dehydrogenase complex has also been
found in association with AD (Gibson et al., 1999) and Bubber et al. (2005) sub-
sequently measured the activity of other TCA cycle enzymes and confirmed the
previous finding. This analysis also revealed a significant reduction in the activ-
ities of the pyruvate dehydrogenase complex and the isocitrate-dehydrogenase in
AD brains (Bubber et al., 2005).
1.4.4 Intracellular binding partners of APP and Aβ
In order to understand the implications of the presence of intracellular Aβ for
the development of AD, it is of interest to consider its interaction partners. A
number of studies suggest direct interactions of mono- or oligomeric Aβ with in-
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tracellular proteins and these specific interactions are likely to be critical events
in AD, as they might represent early steps in the development of this disorder.
Interestingly, some data suggests that not only the oligomerisation state but also
the intracellular concentration of Aβ can determine which pathways are activated.
For example, plasmids leading to the expression of APP with FAD mutations that
cause moderate production of Aβ have been found to activate cAMP-response
element (CRE) regulated gene expression, while this response was not observed
when high levels of Aβ were produced (Arvanitis et al., 2007).
Phosphoinositide dependent kinase (PDK): As mentioned before, in-
volvement of the PDK/Akt kinase pathway in AD had been suggested (Ryder
et al., 2004). Lee et al. investigated the effect of Aβ on the expression and
activity of PDK and its target Akt and demonstrated the inhibition of this sig-
nalling cascade by Aβ in vitro and the dissociation of Akt from PDK in the
human AD-affected brain (Lee et al., 2009). Their study also revealed an in-
creased association of Aβ with Akt and PDK in Aβ exposed cell cultures by
co-immunoprecipitation and western blotting (Lee et al., 2009), although this ef-
fect could also be mediated by scaffolding proteins, as no direct binding studies
with PDK or Akt and Aβ were performed.
Superoxide dismutase (SOD1): The Cu/Zn dependent SOD1 is a cru-
cial enzyme in the cellular response to oxidative stress in the cytosol, which is
known to be associated with neurodegeneration and memory deficits (Butterfield
et al., 2001; Liu et al., 2002). A specific interaction between Aβ and SOD1 has
been shown in a human neuroglioma cell line by co-immunoprecipitation and
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co-localisation and this interaction resulted in the inhibition of SOD1 activity
in vitro (Yoon et al., 2009). Interestingly, GFP-tagged Aβ and SOD1 eventually
co-localised in aggregates in the perinuclear region of cells (Yoon et al., 2009) and
similar Aβ aggregates have recently been reported to correlate with the attenua-
tion of the actions of the proteasome and lead to apoptosis in neuronal cells (Park
et al., 2009). Aggregates of SOD 1 have also been detected in brain tissue affected
by AD and PD and SOD1 has also been found to be significantly up-regulated
in these brains (Choi et al., 2005). Significantly, an oxidative modification of
SOD1 on a Cys-residue was identified during this study, which is also relevant
for the pathogenesis of amyotrophic lateral sclerosis (ALS) (Choi et al., 2005),
potentially pointing towards common pathological mechanisms in these diseases.
Catalase: Catalase is another enzyme in the cellular defence against oxida-
tive stress, which degrades H2O2 in peroxisomes and mitochondria and has been
shown to interact with Aβ. Evidence has been brought forward for this by in
vitro experiments with biotinylated Aβ peptides, which inhibited catalase activ-
ity (Milton, 1999; Milton and Harris, 2009). Narrowing in on the mechanism
of this inhibition, it was reported that inhibition could be achieved by Aβ42
and Aβ(25-35) but not by Aβ(12-28) peptides, suggesting that the hydrophobic
stretch in the peptide is needed. The inhibition was also observed in cell cultures
and caused cytotoxicity which was aggravated by addition of 3-aminotriazole, a
known inhibitor of catalase activity (Milton, 2001).
Amyloid binding alcohol dehydrogenase (ABAD): The most charac-
terised intracellular Aβ binding protein has been ABAD. ABAD (also known as
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ER-associated amyloid-binding protein (ERAB)) was first identified as an Aβ
interaction partner using a yeast two-hybrid screen (Yan et al., 1997). ABAD
acts as a short chain dehydrogenase/reductase (SDR) and catalyses the second
step in the β-oxidation of fatty acids (He et al., 1998), thereby helping to pro-
duce energy through NAD+ reduction and its activity has also been shown to
protect cells against the effects of the toxic aldehydes 4-hydroxynonenal (HNE)
and malondialdehyde (MDA) (Murakami et al., 2009). Studies in cell cultures
as well as the brain showed that ABAD localises inside mitochondria as well as
the ER (Yan et al., 1997; Oppermann et al., 1999; He et al., 1999; Frackowiak
et al., 2001). In mouse brain, ABAD protein levels have been found to be ele-
vated during the cellular response to glucose deprivation and hypoxia (Yan et al.,
2000) and expression is also increased in brains from AD sufferers compared to
non-demented controls (Yan et al., 1997).
Binding of a minimal sequence comprising amino acids 12–24 of Aβ to ABAD
was found to inactivate its activity towards its usual substrates (Oppermann
et al., 1999; Yan et al., 1999) and, interestingly, to enhance Aβ toxicity (Yan et al.,
1997; Takuma et al., 2005), indicating that factors other than just binding and
inhibition of ABAD were at play. Apoptosis and DNA fragmentation were greatly
enhanced in COS cells exposed to Aβ when they overexpressed ABAD (Yan et al.,
1997) and in neuroblastoma cells co-transfected with mAPP and ABAD plasmids
compared to those transfected with mAPP or ABAD alone (Yan et al., 1999).
The presence of ABAD and Aβ together also resulted in increased production
of MDA and HNE (Yan et al., 1999) and consequently, addition of anti-ABAD
antibodies abolished the negative effects of Aβ in the human neuroblastoma cells
(Yan et al., 1997). Notably, an enzymatically inactive ABAD mutant expressed
62
CHAPTER 1. INTRODUCTION
in cell cultures could bind Aβ with similar affinity compared to the wild-type
enzyme but was unable to enhance Aβ toxicity like active ABAD (Yan et al.,
1999). ABAD also redistributes from its location inside the ER and mitochondria
towards the plasma membrane in response to Aβ exposure (Yan et al., 1997, 1999)
but the implications of this relocation have not yet been explained.
The toxic effect of increasing levels of ABAD together with Aβ has also
been confirmed in an AD mouse model. Compared with neurons from non-
transgenic mice and mice overexpressing ABAD or mAPP alone, cortical neurons
cultured from mice mAPP/ABAD double transgenic mice exhibited higher lev-
els of H2O2, impaired mitochondrial function and increased cell death (Takuma
et al., 2005). Exacerbated mitochondrial dysfunction was also detected in these
mAPP/ABAD double transgenic animals in vivo (Takuma et al., 2005). More-
over, the mAPP/ABAD transgenic animals presented with deficits in spatial and
temporal memory and performed worse than non-transgenic mice as early as 4–5
months of age even before such deficits could be observed in mAPP single trans-
genic animals (Lustbader et al., 2004).
Cyclophilin D (CypD): Recently, another major interaction site for Aβ has
been found within mitochondria. CypD is a peptidylprolyl isomerase F found in
the mitochondrial matrix and during times of oxidative stress, it translocates to
the inner mitochondrial membrane during the opening of the mPTP (Connern
and Halestrap, 1994). By isomerising peptide bonds containing proline, it usually
assists in the folding of other proteins (Schiene-Fischer and Yu, 2001; Freeman
et al., 1996) and is thought to have this same function during mPTP formation
and opening of the pore. Accordingly, genetic deficiency in CypD hinders opening
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of the mPTP (Baines et al., 2005) and protects cells from Ca2+ and oxidative
stress-induced death (Schinzel et al., 2005; Basso et al., 2005).
CypD levels have been found to be increased in an mAPP transgenic mouse
model as well as in the human AD brain and this study also demonstrated that
CypD can bind Aβ, especially oligomeric Aβ42 (Du et al., 2008). An association
of Aβ with the inner mitochondrial membrane had been suggested by other groups
(Hansson Petersen et al., 2008; Devi et al., 2006) and accordingly, Du et al. con-
firmed the co-localisation of CypD and Aβ in mitochondria by immunoelectron
microscopy. Importantly, their study also revealed that the association between
CypD and Aβ was increased in human AD brains and mAPP transgenic animals
compared to controls (Du et al., 2008) and this resulted in enhanced transloca-
tion of CypD to the inner mitochondrial membrane, mPTP opening and increased
ROS production causing cell death (Du et al., 2008; Singh et al., 2009). Conse-
quently, neurons from the cortices of CypD deficient mAPP transgenic animals
(Ppif−/−/mAPP) were immune against cell death caused by oxidative stress (Du
et al., 2008, 2009) and mitochondria isolated from the cortices of Ppif−/−/mAPP
transgenic mice were resistant to Aβ, Ca2+ induced swelling and opening of the
mPTP (Du et al., 2008, 2009, 2011). Also, Ppif−/−/mAPP transgenic animals
performed better in learning and memory tests and exhibited less reduction of
LTP compared to their Ppif+/+ littermates at 12 (Du et al., 2008, 2009) and
24 months (Du et al., 2011) of age. Thus, the Aβ dependent activation of the
mPTP directly links CypD to the cellular and synaptic perturbation relevant to
the pathogenesis of AD.
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1.4.5 Cellular consequences of the Aβ–ABAD interaction
Proteomic analysis has identified the increased expression of specific proteins
in the brains of ABAD/mAPP transgenic animals, hinting at a more complex
network of downstream effects resulting from the interaction of ABAD with Aβ.
The expression of peroxiredoxin-2 (Prx-2), a cytosolic enzyme which is part
of the defence against protein associated peroxides, was found to be increased
inmAPP transgenic and ABAD/mAPP double transgenic mice. Further analysis
of ABAD/mAPP transgenic brains and human AD brains by western blotting and
immunocytochemistry confirmed the increased expression of Prx-2 in the cerebral
cortex (Yao et al., 2007). Overexpression of Prx-2 in cortical neurons was able to
decrease Aβ toxicity, suggesting that its up-regulation in AD plays a protective
role (Yao et al., 2007). Notably, Prx-2 has also been linked to Parkinsons disease
(PD), where it was found to be phosphorylated and inactivated by CDK5 with
its activator p25 although its expression levels remained normal (Qu et al., 2007).
Similar to its effect in AD models, overexpression of Prx-2 in in vitro and in vivo
models of PD protected against neuronal loss (Qu et al., 2007). In the light of
these findings, the consequences of Prx-2 up-regulation in AD and its association
with ABAD still require a more detailed investigation.
In a related study, endophilin A1 (Ep-1), was also identified as being up-
regulated in ABAD/mAPP transgenic mice compared with ABAD transgenic
and non-transgenic littermates (Ren et al., 2008). Ep-1 up-regulation was then
also found in the hippocampus and cortex of ABAD/mAPP transgenic animals
and in the temporal cortex of human AD brains by western blotting and immuno-
histochemistry (Ren et al., 2008). Ep-1 is a mainly presynaptic protein, which
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has been known for its involvement in synaptic vesicle endocytosis (Ringstad
et al., 1999). Research has also exposed a function of Ep-1 in the activation of
c-jun N-terminal kinase (JNK) in cell lines (Ramjaun et al., 2001). The role of
JNK-activation in AD pathogenesis has been explained in the beginning of this
section and Ren et al. (2008) went on to show that Ep-1 overexpression is able
to cause an increase in JNK activity and cell death in primary neuronal cultures.
Thus, the increase in Ep-1 expression found in the AD brain could be another
mechanism for the activation of the JNK signalling pathway but details of this
have not been explained yet.
An important finding during further analysis of the observed proteomic
changes was that the reported increases in Ep-1 as well as Prx-2 were directly
due to the binding of ABAD and Aβ. Interfering with their interaction in liv-
ing animals using a decoy peptide approach resulted in the expression of these
proteins to be returned to normal (Ren et al., 2008; Yao et al., 2007). Using a
similar approach, Yao et al. demonstrated that the behavioural deficits, which
are exacerbated in the mAPP/ABAD transgenic mice compared to single trans-
genic animals (Yan et al., 1997; Takuma et al., 2005), are also alleviated by the
treatment with this decoy peptide or the expression of a transgene encoding its
sequence (Yao et al., 2011). This emphasises the importance of the ABAD–Aβ
interaction in vivo and underlines its suitability as a drug target for the treatment
of AD (Borger et al., 2011; Muirhead et al., 2010).
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1.5 Conclusions
Despite a large effort in neurodegeneration research in recent years, the search
for new truly disease modifying therapies for AD has so far not been successful.
This is mainly due to a lack of understanding of the precise intracellular events
that lead up to neuronal dysfunction in early and in late stages of the disease. An
increasing awareness of the complex interactions between signalling pathways in
AD, has led to the opening of new promising research avenues which are focused
on the stabilisation of the neuronal networks during aging, the reduction of Aβ
production and its clearance and the interactions of Aβ with intracellular targets.
However, detailed knowledge of the intracellular situation will again be crucial in
order to validate their effectiveness and assess potential long-term side effects of
new innovative AD therapies.
1.6 Aims of this project
The aim of the research carried out for the production of this thesis was to
investigate the cellular effects of proteins whose expression has been found to be
increased in AD.
Firstly, the effects of endophilin-1 and peroxiredoxin-2, which are both up-
regulated in response to the ABAD–Aβ interaction in neurons were investigated.
To this aim, either protein was over-expressed in mouse primary cortical neurons
and cell survival and the activation of the JNK-signalling cascade were assessed
under different conditions.
Secondly, the role of the novel calcium-binding protein EFHD2 (EF-hand domain
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family, member D2) was studied in cell cultures and primary neurons as a poten-
tial link between amyloid and tau pathologies and its expression in brains from
patients with and without dementia (AD and FTLD) was further investigated.
Finally, the protein and mRNA expression levels of Ep-1, Prx-2, ABAD and
APP were investigated in human brains affected by dementia compared to non-
demented controls. This was compared to the expression of these proteins in
different mouse models for neurodegenerative diseases. It was hoped that this
approach would shed new light on the roles of ABAD, Ep-1, Prx-2 and EFHD2
in neuronal cells and on the neuronal network as whole and lead to a character-
isation of the biochemical processes that take place in the human brain affected
by dementia.
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2.1 Biochemical Methods
2.1.1 Protein extraction
2.1.1.1 Protein extraction
Small pieces (approximately 300 mg) of human brain tissue or mouse brain were
broken up in a reaction tube on ice using micropistilles and 1 mL pipette tips after
adding 5 volumes of lysis buffer (8.27 M urea, 4.7%(w/v) CHAPS, 1%(w/v) DTT,
2.5 mM phenylmethylsuflonylfluoride (PMSF)), supplemented with protease in-
hibitors (Roche, Burgess Hill, UK). Homogenised samples were then centrifuged
at 13,000 × g for 10 min. The supernatant containing the protein extract was
removed and the protein concentration was measured using Bradford reagent.
100 µl aliquots were snap frozen in liquid nitrogen and stored at -80 ◦C.
Protein from cell cultures grown in 35 mm dishes was extracted using the same ly-
sis buffer. The culture medium was removed and dishes were washed 2 times with
ice cold PBS (10 mM Na2HPO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4, Sigma) be-
fore addition of 150–200 µl of ice cold lysis buffer. The cells were collected with a
cell scraper, transferred to 1.5 mL reaction tubes and homogenised using a 200 µl
pipette tip. Samples were centrifuged at 13,000 × g for 10 min. A Bradford test
was performed to measure the protein concentration and the supernatant was
snap frozen in liquid nitrogen and stored at -80 ◦C.
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2.1.1.2 Extraction of phosphorylated proteins
If the phosphorylation state of proteins had to be maintained, cells and tissue
samples were extracted as soon as possible following the dissection of the tissue
sample and kept on ice at all times. Protein extracts were produced by addition
150–200 µl ice cold phospho-extraction buffer (50 mM Tris, 100 mM EGTA, 1 mM
EDTA, 1% Triton-X-100, 1 mM Na3VO4, 50 mM NaF, 5 mM Na-PPO4, 207 mM
sucrose, 0.1% beta-mercaptoethanol, 2.5 mM PMSF; (all chemicals from Sigma,
Gillingham, UK)) supplemented with protease inhibitors (Roche) to 35 mm cell
culture dishes or 5 volumes of extraction buffer to tissue samples. Samples were
homogenised using micro-pistilles and pipetting through a 1 mL pipette tip (tis-
sue) or by pipetting through a 200 µl pipette tip (cell cultures). Samples were
centrifuged at 13,000 × g for 10 min at 4 ◦C and the protein concentration in
the supernatant was measured using a Bradford test before samples were used
for SDS-PAGE and western blotting without delay.
For the extraction buffer, a 200 mM stock solution of sodium-orthovanadate
(Na3VO4) was produced and adjusted to pH 10.00. The solution was activated
by boiling it until colourless, cooling it to room temperature and adjusting to
pH 10.00 again. This procedure was repeated until the solution remained stable
and colourless at room temperature at pH 10.00.
2.1.1.3 Bradford test
The concentration of protein in extracts from tissue or cell cultures was mea-
sured by the absorbance of coomassie blue in the Bradford colorimetric assay.
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First, a standard curve was prepared by measuring the absorbance of known di-
lutions of bovine serum albumine (BSA) (0–10 µg/ml) in disposable semi-micro
cuvettes (VWR, Lutterworth, UK) at 595 nm in a UV-vis spectrometer (Shi-
madzu, Wolverton Mill South, UK). The protein concentration of appropriately
diluted samples was then estimated by comparison to the standard curve. The
protein concentrations of larger numbers of samples were measured using Brad-
ford reagent in a microplate assay. For this assay, 5 µl of appropriatedly pre-
diluted samples were distributed into the wells in duplicate and 250 µl Bradford
reagent was added and incubated for 5 min in the dark. A standard curve was
produced from known diltutions of BSA (0.2–1 mg/ml) pipetted in the same mi-
croplate.
2.1.2 SDS-PAGE
10% bis-tris polyacrylamide minigels were produced by preparing first the sepa-
rating gel (375 mM Tris pH 8.8, 1% SDS, 10% Bis-Tris acrylamide (37.5:1), 0.1%
ammoniumpersulfate, 0.04–0.08% TEMED) and then the stacking gel (125 mM
Tris, pH 6.8, 1% SDS, 4% Bis-Tris acrylamide, 0.1% ammoniumpersulfate, 0.1%
TEMED). The percentage of the separating gel was adjusted accordingly if
smaller peptides were analysed (12.5–20 %). Samples were prepared by mixing
an appropriate volume representing up to 40 µg of total protein with 4× protein
sample buffer (106 mM Tris-HCl, 141 mM Tris-Base, 4% SDS, 40% Glycerol,
0.51 mM EDTA, 4% DTT, 0.05 mg/ml bromphenol blue, pH 8.5) and denatu-
ration for 5 min at 95 ◦C. Gels were run with SDS-running buffer (25 mM Tris
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pH 8.3, 192 mM Glycine, 0.1% SDS) in a BioRad gel electrophoresis system at
120 V, 360 mA for 10 min followed by 160 V for 50 min. The prestained protein
markers P7708 or P7710 or the protein ladder P7703 (NEB, Hitchin, UK) were
separated in parallel to the samples.
2.1.3 Western blotting
Following the SDS-PAGE, the proteins were transferred to 0.2 µm supported
nitrocellulose (Whatman) by blotting for 1 h at 30 V, 360 mA in Inivtrogen
transfer buffer (25 mM Tris, 25 mM Bicine, 1 mM EDTA, 10% methanol pH 7.2)
or self-made transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol pH 8.0)
using the Invitrogen X-Cell wet-blotting system. Blotting time was increased to
1 h 15 min if two gels where transferred in the same chamber.
Protein transfer to the nitrocellulose was confirmed by staining with Ponceau
S (Sigma). After removal of the Ponceau staining by washing in TBS (50 mM
Tris, 138 mM NaCl, 2.7 mM KCl, pH 8.3), non-specific antibody binding sites
were blocked by incubating the membranes in blocking solution (50 mM Tris,
138 mM NaCl, 2.7 mM KCl, 0.1% Tween-20, 5% skimmed dried milk or 5%
BSA) for 1 h at room temperature. Primary antibodies were diluted according
to table A.1 in the appopriate blocking solution and incubated over night at 4 ◦C
either using 10 mL of diluted antibody per blot in a tray or with 3–4 mL of
diluted antibody per blot in a heat-sealed plastic foil. Excess primary antibody
was removed by washing the membranes 3 x 5 min in TBS-T (50 mM Tris,
138 mM NaCl, 2.7 mM KCl, 0.1% Tween-20). Membranes were incubated with
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the appropriate horse radish peroxidase (HRP) conjugated secondary antibodies
diluted in blocking solution according to table A.2 for 1 h at room temerature.
Immunostained bands were detected using enhanced chemiluminescence (ECL)
peroxidase substrate (Millipore, Watford, UK) by repeatedly pipetting 2 mL of
ECL mixture over the membrane for 1 min. Chemiluminescence images were
taken in a LAS3000 detector (Fuji).
If a second antigen needed to be detected, bound antibodies were removed by
washing the membrane 4 x 10 min in 10% acetic acid, followed by multiple washes
in TBS (50 mM Tris, 138 mM NaCl, 2.7 mM KCl) for appoxmiately 30 min.
Membranes were then blocked and probed with primary and secondary antibodies
as described above.
2.1.4 Small induction of bacterial protein expression
Bacterial expression plasmids were transformed into chemically competent BL21
E .coli bacteria as described in section 2.2.12 and grown over night at 37 ◦C on
LB-agar plates containing the appropriate antibiotic. Single colonies were picked
the next day and grown in 10 mL of LB medium containing the appropriate
antibiotic in a 50 mL falcon tube. On the following day, 10 mL over night culture
were expanded in 1 L of LB-medium with antibiotic at 37 ◦C in a 3 L conical flask,
shaking at 210 rpm until an OD(600 nm) of 0.5–0.9 was reached. A 1 mL sample
of the culture was then removed and the bacteria pelleted at 13,000× g for 10 min.
The pellet was then resuspended in 100 µl 1x protein sample buffer and the sample
denatured at 95 ◦C for 15 min and then left on the bench top for an analytical
gel. Protein expression was induced in the remaining 9 mL culture by addition
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of isopropyl β-D-1-thiogalactopyranoside (IPTG, Sigma) to a final concentration
of 1 mM. The culture was incubated at 25 ◦C shaking at 180 rpm for 1 h and
another analytical sample was taken. Further samples were removed after 2 h
and 4 h of induction with IPTG. The samples were then subjected to SDS-PAGE
on a 10% gel. Proteins were visualised in the gel by staining with Coommassie
blue dye. The gel was incubated in Coommassie blue stain for 10–15 min and the
staining solution was saved for re-use. Residual staining solution was removed
with tap water and the gel was transferred to a microwavable container which
was filled with tap water. Destaining was achieved by microwaving 2 times at
full power for 5–7.5 min and the water was exchanged in between.
2.1.5 Purification of His-tagged proteins
Bacterial expression plasmids for the expression of 6×His-tagged proteins were
transformed into chemically competent BL21 E .coli bacteria as described in sec-
tion 2.2.12 and grown over night at 37 ◦C. Single colonies were picked the next
day and grown over night in 10 mL LB-medium at 37 ◦C shaking at 210 rpm. On
the following day, the culture was expanded in 1 L LB medium containing the
same antibiotic and grown at 37 ◦C shaking at 210 rpm until an OD of 0.5–0.9
was reached. A 1 mL analytical sample was taken from the culture, the bacteria
pelleted and resuspended in 100 µl protein sample buffer before boiling of the
sample at 95 ◦C for 15 min. Protein expression was induced in the remaining
culture by addition of IPTG to a final concentration of 1 mM and the culture
was returned to the incubator and grown at 25 ◦C shaking at 180 rpm for 4 h.
Another 1 mL analytical sample ws taken and processed as before. The bacteria
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were harvested by centrifugation at 6500 rpm in a Beckman J2-M6 centrifuge for
10 min. The bacterial pellet was then removed from the centrifuge container and
the weight of the pellet was determined. If not used on the same day, the bac-
terial pellet was stored at -80 ◦C. For lysis, the bacterial pellet was resuspended
in 5 volumes (approximately 15 mL for a 1 L culture) of lysis buffer (50 mM
Tris, pH 8.0, 0.5 M NaCl, 100 µg/mL DNase I, 100
mg/mL lysozyme, 10% glyc-
erol, protease inhibitors without EDTA (all chemicals from Sigma)) per weight
of bacterial pellet. The resuspended bacteria were then broken up by 6 times
sonication for 10 s on ice. The lysate was cleared by centrifugation at 20,000 rpm
at 4 ◦C for 20 min in a Beckman J26 centrifuge and filtered through a 0.45 µm
syringe filter.
Proteins were then bound to Ni-NTa Agarose (QIAGEN) for purification of
the 6 × His-tagged protein. For equilibration, 2 mL of Ni-NTA agarose slurry
were transferred to a 15 mL falcon tube and spun at 500 × g for 1 min at 4 ◦C
in a Heraeus tabletop centrifuge. The supernatant was removed and 4 mL lysis
buffer were added and mixed with the agarose by inversion. The equilibrated
agarose was centrifuged again at 500 × g for 1 min at 4 ◦C and the supernatant
removed. The filtered bacterial lysate was then added to the Ni-NTA Agarose
and mixed with it by inversion. The mix was transferred to a 50 mL falcon tube
and incubated tumbling at 4 ◦C for 2 h. At the end of the incubation period, the
agarose beads were collected by centrifugation at 500 × g for 3 min at 4 ◦C and
the supernatant transferred to a fresh 50 mL tube and stored on ice for subsequent
analysis on an analytical gel. The beads were then washed 5 times with 10 mL
(≥5 × the bead volume) wash buffer (50 mM Tris pH 8.0, 0.5 M NaCl, 10 mM
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imidazol, 10% glycerol, protease inhibitors) followed by centrifugation and at 4 ◦C
and each of the wash fractions was saved and stored on ice for subsequent analysis.
Proteins were eluted from the agarose beads by 5 washes with 4 mL (2 times bead
volume) of elution buffer (50 mM Tris pH 8.0, 0.5 M NaCl, 300 mM imidazol,
10% glycerol, protease inhibitors) at 4 ◦C and all the fractions were saved again
for analysis. The protein concentration of all saved fractions was measured and
an aliquot of the samples was mixed with an appropriate amount of 4x protein
sample buffer and denatured for 10 min at 95 ◦C. 10 µl of the samples from all
fractions were then analysed by SDS-PAGE and Coommassie staining.
2.2 Molecular Cloning
2.2.1 Polymerase Chain Reaction (PCR)
PCR reactions for molecular cloning were performed as 50 µl reactions with 25 ng
template vector DNA using 2.5 U PfuTurbo polymerase (Agilent, Edinburgh),
200 µM dNTPs and 5 µl of 10x cloned Pfu reaction buffer (200 mM Tris, 20 mM
MgSO4, 100 mM KCl, 100 mM (NH4)2SO4, 1% Triton-X-100, 1
mg/ml nuclease-
free BSA). Forward and reverse primers were added to a final concentration of
0.2 µM. The reactions were performed in the presence of 5% DMSO (Sigma)
for EFHD2 cloning. The thermal cycles were run according to the protocol in
Table 2.1 in a standard PCR machine (Biometra) using an appropriate annealing
temperatures (AT) for the primers, which was determined by gradient PCR with
varying annealing temperatures.
Standard PCR reactions were performed using a Taq DNA polymerase kit from
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Step Temperature Duration [s]
1 95 ◦C 180
2 95 ◦C 30
3 AT 30 repeat 35 x
4 72 ◦C 45–60
5 72 ◦C 600
6 4 ◦C ∞
Table 2.1: Thermal cycle profile standard and cloning PCR reactions
Roche. 200 µM dNTPs, 0.8 U Roche Taq polymerase and 200 nM forward and
reverse primers (all from Invitrogen, Paisley, UK) as well as 200 ng cDNA or
25 ng plasmid DNA were added to the reaction mix containing the appropriate
amount of 10x reaction buffer (100 mM Tris-HCl, 15 mM MgCl2, 500 mM KCl,
pH 8.3) and the thermal cycles were run according to the protocol in Table 2.1.
2.2.2 Reverse transcription PCR (RT-PCR)
For reverse transcription PCR (RT-PCR) total RNA was extracted from tissue
samples using Tri-reagent (Sigma). Before starting any RNA work, all surfaces
and equipment were cleaned with autoclaved water containing 0.1% Diethylpy-
rocarbonate (DEPC, Sigma). 50–100 mg tissue was homogenised in 1 mL Tri-
reagent using a micropistille and a 1 mL pipette tip at room temperature. The
sample was then left at room temperature for 5 min for complete disintegration.
200 µl of chloroform were added per 1 mL of Tri-reagent used for the homogenisa-
tion inside the fume hood. The sample was shaken vigorously for 15 s and left at
room temperature for 2 min followed by centrifugation at 12,000 × g for 15 min at
4 ◦C. The aqueous colourless phase containing the RNA was then transferred to
a fresh reaction tube and 0.5 mL isopropanol were added per 1 mL of Tri-reagent
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used. The samples were mixed by inversion and left 5 min at room temperature
followed by centrifugation at 12,000 × g for 10 min at 4 ◦C. The RNA pellet
was washed with 1 mL 75% ethanol and centrifuged at 7,500 × g for 5 min at
4 ◦C. The RNA-pellet was then air dried and resuspended in destilled DEPC-
treated H2O by incubation at 55–60
◦C for 10 min. The RNA concentration was
measured in a spectrometer at 260 nm and the total RNA was stored at -80 ◦C.
Total RNA was digested with DNAse I. 5 U of RQI DNAse (Promega, Southamp-
ton, UK) were added to a mix of 5 µg total RNA and an appropriate amount of
10x RQI reaction buffer (Promega). The reaction mix was incubated at 37 ◦C for
45 min. 1 µl RQI DNAse Stop solution (Promega) was added per 10 µl reaction
and the mix was incubated for 10 min at 65 ◦C.
cDNA was produced from the DNAse digested RNA using the Transcriptor First
Strand cDNA Synthesis Kit (Roche) or the RevertAid Reverse Transcriptase (Fer-
mentas, York, UK). 11 µl of the digested total RNA was mixed with 2 µl of
random hexamer primers (60 µM final concentration) in a PCR reaction tube.
RNA and primers were denatured for 5–10 min at 65 ◦C. 4 µl 5x reaction buffer
(8 mM MgCl2, 50 mM Tris-HCl, 30 mM KCl final concentration, pH 8.5), 20 U
RNase inhibitor, 20 nmoles dNTPs and 10 U Transcriptor Reverse Transcriptase
or 200 U RevertAid reverse transcriptase were added to the mix and made up
to a final volume of 20 µl. The reaction mix was incubated at 25 ◦C for 10 min
followed by 30 min at 55 ◦C (Transcriptor Reverse Transcriptse) or 60 min at
42 ◦C (RevertAid reverse transcriptase). The reverse transcriptase was then in-
activated by heating to 85 ◦C for 5 min. 1 µl of the resulting cDNA was used for
PCR reactions as described above using an appropriate PCR protocol.
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2.2.3 Real time quantitative RT-PCR (qRT-PCR)
Real time quantitative RT-PCR reactions were performed on a MX3005P in-
strument (Agilent) and analysed using the MXPro QPCR software. qRT-PCR
reactions were performed with 1 µl 1:2 diluted cDNA produced from DNAse
digested total RNA from human brain using the Brilliant SYBR Green Mix (Ag-
ilent) adding gene specific primers to a final concentration of 100-200 nM. The
qRT-PCR cycles were performed as described in Table 2.2.
Step Temperature Duration [sec]
1 95 ◦C 600
2 95 ◦C 10
3 AT 15 repeat 35 x
4 72 ◦C 20
5 95 ◦C 60
6 55–95 ◦C 5 sec/step
(0.5 ◦C inc.)
7 4 ◦C ∞
Table 2.2: Thermal cycle profile for qRT-PCR
Gene expression levels were calculated according to the ∆∆Ct-Method, using
actin-PCR as a housekeeping gene. Calculations were done using the following
formula:
∆Ct = CtGOI − Ctactin
∆∆Ct = ∆CtFTLD −∆CtNormal
or : ∆∆Ct = ∆CtAD −∆CtNormal
Foldexpression(f.e.) = 2(−∆∆Ct)
SEf.e. =
√
(ln(2)xf.e.)2xSE∆∆Ct
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2.2.4 Restriction enzyme digest
Restriction digest reactions were performed on 5 µg template DNA using 50 U of
high fidelity restriction enzymes (NEB) and NEB 10x restriction buffer 4 for 1 h or
using 25–50 U of restriction enzymes (Promega) together with the appropriate 10x
buffer (Promega) for 1–4 h at 37 ◦C. Restriction enzymes were then inactivated
by incubation at 65 ◦C for 20 min. If possible, double restriction digests were
performed at the same time. If enzymes were not compatible for double digest
in the same buffer, the first restriction digest was performed, the product was
cleaned up (see section 2.2.8) and the second restriction digest was performed as
before.
2.2.5 Alkaline phosphatase treatment
DNA-samples were treated with calf intestine alkaline phosphatase (CIAP,
Promega) in order to prevent the re-ligation of compatible ends. Following the
restriction digest of typically 5 µg of vector DNA in a 20 µl reaction, 5 µl of
10x-CIAP-buffer (500 mM Tris, pH 9.3, 10 mM MgCl2, 1 mM ZnCl2, 10 mM
spermidine) and 1 µl of 1 u/µl CIAP were added and the mixture was incubated
for 30 min at 37◦C. These conditions usually approximated the use of 0.01 U of
CIAP per picomole of DNA-ends. The treated DNA was then purified by agarose
gel electrophoresis.
2.2.6 Agarose gel electrophoresis
Agarose gels were produced by melting the appropriate amount of agarose in
50 mL TBE buffer (89 mM Tris-Borate, 2 mM EDTA, pH 8.3 (Sigma)). Ethidium
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bromide (Sigma) was added to the gel to a final concentration of 0.5 µg/ml once it
had cooled to about 60 ◦C and the gel was poured into a horizontal gel chamber
(Hoeffer) and left to set for 20 min. DNA samples were prepared by adding an
appropriate amount of 6x Orange G DNA sample buffer (45% glycerol, 89 mM
Tris-Borate, 2 mM EDTA pH 8.3, 0.25% w/v Orange G) or Bromphenol Blue
DNA sample buffer (62.5% glycerol, 0.625% SDS, 0.125% w/v Bromphenol Blue).
DNA bands were separated at 70 V for 30–45 min. 5 µl Hyperladder I (Bioline)
were separated in a seperate lane as a molecular weight marker. DNA bands were
visualised by UV-transmission using a BioRad GelDoc system.
2.2.7 Polyacrylamide electrophoresis of DNA
Polyacrylamide gels for DNA electrophoresis were prepared with 5–8% of a 37.5:1
mixture of acrylamide:Bis-acrylamide, 0.07% APS and 0.04% TEMED in 1x TBE
buffer. Vertical gels were poured between glassplates separated by a 1 mm spacer,
appropriate combs were inserted and the gels were left to polymerise for 30 min–
1 h. DNA samples were run at 50–60 V for 45 min–1 h and then stained with
0.5 µg/ml ethidium bromide in TBE buffer for 15–20 min before gel bands were
visualised by under UV-transmission using a BioRad GelDoc system.
2.2.8 Purification of DNA from agarose and neutral poly-
acrylamide gels
DNA bands were visualized under UV light and excised using a sterile razor blade.
DNA bands were weighed and the DNA was purified from the agarose gel using
a DNA gel-purification kit (QIAGEN) according to the manufacturer’s protocol.
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2.2.9 Ligation
Inserts were ligated into purified plasmids using 50 U T4 Turbo DNA ligase
(Promega) together with the appropriate reaction buffer. Reactions were set up
using different molar ratios of insert to plasmid (insert:plasmid, 0:1, 1:3, 1:6,
1:12), calculated according to the formula below and ligation reactions were per-
formed at 16 ◦C over night or at room temperature over night or at 37 ◦C for 1 h.
(ng vector)x(kb insert)
(kb vector)
x(molar ratio) = (ng insert)
2.2.10 Generation of chemically competent E. coli
DH5α bacterial cells were grown 16–18 h from a glycerol stock in 5 mL Luria
Broth medium (Sigma)shaking at 210 rpm at 37 ◦C. 0.5 mL of this over night
culture was then expanded in 50 mL LB medium until an OD(600 nm) of 0.3–0.5
was reached. Cells were pelleted for 10 min at 3,500 rpm and the bacterial pellet
was resuspended in 20 mL sterile 100 mM CaCl2. Cells were left on ice for 30 min
and pelleted again by centrifugation at 1,500 rpm for 5 min. The resulting pellet
was resuspended in 1 mL sterile 100 mM CaCl2 and left on ice again for 30 min
before they were used for transformations. For long-term storage, glycerol stocks
were prepared according to the protocol in Section 2.2.14.
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2.2.11 Generation of Magnesium-supercompetent E. coli
A frozen glycerol stock of STABL3 E. coli cells was streaked out on a LB-Agar
plate containing 50 µg/ml streptomycin and grown for 16–18 h at 37
◦C. 10–12
large colonies were picked and used to inoculate 250 mL SOB medium (2% w/v
bacto-tryptone, 0.55% w/v Bacto yeast extract, 10 mM NaCl, 10 mM KCl, 5 mM
MgSO4, 5 mM MgCl2; prepared and sterilised without MgCl2. Filter-sterilised
MgCl2 solution was added after autoclaving.) containing 50
µg/ml streptomycin.
The inoculated culture was incubated on ice for 10 min and then incubated at
18 ◦C (for up to 48 h) until an OD(600 nm) of 0.6 was reached. Cultures were
placed on ice for 10 min and transferred to 50 mL centrifuge tubes. Cells were pel-
leted at 2500 × g for 10 min at 4 ◦C. Cells were then resuspended in 80 mL ice cold
transformation buffer (TB: 10 mM PIPES, 55 mM MnCl2, 15 mM CaCl2,250 mM
KCl; prepared without MnCl2 and adjusted to pH 6.7 before MnCl2 was added
and the solution was filter-sterilised.), incubated on ice for 10 min and pelleted
at 2500 × g for 10 min at 4 ◦C. Cells were resuspended in 20 mL TB and DMSO
was added to a final concentration of 7%. The cell suspension was incubated on
ice for 10 min and cells were split into 200–400 µl aliquots in cryogenic tubes and
flash frozen in liquid nitrogen. Cells were stored at -80 ◦C and transformations
were performed according to the standard transformation protocol.
2.2.12 Transformation of E. coli
10 µl of a 20 µl ligation product, 1–5 µl purified DNA or 5–10 µl of a recombination
reaction was added to 200 µl chemically competent bacteria, gently mixed with a
1000 µl pipette tip and on ice for 30 min. Cells were then heat shocked for 45 s at
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42 ◦C and subsequently left on ice for 1–2 min. 800 µl pre-warmed SOC medium
(2% Tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2,
20 mM glucose) were added and the mix was incubated in a 15 mL conical tube
at 37 ◦C shaking at 210 rpm for 1 h. Luria Broth (LB) agar (1% Tryptone, 0.5%
yeast extract, 0.5% NaCl, 1.5% Agar; Sigma) plates were prepared containing
the appropriate antibiotic (ampicillin: 100 µg/ml; chloramphenicol: 34
µg/ml;
kanamycin: 50 µg/ml, tetracycline: 10
µg/ml) and cells were spread and grown for
16–18 h at 37 ◦C. For transformations with pBlueScript plasmid, cells were grown
on plates also containing 0.1 mM IPTG and 2% X-gal and only white colonies
were picked the next day for over night culture.
2.2.13 Plasmid Purification
A single colony from an agar plate grown for 16–18 h at 37 ◦C was picked with
a pipette tip and grown in LB medium (1% Tryptone, 0.5% yeast extract, 0.5%
NaCl; Sigma) containing the appropriate antibiotic for 16–18 h at 37 ◦C, shak-
ing at 210 rpm. DNA was then purified using a QIAGEN Miniprep Spin Column
Kit (QIAGEN) according to the manufacturer’s protocol and eluted from columns
with nuclease-free water. Larger amounts of DNA were purified from 100–150 mL
overnight cultures using the PureYield Plasmid Midiprep kit (Promega) accord-
ing to the manufacturer’s centrifugation protocol or from 250–500 mL over night
cultures using the QIAGfilter Maxiprep kit (QUIAGEN). Nuclease-free water
was produced by stirring with 0.1% Diethyl-pyrocarbonate (DEPC) over night
followed by autoclaving in order to inactivate the DEPC. The DNA concentra-
tion was measured in a UV-1601 spectrophotometer (Shimadzu) by measuring
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the absorbance at 260 nm. DNA purity was estimated by also measuring the
absorbance at 280 nm and building the ratio of the absorbances at 260 nm and
280 nm. A ratio of 1.8–2.0 was regarded as pure. Purified DNA was stored at
-20 ◦C in water or TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0).
2.2.14 Generation of glycerol stocks
For long-term storage of bacterial cultures, glycerol stocks were prepared from
fresh over night cultures by mixing 600 µl over-night LB-culture with 400 µl 50%
glycerol (20% final concentration). Glycerol stocks were flash frozen in liquid
nitrogen and stored at -80 ◦C.
2.2.15 Gateway R© cloning
Lentiviral constructs were produced using the Gateway cloning system (Invitro-
gen) based on site specific recombination. For the first cloning step producing an
entry clone, attB1 and attB2 site containing gene specific primers were created
and PCR products were produced by conventional PCR using TurboPfu poly-
merase (Agilent). PCR products were purified after agarose gel electrophoresis
and then cloned into the pDONR201 donor vector (Invitrogen) by recombination
using the BP-Clonase II kit (Invitrogen). For the BP-reaction 50 fmol (150 ng)
of supercoiled pDONR201 vector and 150 fmol of attB site containing PCR prod-
ucts were used. Reactions were performed over night at 25 ◦C using 0.5 µl of
enzyme together with the appropriate amounts of vector and PCR product and
made up to a final volume of 10 µl with TE-buffer. The amount of PCR product
used in the reaction was calculated using the following formula:
87
CHAPTER 2. MATERIALS AND METHODS
ng = (fmol)x(N)x(
660 fg
fmol
)x(
1 ng
106 fg
)
The recombination reaction was stopped by addition 1 µl of 2 µg/µl Proteinase
K solution and incubation at 37 ◦C for 10 min. 5 µl or all of the reaction was
then transformed into STABL3 E.coli cells (Invitrogen) propagated and made
chemically supercompetent as described in section 2.2.11. These cells do not con-
tain the F1 episome encoding the ccdA gene and allow for negative selection with
the ccdB gene product against failed recombination reactions. Transformants
were plated on agar plates containing the appropriate antibiotic (kanamycin for
pDONR201) and incubated over night at 37 ◦C. Colonies of different sizes were
picked the next day and grown for 16–18 h at 37 ◦C and 210 rpm in 5 mL LB
medium containing kanamycin. Purified entry clones were confirmed by analyti-
cal restriction digest and sequenced using pDONR201 specific primers (see Table
C.1).
Expression clones were produced by recombination of the gene of interest
from the entry clone into the destination vector (pSX69, a kind gift from Dr.
Paul Reynolds/Prof. Richard Elliot) using the LR-clonase II kit (Invitrogen).
Reactions were prepared on ice using 0.5 µl of LR clonase and 50 fmol of each
pSX69 destination vector and the entry clone. The amount of DNA used for these
reactions was calculated in the same way as for the BP-reaction. Reactions were
made up to a total of 10 µl using TE-buffer and incubated at 25 ◦C over night.
Reactions were stopped by addition 1 µl of 2 µg/µl Proteinase K solution and
incubation at 37 ◦C for 10 min. 5 µl or all of the reaction was then transformed
into STABL3 cells and transformants were plated out on agar plates containing
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the appropriate antibiotic (ampicillin for pSX69) and incubated over night at
37 ◦C. Colonies of different sizes were picked the following day and grown grown
for 16–18 h at 3 ◦C and 210 rpm in 5 mL LB medium containing ampicillin.
Purified expression clones were sequenced using psX69 specific primers (see Table
C.1).
2.3 Cell culture
2.3.1 Culture of cell lines
The Human Embryonic Kidney (HEK293) cell line was cultured in high glucose
modified Eagle’s medium (MEM) (Sigma, ] M2279) supplemented with 10 % fetal
calf serum (FCS, Seralab) and 2 mM L-glutamate (Sigma) as well as 100 U/ml
penicillin and 0.1 mg/ml streptomycin (Sigma) and non-essential amino aicds
(Sigma) at 37 ◦C and 5% CO2. The SK-N-SH neuroblastoma and the 293T
Lentigrade HEK cell lines were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM) (Sigma, ] D5671) supplemented with 10 % FCS and 2 mM L-glutamate
(Sigma) as well as 100 U/ml penicillin and 0.1
mg/ml streptomycin (Sigma). Cells
were thawed from liquid nitrogen quickly, resuspended in 10 mL of cold culture
medium and pelleted before they were resuspended in culture medium and plated
out in a culture dish or flask containing fresh culture medium and grown until
confluent. For slow growing cell lines, 50% of the culture medium was changed
every third day. Cells were subcultured 2 times per week in a class II sterile
hood. The culture medium was removed and cultures were rinsed twice with
10 mL pre-warmed sterile PBS. All of the PBS was removed and 1 mL of sterile
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0.025% Trypsin/EDTA solution (Sigma) was added. Cells were trypsinised at
37 ◦C, aspirated with 10 mL of pre-warmed culture medium containint 10% FCS
and transferred to a 15 mL centrifuge tube. Cells were pelleted at 800 × g for
5 min and the cell pellet was resuspended in 5–10 mL of culture medium. An
appropriate amount of cells was plated into a fresh culture dish or flask containing
culture medium and cells were grown in a humidified Heraeus incubator at 37 ◦C
and 5% CO2.
2.3.2 Primary cortical neuron cultures
Primary neuronal cultures were prepared from embryonic day 14 mouse embryos.
At day 14 of pregnancy the mother was sacrificed by cervical dislocation and the
embryos were dissected from the uterus. Brains were dissected from the embryos
using tungsten needles and placed in pre-warmed PBS. Meninges were removed
and cortices were separated from the cerebellum and diencephalon. Cortices from
one litter were transferred to a 15 mL centrifuge tube and rinsed with pre-warmed
PBS. The tissue was then incubated for 5 min at 37 ◦C in PBS containing 50 µg/ml
trypsin (Worthington biochemical corporation, ] TRSEQII). At the end of the
trypsinisation period, the tissue was allowed to settle and the trypsin solution was
removed carefully. The cortices were then rinsed in 1 mL cortical plating medium
(MEM (Sigma, ] M4655), 10% horse serum (HS), 10% FCS) and resuspended in
1 mL medium to produce a single cell suspension. Neurons were plated on culture
dishes coated over night with 1–10 µg/ml poly-D-lysine (30–70 kDa, Sigma) at
a density of 2–2.5 × 105 cells per cm2. The culture medium was changed 6–8 h
after plating in cortical plating medium to cortical serum-free medium (MEM +
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2% serum-replacement 2, 80 µM 5-fluorodeoxy-uridine, 24.5 µM KCl, 100 U/ml
penicillin and 0.1 mg/ml streptomycin (Sigma)). Cells were cultured in cortical
serum-free medium for another 48–72 h before 50% of the medium was replaced
with fresh medium. Experimental procedures were conducted after 72 h in vitro.
50% of the cortical serum-free medium was replaced every 72 h.
2.3.3 Primary neuron transfection
Primary neuronal cells were transfected using the Amaxa nucleofection technique
with the primary mouse nucleofector kit (] VPG1001) according to the manu-
facturer’s protocol (Zeitelhofer et al., 2007). 6 × 106 cells were transfected in
suspension in 100 µl nucleofection solution and cells were plated out in 35 mm
culture dishes containing 2 mL of pre-warmed cortical plating medium. After
6–8 h incubation at 37 ◦C and 5% CO2, the culture medium was replaced with
cortical serum-free medium and cells were cultured for another 48–72 h before
conducting other experimental procedures.
2.3.4 Cell line transfection
HEK293 cells were transfected using GeneJammer reagent (Stratagene). For a
35 mm culture dish, GeneJammer was diluted in a 1:3 ratio to the DNA trans-
fected (i.e. 3 µl Gene Jammer per 1 µg of DNA) in Opti-MEM medium (Sigma)
without antibiotics and incubated for 5 min at room temperature. 2 µg of DNA
was added and the mix with a total volume of 100 µl was then incubated for
20 min at room temperature. The transfection mix was added drop wise to the
cells plated to 80–90% confluency in 2 mL culture medium without antibiotics in
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a 35 mm dish 24 h before. Cells were analysed 48 h post-transfection.
SK-N-SH neuroblastoma cells were transfected using Lipofectamine 2000 (Invit-
rogen) reagent. For a 35 mm cell culture dish, Lipofectamine 2000 was diluted in
a 1:2.5 ratio to the amount of DNA transfected in 125 µl of serum-free DMEM or
OptiMEM medium without antibiotics and incubated for 5 min at room temper-
ature. 2 µg of DNA were diluted in 125 µl of serum-free DMEM, mixed with the
Lipofectamine 2000 containing solution and incubated for 20 min at room tem-
perature. The transfection mix was then added to the SK-NSH cells in 1.75 mL
serum-free DMEM without antibiotics, which were plated in a 35 mm culture dish
to 90% confluency 24 h before. Half of the medium was replaced with DMEM
supplemented with 20% FCS and 4 mM L-glutamate (Sigma) after 4 h and cells
were incubated in this medium for another 48 h before further analysis.
2.3.5 Lentivirus production and cell infection
HEK293T lentigrade cells were grown in DMEM medium supplemented with 10%
FCS and 100 U/ml penicillin and 0.1
mg/ml streptomycin and seeded in a 96 mm
culture dish to 80–90% confluency. The following day, cells were triple transfected
with 1.2 µmol of plasmids encoding the viral packaging and polymerase genes
(2.1 µg pSD11 and 6.3 µg pSD16, see Figure B.2) and an equimolar amount
of the lentiviral expression vector encoding the gene of interest together with
appropriate packaging signals as well as the VSV-G glycoprotein. Cells were
transfected using 2.5 volumes of Lipofectamine 2000 reagent per 1 µg of DNA.
The Lipofectamine 2000 and DNA mixtures were each prepared in 0.75 µl of
Opti-MEM medium (Gibco) per 96 mm dish, vortexed and incubated for 5 min
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at room temperature. The DNA and Lipofectamine 2000 were then mixed and
incubated for 20 min at room temperature and then added drop wise to the cells
cultured in 13.5 mL antibiotic-free DMEM medium containing 10% FCS. With
the start of virus production 24 h after transfection, the transfection medium was
removed, replaced by 4 mL normal DMEM growth medium and the cells were
moved into designated viral incubators and handled in designated viral tissue
culture hoods only. The cells were incubated for another 24 h and the lentiviral
supernatant was collected the next day, stored at 4 ◦C and 4 mL of pre-warmed
normal growth medium was again added to the cells which were incubated for
further 24 h. The second batch of lentiviral supernatant was combined with
the first one and the solution filtered through a sterile 0.45 µm syringe driven
filter in order to remove debirs. Polybrene (Invitrogen) was added to the viral
supernatant at a final concentration of 8 µg/µl. The viral supernatant was then
added to the target cells for infection. After a 4 h incubation period, the viral
supernatant was removed and replaced by normal growth medium. If primary
cortical neurons were infected, the infection time was extended to a maximum of
8 h and the virus production was performed in DMEM supplemented with 0–1%
FCS. Cells were analysed 48–72 h after viral infection.
2.3.6 Amyloid-β treatment of cell cultures
Monomeric amyloid-β peptides were prepared from lyophilised amyloid-β pur-
chased from Innovagen (Sweden) or GenicBio (China) according to published pro-
tocols for Aβ oligomer and fibril formation (Stine et al., 2003). 0.1 mg lyophilised
peptide (22 pmols Aβ42, MW 4514.1 g/mol; 23 pmols Aβ40, MW 4329.9
g/mol)
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was dissolved in 1 mL ice cold hexa-fluoro-isopropanol (HFIP, Sigma) and left
to dissolve for 1 h at room temperature in a closed reaction tube. Ten 100 µl
aliquots were produced and the HFIP wa left to evaporate over night in a fume
hood. Samples were then dried under vacuum for 1 h and subsequently stored at
-20 ◦C.
For cell culture treatments a 0.1 mg aliquot of monomerised peptide was dissolved
in sterile anhydrous dimethylsulfoxide (DMSO, Sigma) to a final concentration of
5 mM, vortexed and sonicated for 10 min. The peptide was then diluted with PBS
to a final concentration of 1 mM and incubated at 37 ◦C (Aβ40) or 4 ◦C (Aβ42 for
24 h. Amyloid-β peptides were then added to 1 mL culture medium to produce
a final concentration of 22-23 µM. Aggregated amyloid-β(25–35) peptides were
also produced from lyophilised amyloid-β. A 1 mM solution of amyloid-β (25–35)
in distilled sterilised water was produced and stored at - 20 ◦C. An aliquot was
then thawed and mixed with 1 volume of sterile PBS and incubated at 37 ◦C for
3–5 days. Aggregated amyloid-β(25–35) was added to the cell cultures at a final
concentration of 25–50 µM.
2.3.7 Cell survival and viability assays
Cell survival was assessed by cell counting. For this, phase-contrast pictures of
5 fields of view in a 20× or 40× objective were taken of each condition before
and after the intended treatment and the number of cells was counted using the
ImageJ software.
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2.3.7.1 MTT assay
The reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) by mitochondrial dehydrogenases was measured in a 96-well plate format.
12.5 µl of a 5 mg/ml solution of MTT in PBS was added per well to 50 µl culture
medium. The cells were then incubated with the MTT for 4 h (cell lines) or up to
6 h (primary neurons) in a humidified CO2 incubator at 37
◦C. The medium and
MTT solution were then removed and the cells were lysed by addition of 100 µl
DMSO. The absorbance of the reduced formazan was then measured at 570 nm
in a FLUOstar OPTIMA multidetection microplate reader.
2.4 Immunocytochemistry
Immunocytochemistry was performed on cells grown on glass-coverslips. Cover-
slips were placed on a piece of Nescofilm (VWR) and directly fixed with cold
4% PFA solution for 10 min (cytoskeleton stainings) or 15–20 min (cytoplas-
mic and organellar stainings) at room temperature. Cells were permeabilised
with PBS-TT (PBS, 0.1% Tween-20, 0.1% Triton-X-100) for 15 min and non-
specific antibody binding sites were blocked with ICC blocking solution (10%
horse serum in PBS-TT) for 20 min. Primary antibodies were diluted in blocking
solution as indicated in Table A.1 and incubated for 2 h at room temperature or
overnight at 4 ◦C, followed by 3 times 5 min washes with PBS-TT. Secondary
fluorochrome conjugated antibodies were diluted in ICC blocking solution as indi-
cated in Table A.1 and incubated for 1 h at room temperature in the dark followed
by 3 times 5 min washes with PBS-TT. 4’,6-Diamidino-2-Phenylindole (DAPI,
Sigma) was added to the secondary antibody solution at a final concentration of
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1 µg/ml as a nuclear counterstain. Coverslips were mounted on microscope slides
in Mowiol-488 mounting medium (10% Mowiol-488, 2.5% glycerol, 100 mM Tris,
pH 8.5) containing 1.5% propyl-gallate as an antifade or in ProlongGold mounting
medium (Invitrogen).
2.5 Statistical analysis
Statistical analysis was performed using Prism statistical analysis softwaere
(Graph Pad). 1-way analysis of variance (ANOVA) with Tukey’s multiple com-
parison post-hoc test, 2-way ANOVA with Bonferroni post-hoc test or T-Test
were performed as indicated in figure legends. Significance was denoted with
stars accoring to p≤0.05 (1 star), p≤0.01 (2 star), p≤0.001 (3 star).
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CHAPTER 3. EP-1 IN STRESS KINASE SIGNALLING
3.1 Introduction
3.1.1 c-Jun N-terminal kinase (JNK) in the CNS
c-Jun N-terminal kinases (JNK) are encoded by 3 genes (JNK1–3), giving rise to
10 isoforms of either 46 kDa or 54 kDa. They belong to the group of mitogen
activated protein kinases (MAPK), which phosphorylate serine and threonine
residues in their targets (Mehan et al., 2011). Similar to p38, JNK is a stress
activated protein kinase (SAPK) and is activated by a wide range of extracellular
signals which leads to the activation of the MAPK kinases MKK4 and MKK7,
which phosphorylate JNK on specific tyrosine and threonine sites, causing its
activation. MKK4/7 are activated themselves by a series of MAP-triple kinases
(MAP3Ks), which are often activated by the small GTPases Ras and Rac, the
Rho-family GTPase Cdc42 or the Ste20-family protein kinase GLK (Mehan et al.,
2011; Diener et al., 1997). Known components of the JNK signalling cascade are
depicted in Figure 3.1.
JNK-interacting proteins 1, 2 and 3 (JIP1/2/3) fulfil crucial functions in the
activation of this signalling cascade by acting as scaffolding proteins for JNK
and positioning it in the vicinity of specific activators, substrates or inactivators
(Mehan et al., 2011). Their scaffolding function is also subject to regulation as,
for example, cleavage of JIP1 by caspase 3 can cause its disassembly from JNK
during apoptosis (Vaishnav et al., 2011).
As suggested by the name, the best described function of JNK is phosphory-
lation of the transcription factor c-Jun at its N-terminus. This phosphorylation
has been reported to increase c-Jun’s half-life and enhance its transcriptional ac-
tivity by forming the important transcription factor complex activating protein
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1 (AP-1) through homo- and heterodimerisation of c-Jun with c-fos or the acti-
vating transcription factor 1 (ATF-1) (Shaulian, 2010). Formation of the AP-1
complexes plays an important role in the context-dependent control of cell cycle
progression, cell survival or p53-mediated cell death (Shaulian, 2010).
Apart from its role in stress-induced cell death, JNK signalling modulates a
number of activities specifically in neurons, which are also summarised in Figure
3.1. As mentioned in Chapter 1, JNK is able to phosphorylate APP at Thr668,
thereby regulating its processing with the help of JIP1b (Colombo et al., 2009;
Matsuda et al., 2001) and JNK has also been implicated in the phosphorylation of
tau (Reynolds et al., 2000; Swatton et al., 2004). Other effects of JNK-signalling
which are important for neuronal function include the stabilisation of micro-
tubules through MAP1 and MAP2 phosphorylation (Chang et al., 2003) and the
dissociation of kinesin proteins from their tubulin tracks (Stagi et al., 2006). In
this respect, it is of interest that a differential effect of JNK isoforms on cell death
(mainly JNK2 translocation to the nucleus) and microtubule dependent neurite
outgrowth (dependent on all isoforms) in hippocampal neurons has been found
(Eminel et al., 2008). A differential role of different JNK isoforms has also been
suggested by studies in different JNK knockout animals where a mainly neuropro-
tective role for JNK1 in contrast to a cytotoxic effect of JNK3 has been described
(Brecht et al., 2005). Positive effects of JNK-signalling on the formation of hip-
pocampal LTP and LTD in neurons have also been reported and might be due to
JNK-mediated modulation of the microtubule network or its proposed effects on
AMPA receptor (AMPA-R) internalisation (reviewed in Mehan et al. (2011)). In
contrast, JNK1 can also be involved in the inhibition of hippocampal LTP and
cell death in response to Aβ exposure (Minogue et al., 2003). This underlines
100
CHAPTER 3. EP-1 IN STRESS KINASE SIGNALLING
Figure 3.1: The SAPK/ JNK signalling cascade. ASK: apoptosis signal regulating ki-
nase, ATF: activating transcription factor, Cdc42: cell division cycle 42, GLK: germinal
center like kinase, LZK: leucine-zipper bearing kinase, MADD: MAP-kinase activating
death domain, MAPK: mitogen activated protein kinase, MKK: MAPK kinase, MLK:
mixed lineage kinase, MLTK: MLK-like mitogen activated protein triple kinase, PAK:
p21 activated kinase, TAK: transforming growth factor β activated protein kinase,
TPL: tumour progression locus. Modified with permission from Humana Press (Mehan
et al., 2011).
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the fact that the outcome of the activation of JNK in neuronal networks strongly
depends on the specific context and the availability of the different isoforms.
3.1.2 Endophilin-1 function and its proposed role in AD
Endophilin A1 (Ep-1) is a plasma- and synaptic vesicle membrane associated pro-
tein. It contains an N-terminal Bin/Amphiphysin/Rvs (N-BAR) domain com-
prising α-helical structures, which allow its interaction with membrane lipids,
induction of membrane curvature and homo- or heterodimerisation with other
endophilins. The N-BAR domain is followed by a proline rich domain (PRD)
and a C-terminal Grb2-like src homology 3 (SH3) domain for the interaction
with specific PRDs in other proteins (see Figure 3.2). Ep-1 also contains a puta-
tive nuclear localisation sequence (NLS) but it has not been reported to localise
to the nucleus in the literature (Reutens and Begley, 2002). Ep-1 is also known
as Sh3p4, SH3GL2, CNSA2, EEN-1 or SH3DA2 and forms a unique group of
SH3 proteins together with the closely related proteins endophilin A2 (SH3p8/
SH3GL1) and endophilin A3 (SH3p13/ SH3GL3). Of these isoforms, Ep-1 is ex-
pressed mainly in the brain, while Ep-3 is enriched in testes and the brain and
Ep-2 is expressed ubiquitously (Giachino et al., 1997). In contrast to endophilin A
proteins, endophilin B1 and B2 are associated with organelle membranes and have
been reported to regulate mitochondrial morphology, apoptosis and autophagy
(Kjaerulff et al., 2010).
Ep-1 was initially identified as a binding partner for the lipid phosphatase
synaptojanin and for dynamin in synapses (Sparks et al., 1996; Micheva et al.,
1997; Ringstad et al., 1997) and also found to co-localise and interact with synap-
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Figure 3.2: Endopohilin A1 structure. N-BAR: N-terminal Bin/Amphiphysin/Rvs
domain, NLS: putative nuclear localisation signal, PRD: proline rich domain, SH3: src
homology 3. Modified with permission from Nature Publishing Group (Gallop et al.,
2006).
tophysin (Ringstad et al., 2001). Accordingly, a role for endophilin-1 in synaptic
vesicle endocytosis, mediated by dimerisation and membrane interaction through
its N-BAR domain, has been demonstrated in vitro and in vivo (Ringstad et al.,
1999; Gallop et al., 2006; Bai et al., 2010). Furthermore, interaction of Ep-1
with voltage-gated Ca2+ channels (VGCC), has been shown to be important for
coordinated synaptic vesicle endocytosis to occur (Chen et al., 2003). Notably,
the study also demonstrated that the interaction with VGCCs was negatively
regulated binding of Ca2+ to Ep-1 in a region around its PRD which occurred at
increased levels of Ca2+. The authors suggested that this might be a mechanism
of targeting of Ep-1 to sites of synaptic activity, where VGCCs are located and
regulating its function in response to Ca2+ fluxes (Chen et al., 2003). Data from
a recent study by Weston et al. (2011) provided evidence that interactions via
the Ep-1 SH3 domain can also modulate its endocytotic function. It has been
found that Ep-1 can interact with the vesicular glutamate transporter VGLUT1
through its SH3 domain (Vinatier et al., 2006; De Gois et al., 2006). Using
VGLUT1/2 knockout models, lentiviral overexpression and knock down of Ep-1,
Weston et al. (2011) showed that inherent differences in the dynamics of gluta-
mate release from VGLUT1 and VGLUT2 expressing synapses are caused by the
binding of Ep-1 to VGLUT1 (but not VGLUT2). The authors therefore proposed
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a mechanism by which binding of VGLUT1 reduces the amount of Ep-1 available
for endocytosis and therefore VGLUT1 recycling, which results in a decreased
probability of glutamate release in VGLUT1 expressing synapses.
Ep-1 also influences the enodcytic trafficking of a number of membrane pro-
teins through direct or indirect interactions via its SH3 domain. Binding of Ep-1
to the G-protein coupled β1-adrenergic receptor has been shown to promote re-
ceptor internalisation and silencing (Tang et al., 1999) and similarly, interactions
with CIN85 (Soubeyran et al., 2002) and ataxin-2 (Ralser et al., 2005; Nonis et al.,
2008) link Ep-1 to ligand induced EGF-receptor internalisation and silencing and
to actin remodelling. It has been proposed that Ep-1 could also modulate the
transport, targeting or processing of ADAM9 and ADAM15, which act as met-
alloprotease disintegrins and are involved in cell–cell interactions (Howard et al.,
1999).
It has emerged that Ep-1 can afurthermore have functions which are not
directly related to its role in endocytosis. Two studies have linked Ep-1 to the
regulation of the turnover of synaptic proteins and to BDNF-induced dendritic
development. Trempe et al. found that all isoforms of endophilin A can interact
with the ubiquitin E3 ligase parkin in a phosphorylation dependent manner and
that Ep-1 can affect the ubiquitination of its PRD containing binding partners
in synaptosomes (Trempe et al., 2009). Dendritic development is dependent on
BDNF-induced signalling events and upon binding of BDNF, its receptor TrkB
is internalised in a process that requires the transmembrane protein retrolinkin
(Fu et al., 2011). The study by Fu et al. revealed that the subsequent activation
of the MAP kinase ERK1/2 depends on the recruitment of Ep-1 by retrolinkin
to early endosomes containing TrkB, rab5 and APP-like protein 1 (APPL1) (Fu
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et al., 2011).
In addition, research has also revealed that Ep-1 is able to activate the
SAPK/JNK signalling cascade. Expression of Ep-1 in cell lines can cause the
phosphorylation of JNK and this depends on the interaction between the Ep-1
SH3 domain and GLK (Ramjaun et al., 2001). In synaptosomes from mouse
cortex, Ep-1 has been found to be associated with the same endocytic vesicles as
JIP3 (also known as Sunday Driver, syd) (Abe et al., 2009), which brings Ep-1
into the proximity of the JNK-signalling components. In 2008, Ren et al. showed
that overexpression of Ep-1 also leads to the activation of JNK in primary cortical
neurons and that this effect is abolished upon deletion of the Ep-1 SH3 domain
(Ep-1∆SH3) (Ren et al., 2008). Ren et al. also demonstrated that Aβ-induced
activation of JNK is reduced to background levels when mutant Ep-1∆SH3 was
expressed, while there was a tendency towards higher levels of phosphorylated
JNK in Aβ treated neurons expressing full length Ep-1 (Ren et al., 2008), sug-
gesting that Ep-1 can facilitate JNK-activation. As mentioned in Chapter 1, the
study also identified Ep-1 as specifically up-regulated in mAPP/ABAD double
transgenic mice and confirmed this finding by western blotting and immunohis-
tochemistry (Ren et al., 2008). Importantly, it was also found that Ep-1 protein
levels are increased in the brains of AD patients compared to controls and con-
cluded that this might point towards a new mechanism of how stress kinase
signalling becomes activated during AD pathology.
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3.2 Aims of this chapter
The cellular outcome of the up-regulation of endophilin A1 in AD has not been
described in detail. Therefore, the aim of the work described in this chapter was
to dissect out which components of the JNK-signalling cascade are activated in
response to the overexpression of Ep-1 in primary neurons. It was first planned to
confirm the activation of JNK and its downstream target c-Jun in human brain
tissue affected by dementia. As a next step, JNK-activation was investigated in
primary neuronal cultures overexpressing Ep-1 and subsequently it was hoped
to identify which targets become phosphorylated as a result of JNK activation
under these circumstances. Finally, the cellular effects of the activation of these
downstream targets was be studied in primary neurons in more detail.
3.3 Activation of JNK and c-Jun in human AD
An increased activation of c-Jun-N-terminal kinase in Alzheimer’s disease has
been described before (see Chapter 1.4). In order to validate these previous
findings, I analysed the status of c-Jun-N-terminal kinase (JNK) in samples of
brains from human dementia sufferers by western blotting. Tissue samples from
five individuals with diagnosis of AD, four individuals with diagnosed frontotem-
poral lobar degeneration (FTLD) and five age-matched non-demented control
individuals were kindly provided by the Manchester brain bank through Prof.
David Mann. From each individual, samples from the frontal cortex (FCx), the
hippocampus (Hippo) and the cerebellum (Cere) were analysed. An assessment
of amyloid plaque pathology and neurofibrillary tangle pathology in these brain
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samples was performed by pathologists at the Manchester brain bank. Scores
representing the extend of pathology found by histological stainings for Aβ and
hyperphosphorylated tau (0 = no pathology detected; 4 = severe pathology with
strong immunoreactivity) are given in Table 3.1.
ID Diagnosis FCx Hippo Cere
tau amyloid tau amyloid tau amyloid
08/01 AD 1 4 4 3 3 0 1
09/15 AD 2 3 3 3 2 0 0
10/07 AD 3 4 4 3 3 0 1
10/08 AD 4 4 4 3 3 0 1
09/01 AD 5 3 3 2 2 0 0
94/13 FTLD 1 (PGRN) 0 0 0 0 0 0
96/14 FTLD 2 (Pick’s) 4 0 4 0 0 0
98/04 FTLD 3 (Pick’s) 4 0 4 0 0 0
01/01 FTLD 4 (exon10 +16) 4 1 4 0 0 0
03/06 FTLD 5 (Pick’s) 3 0 4 0 0 0
09/18 FTLD 6 (exon10 +16) 4 0 4 0 0 0
07/13 control 1 0 0 0 0 0 0
08/04 control 2 1 2 1 2 0 0
08/28 control 3 0 2 1 2 0 0
08/29 control 4 1 3 1 2 0 0
09/05 control 5 0 1 1 0 0 0
Table 3.1: Pathological assessment of human brain samples with dementia from the
Manchester brain bank. Scores refer to the amount of pathology (amyloid plaques or
neurofibrillary tangles) detected by immuo-histochemistry against Aβ or hyperphos-
phorylated tau. Low scores mean little or no detection of amyloid or neurofibrillary
tangles, high scores mean large amount of pathology. FCx: frontal cortex, Hippo: hip-
pocampus, Cere: cerebellum. AD: Alzheimer’s disease, FTLD: frontotemporal lobar
degeneration with mutations in progranulin (PGRN), a mutation in the tau gene on
chromosome 17 in the intron following exon 10 at position +16 (exon10 +16) or with
Pick’s disease (Pick’s), control: age-matched non-demented individuals. The assess-
ment was done by pathologists at the Manchester brain bank.
Proteins were extracted from 300 mg of human brain tissue from control
individuals, AD sufferers or patients diagnosed with FTLD and 20 µg of protein
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was subjected to SDS-PAGE as described in Chapter 2.1.1. Figure 3.3 shows the
results of the western blot analysis and the quantification of the stained bands by
densitometry. Staining for total JNK protein revealed a number of bands in the
human brain samples corresponding to different isoforms and to phosphorylated
species of JNK. A double band appeared at 40–45 kDa, another band separated at
approximately 50 kDa, which was the only band detected by the antibody directed
against Thr183/ Tyr185-phosphorylated JNK and a fourth band appeared at about
60 kDa. Significantly increased signals for phosphorylated JNK relative to total
JNK protein could be detected in samples from brains affected by AD and FTLD
compared to age matched non-demented controls. The strongest increase in JNK
phosphorylation was detected in the hippocampus and cerebellum of these brains,
while in the frontal cortex, only samples from FTLD patients showed a significant
increase in phosphorylated JNK levels.
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(a)
Figure 3.3: Phosphorylated JNK in human brains with dementia.
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(b)
Figure 3.3: Phosphorylated JNK in human brains with dementia (continued). Levels
of Thr183/Tyr185 phosphorylated JNK in different brain regions from human dementia
sufferers. a) FCx: frontal cortex, Hippo: hippocampus, Cere: cerebellum. Actin was
used as a loading control. Approximate molecular weight sizes from a pre-stained
protein marker are indicated on the left of each western blot. b) Quantification of
stained bands by densitometry. Phosphorylated JNK bands were expressed as a ratio
over total JNK levels and mean values were compared. Control = 1. Error bars
show SEM. Significance was tested using 2-way ANOVA and Bonferroni post-hoc test.
FTLD: Frontotemporal lobar degeneration, AD: Alzheimer’s disease.
I then tested the levels of phosphorylated c-Jun at Ser63 in the same samples,
as c-Jun is a target of JNK. Protein samples were prepared in the same way
as before and total and phosphorylated c-Jun was detected by immuno-western
blotting. The results of the western blot analysis and quantification by densito-
metry is shown in Figure 3.4. Compared to samples from non-demented control
individuals, there was a significant increase in the levels of phosphorylated c-Jun
in the frontal cortices from dementia patients. No significant changes of phos-
phorylated c-Jun could be detected in any of the other brain regions. Activated
c-Jun is known to induce its own expression and c-Jun is also able to act as a
transcription factor independent of its phosphorylation state, e.g. in response
to Ca2+-signals (Cruzalegui et al., 1999). I therefore also assessed the amount
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of total c-Jun protein compared to actin, which served as a loading control. A
significant increase in the levels of total c-Jun could be detected in the frontal
cortices from patients with FTLD but not from patients with AD. In addition,
there was a marked increase in the levels of total c-Jun in samples from the cere-
bellum from both AD and FTLD patients. However, there were again no changes
in total c-Jun protein levels detected in the hippocampi from dementia patients.
It was noted that there was a high degree of variability in the levels of JNK
and c-Jun as well as their phosphorylated species between samples of each group.
However, in individual samples, levels of phosphorylated and especially total c-
Jun correlated with levels of phosphorylated JNK, suggesting a link between the
two, which was particularly apparent in the hippocampus and cerebellum samples
(compare Figures 3.3(b) and (c) and Figure 3.4).
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(a)
(b)
Figure 3.4: Total and phospho-Ser63 c-Jun protein in human brains with dementia.
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(c)
Figure 3.4: Total and phospho-Ser63 c-Jun protein in human brains with dementia
(continued). a) Western blot of phosphorylated c-Jun (pc-Jun) and total c-Jun. Actin
staining served as a loading control. FCx: Frontal Cortex, Hippo: Hippocampus, Cere:
Cerebellum. b) Quantification of stained bands by densitometry. Phosphorylated c-
Jun bands were normalised to actin levels and mean values were compared. c) Bands
stained for total c-Jun were normalised to actin stained bands in order to quantify levels
of total c-Jun. Error bars show SEM. Significance was tested using 2-way ANOVA and
Bonferroni post-hoc test. Control = 1, FTLD: Frontotemporal lobar degeneration, AD:
Alzheimer’s disease.
Overall, the results confirmed the activation of JNK-signalling in the frontal
cortex and hippocampus in post-mortem AD samples but this was not always
accompanied by similarly strong phosphorylation of c-Jun and sometimes more by
an up-regulation of total c-Jun levels, especially in those samples with the highest
JNK-phosphorylation. This might be explained by the fact that activation of JNK
measured by its phosphorylation might lead to only a transient phosphorylation of
c-Jun while changes total levels of c-Jun are sustained. Another possibility is that
the signal in the form of activated JNK is transmitted by retrograde transport
in neurons (for example via JIP3 (Abe et al., 2009)) and leads to the activation
of its target c-Jun in neuronal cell bodies in the frontal cortex and cerebellum,
distant from the initial JNK-activation in the hippocampus. The AD brains used
in this study also revealed a significant activation of JNK as well as c-Jun in the
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cerebellum. This finding was not expected initially but could be explained by the
progression of AD pathology throughout the brain in later stages of the disease
as mentioned in Chapter 1.1.1. Of note, there were also particularly high levels of
c-Jun phosphorylation in the cerebella of control samples (Figure 3.4(a)), while
JNK-phosphorylation was absent, suggesting that other additional mechanisms
of c-Jun phosphorylation might be at play here.
3.4 Activation of JNK-signalling in in vitro
models of AD
3.4.1 Aβ exposure leads to phosphorylation of JNK and
c-Jun in primary neurons
We proposed that there might be a link between the activation of JNK reported
in response to Aβ exposure and JNK-activation as it is seen during overexpres-
sion of Ep-1. It was therefore first necessary to verify the experimental system
by demonstrating the activation of the JNK-signalling cascade in vitro in pri-
mary neuronal cultures from the mouse cortex. Primary neuronal cultures were
prepared from embryonic day (ED) 14 mouse embryos as described in Chapter
2.3.2. After 42–72 h the cells had established a neuronal network and virtually
all surviving cells stained positive for the neuronal marker βIII-tubulin as seen
in Figure 3.5.
Amyloid peptides were prepared as described in Chapter 2.3.6 and 72 h after
plating, neurons were exposed to different concentrations of Aβ and phosphory-
lated JNK was analysed by western blotting after a 12 h incubation period. The
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Figure 3.5: Primary neuronal cultures. Cultures were prepared from ED14 mouse
embryos as described in Chapter 2. Images show immunocytochemistry against βIII-
tubulin (red) in two different magnifications. Scale bars are 50 µm (left) and 10 µm
(right). Nuclei were stained with DAPI (blue).
experiment was repeated several times and representative western blot images
are shown in Figure 3.6. Both, Aβ40 and Aβ42 were able to cause modest but
apparent phosphorylation of JNK (Figure 3.6(a) and (b)) after treatment for 12 h
at concentrations of 22 and 25 µM respectively but exposure to 50 µM of Aβ40
did not appear to lead to an additional increase in JNK phosphorylation. It was
noted however, that the results were very variable and highly dependent on the
quality of the culture and the amyloid preparation. Exposure to Aβ40 or Aβ42
also led to an apparent induction of c-Jun phosphorylation and a modest increase
in total c-Jun protein levels (Figure 3.6(c)–(d)).
These results demonstrate that both Aβ40 and Aβ42 can lead to an activation
of JNK-signalling components in our primary neuronal cell cultures. It was noted,
however, that there were subtle differences between the effects exerted by the
different forms of amyloid, when the treatments were performed in parallel. First,
Aβ40 caused phosphorylation of mostly the larger isoform of JNK (Figure 3.6(b)),
while the smaller p46-JNK band in the phospho-JNK western blots seemed to
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respond stronger to exposure of Aβ42 (Figure 3.6(a)). There were also differences
in the effect on total and phosphorylated c-Jun. While Aβ40 strongly increased
c-Jun-phosphorylation but caused only a modest up-regulation of total c-Jun
levels, Aβ42 seeemed to cause only a small induction of c-Jun phosphorylation
while total c-Jun levels increased visibly (Figure 3.6(c)). This could point towards
differences in the isoforms of JNK activated by Aβ40 and Aβ42 respectively.
Alternatively, it is possibly that there are differences in the dynamics of signalling
events caused by exposure to either forms of amyloid (Aβ42 acting faster) which
might be due to the different aggregation protocols used for this study. It would
therefore be necessary to compare the two forms of amyloid under more controlled
conditions (aggregation temperature) with larger sample numbers in order to
draw any conclusion.
(a) (b)
Figure 3.6: Aβ-induced phosphorylation of JNK and c-Jun.
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(c) (d)
Figure 3.6: Aβ induced phosphorylation of JNK and c-Jun (continued). Western blot
analysis for phosphorylated JNK and c-Jun in protein extracts ED14 primary neurons
treated with (a)/(c) 22 µM Aβ42 or (b)/(d) 25–50 µM Aβ40 for 12 h. Actin was used
as a loading control in (c) and (d).
3.5 Endophilin-1 activates the JNK-signalling
cascade in vitro
Data from the initial identification of endophilin A1–A3 indicated that Ep-1 is
expressed in human fetal and adult brain (Giachino et al., 1997) and in rat hip-
pocampal cultures (Ringstad et al., 2001). In order to investigate the role of Ep-1
in stress signalling pathways in mouse embryonic primary neurons, I next asked
if Ep-1 is expressed in these cultures.
RNA from primary neuronal cultures was extracted after 72 h in vitro using
Tri-reagent and DNase digestion and RT-PCR with mouse-specific primers for
Ep-1 were performed as described in Chapter 2. The primer sequences used (see
appendix, Table C.1) were specific to both the mouse and the human Ep-1 mR-
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NAs and were expected to result in a 107 bp product. Separation of the PCR
products on a 2% agarose gel and staining with ethidium bromide revealed a
single product of the expected size but no product in a control reaction where
no template was added at the reverse transcription step (Figure 3.7). Amplifica-
tion of a non-specific product from potential genomic DNA contamination could
be excluded due to the fact that the expected PCR product was overlapping
an intron in the genomic sequence of Ep-1, which would therefore preclude the
amplification of a product of the same size from genomic DNA. The RT-PCR
results clearly demonstrate that Ep-1 is expressed in ED14 primary neurons and
expressed stronger in adult mouse cortex. The same results were obtained using
different intron-spanning primers, which only detected mouse Ep-1 mRNA.
Figure 3.7: Ep-1 mRNA in primary neurons. RT-PCR on cDNA produced from two
different ED14 primary cortical neuron cultures after 72 h in vitro. cDNA from adult
mouse cortex served as a positive control. RT-PCR of actin was used as a loading
control.
3.5.1 Ep-1 overexpression can lead to the activation of
JNK-signalling
With the knowledge that Ep-1 is expressed in embryonic mouse neurons under
physiological conditions, I now explored if overexpression of Ep-1 can influence the
phosphorylation and expression of JNK and c-Jun as seen for Aβ. Overexpression
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of Ep-1 in these cultures was achieved by transfection of 6 × 106 ED14 primary
neurons with 2 µg of a plasmid containing Ep-1 in a pcDNA3 expression vector
(a kind gift from Dr. Peter McPherson, McGill University, Montreal (Micheva
et al., 1997), see also appendix, Figure B.1) or with 2 µg of an empty pcDNA3
plasmid by nucleofection and cells were plated on 3 poly-D-lysine coated 35 mm
Petri dishes per transfection condition. The analysis of Ep-1 expression was
performed after 72 h in vitro on protein extracts from the combined lysates of 3
dishes per condition and 30 µl of the combined protein lysate was separated by
SDS-PAGE and transferred to nitrocellulose for immuno-staining. A strong band
corresponding to Ep-1 was detected in Ep-1 transfected neurons but was weaker in
vector controls (Figure 3.8). Quantification of the stained bands by densitometry
as a ratio over actin staining intensity revealed a 2–3-fold increase in Ep-1 levels in
Ep-1 transfected neurons. It was noted however, that nucleofection caused a large
amount of cell death and affected the morphology of the cultures considerably
with neurons building only a sparse network of cells and accordingly a low protein
yield after extraction of cells in lysis buffer was obtained.
Figure 3.8: Ep-1 overexpression by nucleofection. Western blot of ED14 primary
cortical neuron lysates after transfection with Ep-1 or an empty pcDNA3 vector as
indicated. A monoclonal anti-SH3GL2 antibody (Abcam) was used for Ep-1 detection.
Actin staining served as a loading control.
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3.5.1.1 Ep-1 induced JNK-phosphorylation in primary neurons
I then analysed the activation of JNK in primary neuronal cultures transfected
with Ep-1 after 72 h in vitro. Neurons were prepared and transfected in the
same way as before and Figure 3.9 shows the results of the western blot analysis
of total JNK and phosphorylated JNK. Compared to the empty vector control,
neurons transfected with the Ep-1 expression vector exhibited significantly more
phosphorylation of JNK, relative to the total amount of JNK present. This result
is in line with the results presented by Ren et al. (2008) and it was concluded
that the experimental system was suitable for studying the signalling pathways
activated by Ep-1 in primary neurons in more detail.
(a) (b)
Figure 3.9: JNK activation in Ep-1 transfected neurons. (a) Western blot analysis
of JNK phosphorylation and total JNK expression in ED14 cortical neurons 72 h in
vitro after transfection with Ep-1 or an empty pcDNA3 vector. (b) Quantification of
bands by densitometry. The bar chart represents the ratio of the band intensities of
phospho-JNK over total JNK. Error bars show SD. n = 4. Significance was tested with
T-test.
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3.5.1.2 Ep-1 overexpression leads to c-Jun phosphorylation
I next tested if Ep-1 will also lead to the phosphorylation of known targets of JNK
in primary neurons, namely c-Jun. To this aim, Ep-1 was again overexpressed
in ED14 primary neurons. 2 µg of Ep-1 expression plasmid or 2 µg of an empty
pcDNA3 vector were transfected into 6 × 106 neurons by nucleoporation and
cells were plated on 3 poly-D-lysine coated 35 mm Petri dishes. 30 µl of the
combined lysates of 3 dishes per transfection condition were analysed by SDS-
PAGE and western blotting 72 h after plating. As shown in Figure 3.10(a)(left),
transfection of Ep-1 led to an increase in the phosphorylation of c-Jun. Total c-
Jun protein levels were not changed significantly in Ep-1 overexpressing neurons
in general (see Figures 3.10(a) and (b)). The increase in c-Jun phosphorylation
could also be attributed to the activity of JNK, as inhibition of JNK activity
by application of the ATP-competitive JNK-inhibitor SP600125 abolished the
effect of Ep-1 on c-Jun phosphorylation (Figure 3.10(a), right). Also, deletion
of the SH3-domain of Ep-1 resulted in the reduction of c-Jun phosphorylation
to levels indistinguishable from vector controls (Figure 3.10(b) and (c)). Taken
together with the observed phosphorylation of JNK following transfection of Ep-
1, these results demonstrate that Ep-1 can activate several components of the
JNK-signalling cascade in primary neurons in vitro. They also confirm that the
Ep-1 SH3 domain is necessary for this activation to occur. This suggests that
interaction of Ep-1 with other proteins is needed for canonical JNK signalling to
succeed.
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(a)
(b) (c)
Figure 3.10: Ep-1 induces phosphorylation of c-Jun. Western blot analysis of c-
Jun phosphorylation and total c-Jun levels in ED14 primary cortical neuron cultures.
Actin was used as a loading control. (a) Transfection with Ep-1 or the empty pcDNA3
vector. Cells were treated with a vehicle control or 5 µM of JNK-inhibitor SP600125
and cells were analysed 72 h after plating. (b) Western blot after transfection with Ep-
1, Ep-1∆SH3 or the empty pcDNA3 vector. (c) Quantification of stained bands after
transfection with Ep-1, Ep-1∆SH3 (dSH3) or empty pcDNA3 vector. n = 8. Error
bars show SD. Significance was tested using 1-way ANOVA.
3.5.2 Ep-1 overexpression alone does not activate JNK-
signalling
3.5.2.1 Lentiviral transduction of of Ep-1 into primary neurons
Following from the observed activation of JNK-signalling components, I next
aimed to shed light on up-stream events that link Ep-1 to JNK in primary neu-
122
CHAPTER 3. EP-1 IN STRESS KINASE SIGNALLING
rons. As previously mentioned, Ep-1 has been shown to interact with the up-
stream kinase GLK via its SH3 domain in human embryonic kidney cells (Ram-
jaun et al., 2001) and it is therefore conceivable that GLK might be the relevant
kinase interacting with Ep-1 in primary neurons, which leads to the activation of
JNK, possibly mediated by the JNK-interacting protein JIP3 (Abe et al., 2009).
In the light of the cell toxicity caused by the nucleofection technique and the
variable transfection efficiency achieved by this method, I established a lentiviral
infection protocol for the expression of full length Ep-1, Ep-1∆SH3 from lentivi-
ral expression vectors (kind gifts from Prof. Christian Rosenmund, Charite´-
Universita¨tsmedizin Berlin (Weston et al., 2011); see also appendix Figure B.2)
or expression of EGFP from a control EGFP lentiviral vector (a kind gift from
Prof. Chang-Duk Jun, GIST Gwangju, South Korea (Thylur et al., 2009); see
also appendix Figure B.3(a)) in primary neurons. Transfection of constructs for
the production of lentiviruses for each expression construct into the HEK293T
packaging cell line was performed in 10 cm Petri dishes on the day when neurons
were prepared as described in Chapter 2.3.5. 2 × 106 neurons from ED14 mouse
cortices were plated in poly-D-lysine coated 35 mm dishes or 6-well plates and
cells were infected 48–72h after plating as described in Chapter 2.3.5. Fluores-
cence images of infected cells 72 h after infection, expressing either red fluorescent
protein (RFP), which is co-expressed from the Ep-1 and Ep-1∆SH3 plasmids, or
enhanced green fluorescent protein (EGFP) are shown in Figures 3.11 A–C. To-
gether with the phase contrast images (Figures 3.11 D–F), they illustrate the
high efficiency of lentiviral transduction and the good viability of the cultures.
It was hoped that this improvement of cell viability and yield will facilitate the
detection of upstream signalling components, which are typically less abundant.
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Figure 3.11: Fluorescence imaging of lentivirally infected of primary neurons. Red
fluorescence images of A) Ep-1 B) Ep-1∆SH3 expressing neurons co-expressing RFP or
C) EGFP expressing cells. D–F) Phase-contrast images of the respective fluorescence
images in A–C) above. Scale bar in F) = 50 µm
I also analysed the expression of full length Ep-1 or mutant Ep-1∆SH3 in
infected cultures by western blotting. For this analysis, neurons were grown in
2 wells of a 6-well plate for each experimental condition and infected 48 h after
plating with lentiviruses for the expression of full length Ep-1, mutant Ep-1∆SH3
or EGFP. 72 h later, cells from each well were lysed and the lysates analysed by
western blotting. Figure 3.12 shows the results of the immunostaining, which
demonstrates overexpression of Ep-1. Note the lower loading, indicated by the
weaker actin staining, in the Ep-1 infected condition compared to the EGFP con-
trol vector. Densitometry of the the stained bands revealed an approximately
2-fold overexpression in the Ep-1 infected condition compared to the EGFP con-
trol when the intensities were normalised to actin as a loading control. The faster
migrating truncated Ep-1∆SH3 mutant could only be detected in lanes 3 and 4.
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Figure 3.12: Western blot analysis of lentivirally infected primary neurons. 2 wells
of ED14 primary neurons in a 6-well plate were infected with full length Ep-1, mutant
Ep-1∆SH3 or EGFP expression vectors. Arrows point to full length Ep-1 (top) or
truncated Ep-1∆SH3 (middle). Actin staining (bottom) served as a loading control.
Using the new lentiviral transduction technique, it was necessary to confirm
that differences in JNK-activation in response to Ep-1 over-expression can still be
detected in infected neurons. Therefore, 48 h after plating, primary neurons were
infected with lentiviruses transducing Ep-1, Ep-1∆SH3 and pHJ-EGFP plasmids
into 2–3 35 mm dishes for each condition as described above and the cultures were
analysed by western blotting 72 h after infection. Figure 3.13(a) (left) shows west-
ern blot images which are representative for 3 independent experiments. They
demonstrate that Ep-1 was again able to cause changes in the phosphorylation
status of JNK compared to the GFP-control or the Ep-1 construct lacking the
SH3 domain (Ep-1∆SH3). Quantification of stained bands from >3 repeats of
the experiment revealed a significant increase in JNK-phosphorylation due to
over-expression of Ep-1 (Figure 3.13(a), right), which matched with the increase
in JNK-phosphorylation seen after nucleoporation (Figure 3.9). However, no
changes in total c-Jun protein levels or c-Jun phosphorylation could be measured
(Figure 3.13(b)) and quantification of phosphorylated c-Jun as shown in Figure
3.13(b) (right) demonstrated clearly, that there was no effect on c-Jun phospho-
rylation, despite the effect on JNK-phosphorylation seen in Figure 3.13(a).
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(a)
(b)
Figure 3.13: JNK-signalling after lentiviral transduction of Ep-1. (a) Left: Represen-
tative images of the western blot analysis of 3 samples of Ep-1, Ep-1∆SH3 or pHJ-EGFP
infected neurons, stained for phosphorylated and total JNK. Right: Quantification of
stained bands by densitometry. The bar chart shows the ratio of phosphorylated JNK
over total JNK, GFP-control = 1, n = 3. Significance was tested using 1-way ANOVA.
(b) Left: Representative images of the western blot analysis of 3 samples of Ep-1,
Ep-1∆SH3 or pHJ-EGFP infected neurons, stained for phosphorylated c-Jun and to-
tal c-Jun. Right: The bar chart shows the ratio of phosphorylated c-Jun over actin.
GFP-control = 1. Error bars show SD. n = 5.
The results obtained with the lentiviral transduction method were unexpected
considering the results from earlier experiments using the nucleofection technique.
Importantly, by using empty expression vectors of similar size as controls, which
were delivered into the cells using the same technique, any effect seen in the Ep-1
overexpressing cells could be attributed specifically to expression of the Ep-1 in
either case, rather than effects of the technique. It could therefore be concluded
that the overexpression of Ep-1 compared to the Ep-1∆SH3 mutant or the empty
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control vector, did specifically cause phosphorylation of JNK and c-Jun when
delivered by nucleoporation (Section 3.5.1) but was not able to exert the same
effect when lentiviral expression was used as described in this section. This led to
the hypothesis that other factors introduced by the nucleofection technique might
facilitate the activation of JNK-signalling by Ep-1 in a way that is not present in
the lentiviral technique.
Good viability of cultures transfected by nucleofection have been reported by
some groups, who assessed the morphology and transgene expression in these cul-
tures over a short-term culture period of 3–5 days (Zeitelhofer et al., 2007; Viessel-
mann et al., 2011). However, an assessment of the electrophysiological properties
and cell stress kinase signalling in these cultures has not been published to this
date. At the same time, some researchers have previously raised concerns about
the electrophysiological properties of neuronal cultures transfected using nucleo-
fection (Scottish Neuroscience Group Meeting 2011, personal communication). It
is not difficult to imagine that neurons exposed to electrical pulses strong enough
to disrupt their cell and nuclear membranes in order to deliver genetic material
will respond to this treatment with the activation of stress signalling cascades,
which might be enhanced by components of the nucleofection solution. There-
fore, sustained changes in some signalling molecules could be caused and thus
have implications for studies on the pathways these molecules are involved in.
Meanwhile, this effect might not be relevant when investigating other properties
of the neuronal cultures such as their overall morphology or transgene expression.
With this in mind, it is of interest that there are in fact subtle changes in
the species of phosphorylated JNK between neurons transfected by nucleofection
(Figure 3.9) and neurons infected with lentiviruses (Figure 3.13). In neurons
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transfected using nucleoporation, it is consistently only the larger p54 isoform of
JNK that can be detected using the phospho-specific antibody, which is the same
isoform that has been detected in the human brains (Figures 3.3 and 3.9). How-
ever, in neurons infected using the lentiviral technique, mainly the the smaller
p46 isoform of JNK is phosphorylated in response to Ep-1 overexpression (Figure
3.13) and this is more similar to the pattern of phosphorylated JNK detected in
neurons that have not been transfected but exposed to Aβ (Figure 3.6). Robust
changes are therefore present in neurons which have been exposed to the stress
of nucleoporation, even 72 h after plating, which bear similarity to the situa-
tion present in samples from human AD patients. In conclusion, it was realised
that Ep-1 might only be able to activate JNK-signalling in the presence of other
stresses. In the case described above these stress factors are of an electrochemical
nature but in an in vivo situation these stresses could be mitochondrial dysfunc-
tion, the deprivation of glucose, increases intra- and extracellular Aβ and changes
in ABAD function.
3.6 Discussion and outlook
The data provided in this chapter demonstrates that Ep-1 is able to activate
JNK in primary neurons in vitro. However, full activation of the canonical path-
way appears to require the presence of other insults, which cause robust changes
in signalling molecules possibly through the pre-assembly of protein scaffolds in
the cell or aberrant targeting of Ep-1. This concept is corroborated by find-
ings from our collaborator Prof. Shi Du Yan (Department of Pharmacology and
Toxicology, University of Kansas), who could not detect any changes in the phos-
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phorylation status of JNK or c-Jun in transgenic mice overexpressing Ep-1 alone.
Behavioural testing for memory deficits did also not reveal any changes in animals
overexpressing Ep-1 compared to their non-transgenic littermates. However, some
behavioural deficits could be detected in double transgenic animals overexpress-
ing Ep-1 together with mutant APP (mAPP) compared to their single-transgenic
littermates (Prof. Shi Du Yan, unpublished results), indicating that Ep-1 has a
negative effect on the AD pathogenesis in a situation of increased Aβ production.
Studies exploring the co-localisation of Ep-1 with proteins such as JIP3, GLK
and JNK itself in these mouse models or neuronal cultures exposed to insults
will shed light on the question of how and where JNK activation occurs under
these conditions. The lack of any effect of lentiviral Ep-1 overexpression on c-
Jun protein levels or phosphorylation, while some phosphorylation of JNK could
still be detected (see Figure 3.13) also requires further investigation. Considering
the distance of the synapse from the cell soma where c-Jun is located, JNK
activated via Ep-1 in the synapse might be more likely to interact with other
targets present in the neurites and dendrites, such as MAP1 and 2, tau or p66Shc,
rather than with the transcription factor c-Jun. Probing the phosphorylation
status of these targets in response to lentiviral Ep-1 overexpression will be able
to resolve this question. In order to explain the effect of Ep-1 up-regulation in
AD in more detail it will also be important to investigate the precise location of
Ep-1 and JNK in AD models at high resolution. Accumulation of Ep-1 in the
pre- or post-synaptic compartments will have different consequences depending
on the interaction partners present and resolving the spatial distribution of Ep-
1 under pathological conditions will inform future research into the function of
Ep-1 during AD pathogenesis. A summary of the AD associated pathways which
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would be affected by Ep-1 up-regulation is given in Figure 3.14.
(a) pre-synapse
(b) post-synapse
Figure 3.14: Roles of Ep-1 over-expression at the synapse.
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Figure 3.14: Roles of Ep-1 overexpression at the synapse (continued). (a) Ep-1 in
the pre-synapse: 1) Ep-1 (red circle) functions in the endocytotic recycling of synaptic
vesicles and membrane proteins like VGLUT1. Ep-1 would thereby also assist in the
uptake of excess Aβ. 2) An increase in Ep-1 could disturb synaptic transmission by
influencing VGLUT1 recycling and increasing the probability of glutamate release. 3)
Excess Ep-1 could lead to the activation of JNK (yellow triangle) in neurites with
the help of JIP3 (orange cross) and GLK (green triangle). (b) Ep-1 in the post-
synapse: 1) Ep-1 also functions in endocytosis and the recycling of membrane receptors.
2) Ep-1 is involved in the activation ERK (blue chevron) after recruitment to TrkB
carrying endosomes (blue rectangle) by retrolinkin (RTLN, light blue oval) which leads
to dendritogenesis. 3) Ep-1, together with GLK and JIP3 could also activate JNK in
dendrites.
A better understanding of the reasons for the up-regulation of Ep-1 in AD
and ABAD/mAPP transgenic mouse models will also contribute to this field of
research. Synaptic failure caused by the pronounced mitochondrial dysfunction
in AD and the transgenic AD mouse models might be a causative factor, as
Ep-1 could be up-regulated in order to increase synaptic transmission (at the
pre-synapse) or synaptogenesis (at the post-synapse). Therefore, future research
should address if Ep-1 levels change in response to metabolic stresses or changes
in cellular Ca2+ levels in the presence or absence of Aβ, which is also known to
affect ABAD activity (Allen, 2012).
An indication of how Ep-1 might become up-regulated during neurodegener-
ation comes from a proteomics study in schizophrenia patients, where Ep-1 has
been found to be more abundant in the prefrontal cortices compared to control
subjects (de Souza et al., 2009). This result has not been confirmed by other meth-
ods so far but there are intriguing parallels between AD and schizophrenia which
could cause its up-regulation. Both AD and schizophrenia involve dysfunction of
the prefrontal cortex and defects in synaptogenesis, synaptic plasticity and energy
metabolism (de Souza et al., 2009; Goto et al., 2010; Schindowski et al., 2008).
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In their analysis of proteins differentially expressed in schizophrenia, de Souza et
al. point out that some of the proteins they identified also have implications for
AD, such as ApoE and Prx-2 and fittingly, they also observed an up-regulation
of EFHD2 and Ep-1 (de Souza et al., 2009). Furthermore, impairment of activity
dependent BDNF secretion, TrkB signalling and the establishment of LTP and
LTD are believed to play an important role in the pathogenesis of schizophre-
nia (Lu and Martinowich, 2008) and these processes are also impaired in AD
mouse models (Chapman et al., 1999). As mentioned before, Ep-1 is also part
of the TrkB signalling cascade. Ep-1 might therefore be up-regulated in both
diseases in order to restore TrkB signalling in dendrites and synaptic plasticity.
This could have far-reaching consequences, since Ep-1 also influences glutamate
release in neurons through its interaction with VGLUT1 (Weston et al., 2011).
An increase in Ep-1 levels during neurodegeneration as shown by Ren et al.
(2008) and de Souza et al. (2009), leading to an increase in glutamate release at
the synapse, could tip the balance of glutamatergic signalling, which is crucial
for synaptic plasticity and learning. Taken together, Ep-1 is involved in several
neuronal mechanisms, which are crucial for learning and memory as well as the
modulation of stress kinases in neurons as depicted in Figure 3.14. Elucidating
the physiological and pathological functions of Ep-1 and the time point of its up-
regulation during neurodegenerative processes could thus be of major importance
for the understanding of Alzheimer’s disease as well as other neurological diseases
such as schizophrenia.
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4.1 Introduction
4.1.1 EFHD2 genetics and structure
The EF-hand domain family, member D2 (EFHD2), also known as swiprosin-1,
is a 240 amino acid (33 kDa) protein. The gene encoding for EFHD2 is located
on chromosome 1 in the human genome and on chromosome 4 in the murine
genomes and homologs of EFHD2 have been found in a wide range of species
including C. elegans, Danio rerio and Drosophila melanogaster as well as rodents
(Duetting et al., 2011). EFHD2 expression has been identified in differentiating
hematocytes and myoblasts in Drosophila (Hornbruch-Freitag et al., 2011), in
mast cells and lymphocytes in mouse (Avramidou et al., 2007; Ramesh et al.,
2009) and in lymphocytes and the brain in humans (Vuadens et al., 2004; Vega
et al., 2008). In mice, EFHD2 expression has been found to be particularly high
in the central nervous system (Avramidou et al., 2007).
The EFHD2 protein consists of a disordered N-terminus, followed by a region
containing a proline-rich domain (PRD) for the interaction with SH3-domain con-
taining proteins, two EF-hand domains (EF1 and EF2) and a C-terminal coiled
coil domain, which can be involved in protein dimerisation (Figure 4.1). The
calcium binding activity of purified EFHD2 has been demonstrated in an in vitro
binding assay using radioactive 45Ca (Vega et al., 2008). The N-terminal domain
also contains an IAP-binding motif (IBM), which can interact with inhibitor of
apoptosis (IAP) proteins and is found in pro-apoptotic proteins, which bind IAPs
and therefore release caspases for activation during apoptosis. With regard to its
IBM, it is interesting that one study found EFHD2 in protein complexes with pro-
caspase 9 specifically before the induction of apoptosis in a human non-small lung
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cancer cell line (Checiska et al., 2009) but the potential role of this interaction or
involvement of the IBM in EFHD2 has not been studied so far.
Figure 4.1: EFHD2 domain structure. IBM: inhibitor of apoptosis (IAP) binding
motif (aa 1–5), PRD: proline rich domain (aa 72–77), EF1/2: EF-hand domain 1(aa
96–124)/ EF-hand domain 2 (aa 132–160), CC: coiled coil domain, phosphorylation
sites at serine 74 (S47), serine 76 (S76) and tyrosine 83 (Y83) are indicated by arrows.
(Linear sequence analysis: http://www.elm.eu.org/)
Phosphorylation of EFHD2 at predicted sites in and around the PRD has
also been shown. Blethrow et al. identified Ser74 as a phosphorylation site for
CDK1 (Blethrow et al., 2008) and Ser76 also lies within the recognition domain
for cyclin-dependent kinases, although its phosphorylation has not been detected
in this assay. CDK5 has also been suggested to phosphorylate Ser74 (Irving Vega,
personal communication). Phosphorylation of Tyr83 has been detected by Ballif
et al. in a large scale screen for tyrosine-phosphorylation sites in the murine brain
(Ballif et al., 2008). A potential role for this phosphorylation site in living cells
comes from a screen for proteins phosphorylated in response to EGF-receptor
activation in HeLa cells (Blagoev et al., 2004). This study identified EFHD2 as
a protein specifically phosphorylated at a tyrosine residue in response to EGF-
R activation, which, interestingly, coincided with the phosphorylation of known
actin-modulators (Blagoev et al., 2004) (see Section 4.1.2).
The EFHD2 protein sequence is highly conserved between rodents and hu-
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mans. An alignment of the protein sequences as shown in Figure 4.2 revealed
only minor amino acid substitutions in the human sequence compared to the ro-
dent sequences, which are not located in any of the major protein domains. This
suggests that the various domains of EFHD2 are of crucial importance for its
specific function in different organisms.
Figure 4.2: Homology of EFHD2 between human and rodents. Alignment of the
amino acid sequences of EFHD2 from human (Homo sapiens, acc. no. NP 077305.2),
mouse (Mus musculus, acc. no. NP 080270.2) and rat (Rattus norvegicus, acc no. NP
001026818.1) according to the NCBI database. The two EF-hand domains are marked
by grey shading. Amino acids which differ in the human sequence (K138, C172 and
S192) are underlined.
4.1.2 EFHD2 function in immune cells
EFHD2 was initially identified in lymphocytes as a protein specifically associ-
ated with cytotoxic CD8-expressing T-cells compared to their CD4+ and CD19+
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counterparts (Vuadens et al., 2004). Most of the currently available functional
data relating to EFHD2 therefore stems from studies in the field of immunol-
ogy. Meng et al. identified it in a natural killer-like cell line associated with
the cytoskeleton of these cells (Meng and Wilkins, 2005) and an association of
EFHD2 with the actin cytoskeleton has also been proposed in mast cells (Ramesh
et al., 2009). The reported concurrence of EFHD2 Tyr-phosphorylation with the
phosphorylation of the known actin regulator ARP 2/3 in response to EGF-R ac-
tivation in HeLa cells also suggests a function of EFHD2 in the modulation of the
actin cytoskeleton (Blagoev et al., 2004). In mast cells, EFHD2 has been found
to be an inducible protein under the control of Ca2+ signals via PKC-β/η and its
expression has been associated with the induction of cytokine expression (Thylur
et al., 2009). This activation of mast cell function has been shown to depend on a
complex signalling cascade including PI3-kinase, association of EFHD2 with the
actin cytoskeleton and activation of ERK- as well as p38-MAPKs and transcrip-
tional regulation through the Ca2+ dependent transcription factors nuclear factor
(NF)κB and NF-AT (Ramesh et al., 2009).
More functions of EFHD2 have been identified by Mielenz et al., who identi-
fied EFHD2 in the lipid rafts of an immature B-cell line (Mielenz et al., 2005). It
was then demonstrated that the presence of EFHD2 in lipid rafts enhanced B-cell
receptor (BCR) induced apoptosis by facilitating BCR-induced Ca2+ signals in
these cells (Avramidou et al., 2007). Interestingly, Avramidou et al. also demon-
strated that this apoptotic role of EFHD2 involved a reduction in transcription of
the anti-apoptotic protein Bcl-XL, which is controlled by the NFκB-transcription
factor. Accordingly, it turned out that EFHD2 caused the inhibition of NFκB by
protecting its inhibitor IκB from degradation (Avramidou et al., 2007). These
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findings are in direct contrast to the data presented by Ramesh et al. from
mast cells (Ramesh et al., 2009) and suggest that EFHD2 has highly specialised
functions in different cell types.
The mechanism of enhanced BCR-signalling by EFHD2 in immature B-cells
has since been characterised in more detail. Kroczek et al. (2010) demonstrated
that early BCR-induced Ca2+ release from intracellular stores coincided with
increased phosphorylation and activity of the src-kinase Syk and also phosphory-
lation and targeting of the adaptor protein SLP65, the phospholipase PLCγ2, the
BCR and Syk itself to lipid rafts. EFHD2 was found to interact with the SH3 do-
mains of PLCγ2 as well as the src-kinases Lyn and Fgr and the authors suggested
that binding of Lyn, which is located in lipid rafts, could be the key for EFHD2
to access these domains and regulate the Ca2+ signal via PLCγ2. Notably, Fgr
and PLCγ2 shared the same interaction site in EFHD2 (amino acids 72–83) and
binding occurred in a phosphorylation dependent manner, where phosphorylated
EFHD2 preferentially bound to Fgr and via a different phospho-epitope to Lyn
(Kroczek et al., 2010). Together, the studies in immature B-cells give the most
detailed picture of EFHD2 function so far and indicate that it can act as a scaf-
fold molecule in lipid rafts, interact with the SH3 domains of src kinases and
that its function can be modulated by phosphorylation. Kroczek et al. noted
the intriguing discrepancy that EFHD2 can increase intracellular Ca2+ but at
the same time inhibit the Ca2+-dependent transcription factor NFκB in B-cells.
They concluded that EFHD2 is likely to bind the Ca2+ ions released from the
ER and cause negative feedback to occur, which inhibits cell survival signalling
from the BCR (Kroczek et al., 2010). The possible interactions of EFHD2 and
its proposed function based on the above studies are illustrated in Figure 4.3.
139
CHAPTER 4. THE NOVEL CALCIUM-BINDING PROTEIN EFHD2 IS
ASSOCIATED WITH FRONTOTEMPORAL DEMENTIA
Figure 4.3: EFHD2 as a scaffold protein at the BCR. Left: EFHD2 can interact
with the src-kinase Lyn and PLCγ2 and cause the association of the src kinase Syk,
the adaptor protein SLP65 and PLCγ2 with the BCR in lipid rafts in unstimulated
cells. The interaction of PLCγ2 and EFHD2 is reduced by EFHD2 phosphorylation,
which enhances binding of the src kinase Fgr to the same motif in EFHD2. Right:
Activation of the BCR induces phosphorylation of Syk and SPL65, binding of PLCγ2
to SLP65 and recruitment of the Bruton’s kinase (Btk), which phosphorylates and
activates PLCγ2. IP3 induced Ca2+ release from internal stores could cause negative
feedback through binding of Ca2+ to EFHD2, which then counteracts BCR-induced
cell survival signalling.
4.1.3 EFHD2 as a novel player in neurodegeneration
In addition to its role in immune cells, EFHD2 has recently been associated with
neurodegeneration. In 2008, Vega et al. identified EFHD2 in a screen for pro-
teins associated with insoluble tau-aggregates in the JNPL3 tauopathy mouse
model for frontotemporal dementia (Vega et al., 2008). In their study, they
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demonstrated that EFHD2 is associated with sarkosyl-insoluble (tangle forming)
tau protein in the brains of terminally ill JNPL3 mice but not in younger mice
lacking neuropathology. By immunoprecipitation from human brains affected by
frontotemporal dementia (FTDP17), AD and non-demented control individuals,
they also showed an increased association of EFHD2 with tau in an AD brain
containing insoluble tau-aggregates but on in a brain affected by FTDP17 com-
pared to age-matched controls. Furthermore, the study suggested an increased
expression of EFHD2 in the temporal cortices of cases with AD, FTLD or pro-
gressive supranuclear palsy (PSP) compared to a non-demented brain. Although
loading control was not shown in this context (Vega et al., 2008), unpublished
data from studies on the temporal lobe tissue of more AD affected brains also
pointed towards an up-regulation of EFHD2 protein level (Irving Vega, personal
communication).
This is the first study linking EFHD2 to neuronal function and to neurode-
generation. As mentioned in Chapter 3, EFHD2 has since also been found to be
up-regulated in the frontal cortices from human schizophrenia patients compared
to control individuals (de Souza et al., 2009). This finding is interesting in the
light of the parallels in synaptic dysfunction between AD and schizophrenia out-
lined in Chapter 3.6. However, the function of EFHD2 in neurons and its role in
tauopathy or in synaptic function have not been described in detail to date.
EFHD2 has also been linked to amyotrophic lateral sclerosis, which is a form
on motor neuron disease characterised by the degeneration of motor neurons in
the motor cortex and associated spinal cord. Zhai et al. (2009) found an increased
association of EFHD2 with lipid rafts in the spinal cords from transgenic mice
expressing a mutant version of superoxide dismutase (SOD1G93A) compared to
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their wild-type SOD transgenic littermates using a proteomics approach. ALS
can be caused by mutations in the Cu/Zn SOD1 gene on chromosome 21 such as
the G93A mutation but interestingly, another gene which had been linked to ALS
with dementia (C9orf72) has meanwhile, like EFHD2, also been linked to FTLD
(Mayeux, 2003; Goedert et al., 2012), indicating possible common pathological
mechanisms. It has been suggested, that the mutations in SOD1 leading to ALS
cause a decrease in the enzyme’s activity by unkown mechanisms, possibly involv-
ing misfolding of the protein and that similar defects, resulting in excess oxidative
stress, might also underlie sporadic ALS cases (Deng et al., 1993; Bosco et al.,
2010). As mentioned in Chapter 1.4.4, SOD1 has also been linked to amyloid
pathology in AD (Yoon et al., 2009) and oxidative modifications of SOD1 which
mimick known ALS-linked mutations have been identified in AD and PD affected
human brains (Choi et al., 2005). However, a link between mutations in SOD1
and the development of FTLD, AD or PD could not be established, indicat-
ing that altered SOD function might be secondary to the underlying pathologies
present in either of these diseases. It is therefore thinkable, that neurodegenera-
tive processes, possibly involving oxidative stress and/or synaptic failure can lead
to an up-regulation of EFHD2 or changes in its function in a similar way and that
EFHD2 could represent a link between these diseases.
4.2 Aims of this chapter
Some evidence from proteomics studies performed our lab had pointed towards a
possible up-regulation of EFHD2 protein levels in mAPP transgenic AD mouse
models. The first aim of this chapter was therefore to verify an increased ex-
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pression of EFHD2 protein and mRNA in AD mouse models and also in brains
from human dementia sufferers. I then aimed to elucidate the effects of an up-
regulation of EFHD2 in neuroblastoma cell cultures and embryonic mouse pri-
mary cortical neurons by studying cell survival and the activation of potential
cell signalling cascades (see Section 4.1.2) in response to EFHD2 overexpression
in vitro. Lastly, by studying the localisation of EFHD2 in cell lines and primary
neuronal cultures under normal conditions or in response to cell stress, I hoped to
shed light on dynamics of EFHD2 distribution in the cell and hence the cellular
functions it is involved in in neuronal cells.
4.3 Human isoforms of EFHD2
In order to create specific primers for the mRNA expression analysis in human
and mouse tissue and cells, it was first necessary to identify human and rodent
mRNA sequences of EFHD2 and their potential splice variants. There is only
one predicted isoform of EFHD2 in rodents, while in humans, three potential
protein coding transcripts have been identified (see Figure 4.4). The longest iso-
form, EFHD2-001, produces the longest protein isoform with 240 amino acids
(approximately 27 kDa) and isoforms EFHD2-002 and EFHD2-201 use an alter-
native start codon and contain an alternative exon after exon 3 (Figure 4.4(a)),
which encodes a disordered protein domain and a stop codon. Due to these al-
terations, the resulting putative 177 amino acid (approximately 20 kDa) proteins
from EFHD2-002 and EFHD2-201 comprise the EF-hand domains but lack the
first 99 amino acids and do also not contain the coiled coil domain present in the
longest isoform (Figure 4.4(b)). The expression of these isoforms has so far not
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been verified in humans.
(a)
(b)
Figure 4.4: Human variants of EFHD2. a) The EFHD2-001 gene (top) and its
predicted transcript variants EFHD2-201 (middle) and EFHD2-002 (bottom). Shown
are introns (thin lines) and exons (black boxes) as well as 5’- and 3’-untranslated regions
(white boxes). b) Alignment of the mRNA translation of EFHD2-001 (top line) and
EFHD2-201/002 (bottom line), which are identical. Amino acid alignment is indicated
by bold font and comprises the region containing the EF-hand domains EF1 and EF2,
indicated by black boxes. The coiled coil domain present in EFHD2-001 but not in
EFHD2-201/002 is indicated by a grey box.
In order to establish if all isoforms of EFHD2 are expressed in the hu-
man brain, specific primers were designed, which recognise either EFHD2-001
or EFHD2-002/201 specifically (Table C.1). To this aim, the forward primer
5-TCGACCTGATGGAGCTGAAACTCA-3 was designed so that it could be
used for both pairs. For EFHD2-001, the reverse primer 5-GATGGCCTGGA
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CCTTGGCCTCAAAG-3 was used, which would hybridise in the region spanning
the exon border between exons 3 and 4, so that amplification from EFHD2-002
or EFHD2-201 or from genomic DNA would be precluded and it would produce
a 269 bp product. A second reverse primer specific for the EFHD2-002 and 201
splice variants 5-GCAAAGCAAGGGCGCTCGA-3 was designed, so it would hy-
bridise in a region inside the additional exon, which is present in these variants
and produce a 351 bp product. These primers were used in RT-PCR reactions to-
gether with 1 µl cDNA produced from DNase I digested 5 µg of total RNA isolated
from approximately 100 mg human hippocampus (Control 1) tissue as described
in Chapter 2.2.2. The tissue was kindly provided by the Manchester brain bank
through Prof. David Mann. Figure 4.5 shows a PCR product produced with the
EFHD2-001 reverse primer that separated at the expected molecular weight in-
dicated by a 1 kb DNA-ladder between 200 and 400 bp. The identity of the PCR
product was also confirmed by ligation into a linearised pGEM-T-easy vector con-
taining TA-cloning sites (Promega), which also allowed for blue-white screening
after transformation of the ligated vector into DH5α E.coli bacteria (Chapter
2) and sequencing of the insert. This primer pair was subsequently used for
quantitative real-time PCR analysis on human tissue (Section 4.5). At the same
time, no PCR product could be produced using the alternative reverse primer
EFHD2-002 under the same conditions (data not shown). Increasing the amount
of cDNA (up to 5 µl), testing a sample from a different brain region, namely the
cerebellum from FTLD patients, increasing the number of PCR cycles (up to 42
cycles) or the amount of primers (up to 1 µM) did also not result in the amplifi-
cation of a specific product at the expected size. It was therefore concluded that
the EFHD2-002 and EFHD2-201 splice variants are not expressed in the human
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brain at a detectable level.
Figure 4.5: EFHD2-001 expression in human brain. Forward primer EFHD2-Fwd:
5-TCGACCTGATGGAGCTGAAACTCA-3 and reverse primer EFHD2-001-Rev: 5-
GATGGCCTGGACCTTGGCCTCAAAG-3 were used together with 1 µl of cDNA
produced from human hippocampus and a specific 269 bp product was amplified using
Taq-polymerase (Roche) as described in Chapter 2.2.2.
4.4 Anti-EFHD2 antibodies
I planned to investigate EFHD2 protein levels in human and in mouse brain tissue
by western blotting. Because of the limited number and quality of commercial
anti-EFHD2 antibodies, I tested a mouse derived monoclonal anti-EFHD2 anti-
body which was kindly provided by Dr. Irving Vega (University of Puerto Rico)
as well as a commercial anti-EFHD2 antibody raised in goat for the detection of
transfected and endogenous EFHD2 protein in cell and tissue lysates. Phospho-
rylated cell lysates were prepared from SK-N-SH cells 72 h after infection with
lentiviruses containing the pHJ-EGFP-SW1 plasmid or an empty pHJ-EGFP
plasmid as described in Chapter 2.3.5. Expression from both plasmids (see Fig-
ure B.3) is driven by a CMV-promoter and in the case of pHJ-EGFP-SW1 this
leads to the expression of a N-terminal fusion of human EFHD2 (swiprosin 1,
SW1) with EGFP (expected size: 53 kDa). However, due to the cloning strategy
used in the creation of the pHJ-EGFP-SW1 plasmid, untagged EFHD2 (expected
size: 27 kDa) can also be expressed from this plasmid. This is, because the start
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codon present in the EFHD2 sequence in the vector is preceded by a Sal 1 re-
striction site (recognition sequence GTCGAC) which together with the guanine
in GCC triplet following the ATG codon, represents a strong Kozak consensus
sequence (gccRccAUGG, where “R” at the -3 position from the AUG is a purine).
Tissue lysates were prepared from human frontal cortex as described in Chap-
ter 3.3 and for this test, mixed samples with a protein concentration of 1 mg/mL
from all FTLD samples together or from control samples together were prepared.
Mouse brain phosphorylated protein lysates were produced from 8 month old
wild-type or mAPP expressing mouse brains or from embryonic day 14 (ED14)
mouse cortices as described in Chapter 2.1.1 and diluted to 1 mg/mL in protein
sample buffer. 25 µl of the denatured protein samples were separated on a 12.5%
SDS-PAGE and transferred to supported nitrocellulose membrane for immuno-
staining. Blots were incubated overnight at 4 ◦C with primary antibodies and
detected the next day with a horse-radish peroxidase coupled anti-mouse anti-
body raised in goat (Abcam, see Table A.2). As a negative control, the mouse
anti-EFHD2 antibody was pre-absorbed by mixing the antibody in a 1:1 ratio
with purified His-tagged EFHD2 protein (see Section 4.4.1) for 3 h at room tem-
perature. Figure 4.6 shows the result of the western blot analysis.
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(a)
(b)
Figure 4.6: Evaluation of a Mouse anti-EFHD2 antibody.
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Figure 4.6: Evaluation of a mouse anti-EFHD2 antibody (continued). (a) Western
blot of samples from human frontal cortex (Hu FCx), mouse cortex from an embryonic
day 14 (ED14) mouse embryo, adult wild-type (WT) and mAPP transgenic mice and
from SK-N-SH cells infected with EFHD2 (pHJ-Sw-1) or EGFP (pHJ-EGFP) express-
ing plasmids. Images show staining with a monoclonal mouse anti-EFHD2 antibody
after short exposure (top) and long exposure (middle). Staining with a monoclonal
mouse anti-actin antibody served as a loading control (bottom). Arrows point to
EGFP-EFHD2 or endogenous human EFHD2. Arrowheads point to a non-specific band
caused by the secondary antibody. b) The same samples stained with pre-absorbed
mouse anti-EFHD2 antibody. Top: short exposure, bottom: long exposure. Arrows
and arrowheads point to EFHD2 or the non-specific band as in (a).
Staining with the monoclonal mouse anti-EFHD2 antibody revealed a strong
band migrating above the 50 kDa molecular weight marker, which corresponds
to the EGFP-EFHD2 (expected size 53 kDa) in infected SK-N-SH cells, which
could not be detected in the control EGFP-infected SK-N-SH cells (Figure 4.6(a),
top)). Longer detection times also revealed a band migrating at about 30 kDa,
corresponding to untagged EFHD2 in these samples, which was stronger in the
infected SK-N-SH cells due to overexpression of untagged human EFHD2 from
the pHJ-Sw-1 plasmid (Figure 4.6(a), middle)). Equal loading between the SK-
N-SH cell samples, the wild-type (WT) and mAPP mouse cortex samples and
the human frontal cortex samples was indicated by comparable band intensity
in the actin immunostaining below (Figure 4.6(a), bottom). In addition, strong
bands separating at 25 kDa and above 50 kDa (arrowheads) were detected at
longer detection times, which could however also be seen when the EFHD2 an-
tibody was pre-absorbed with His-EFHD2 (arrowheads in Figure 4.6(b)) as well
as in the blot stained with a monoclonal mouse anti-actin antibody (arrowhead
in Figure 4.6(a), bottom). This indicated that these were non-specific bands,
caused by the secondary antibody used in this experiment. A different goat anti-
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mouse secondary antibody was therefore used in subsequent analyses of tissue
samples. Bands migrating at approximately 30 kDa could also be detected in the
samples from human frontal cortex but not in the samples from mouse cortex
(Figure 4.6(a), middle). These bands were nearly abolished by pre-absorption of
the primary antibody with purified His-EFHD2 protein (arrow in Figure 4.6(b),
middle), indicating that they represented endogenous human EFHD2. Because of
the strong overexpression of EFHD2 in the SK-N-SH cells, EGFP-EFHD2 could
still be detected even after pre-absorption of the antibody (Figure 4.6(b), top).
Immunostaining with a commercial goat anti-EFHD2 antibody also revealed
a strong band corresponding to EGFP-EFHD2 in infected SK-N-SH cells (arrow
in Figure 4.7, top) and also endogenous and untagged overexpressed EFHD2 mi-
grating at approximately 30 kDa (arrow in Figure 4.7, bottom). Human EFHD2
in frontal cortex as well as SK-N-SH cells was only weakly detected with this an-
tibody, whereas endogenous murine EFHD2 in adult wild-type (WT) and mAPP
mouse brains was stained efficiently (arrow in Figure 4.7, bottom). A strong non-
specific band was caused by the primary goat anti-EFHD2 antibody at about
50 kDa. This part of the membrane was therefore removed when endogenous
EFHD2 had to be detected in mouse derived samples in subsequent analyses in
order to improve the staining result.
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Figure 4.7: Detection of murine EFHD2. Western blot of samples from human frontal
cortex (Hu FCx), mouse cortex from an embryonic day 14 (ED14) mouse embryo, adult
wild-type (WT) and mAPP transgenic mice and from SK-N-SH cells infected with
EFHD2 (pHJ-Sw-1) or EGFP (pHJ-EGFP) expressing plasmids. Images show staining
of murine EFHD2 by the a goat anti-EFHD2 antibody after short exposure (top) and
long exposure (middle). Arrows point to endogenous EFHD2 in adult mouse brain and
overexpressed human EFHD2 in SK-N-SH cells.
In summary, both, the monoclonal mouse anti-EFHD2 antibody as well as the
goat anti-EFHD2 antibody were able to detect overexpressed and endogenous
EFHD2. However, the commercial goat derived antibody appeared to prefer-
entially detect murine EFHD2, whereas the monoclonal mouse derived antibody
detected human EFHD2. Interestingly, only a very faint protein band for EFHD2
could be detected in the sample from embryonic day 14 (ED14) mouse cortex,
suggesting that the protein levels are lower in the embryonic compared to the
adult mouse cortex.
I therefore performed semi-quantitative reverse transcription PCR (RT-PCR),
in order to verify these difference in EFHD2 protein expression. I extracted total
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RNA from ED14 and ED16 mouse cortices as well as from an adult wild-type
mouse cortex and performed cDNA synthesis using random hexamer primers
with a Roche cDNA synthesis kit. The PCR reaction as described in Chapter
2.2.2 was performed using the primer set EFHD2-Fwd and EFHD2-001-R for
the EFHD2 reaction and actin specific primers as a loading control with an an-
nealing temperature of 58 ◦C (see Table C.1). Figure 4.8, shows the results of
the RT-PCR. It can be seen that despite equivalent cDNA loading demonstrated
by similarly strong amplification of the actin PCR-product in all samples, the
EFHD2 message was clearly less abundant in the embryonic samples than in the
adult brain. Quantification of the band intensities by densitometry normalised
to the band intensity of the actin RT-PCR product in each sample revealed that
the band in ED16 mouse brain sample corresponded to 57% and the band in the
ED14 mouse brain to only 27% of the PCR-product detected in the adult mouse
brain. Further analysis will be necessary in order to explain the developmental
regulation of EFHD2 expression. RT-PCR or real-time PCR analysis on a larger
number of samples from embryonic, adult and early postnatal brains would be
able to demonstrate when changes in EFHD2 expression levels occur. Further-
more, mapping of EFHD2 expression in the mouse brain at these developmental
stages by immunohistochemistry or in-situ hybridisation might help to explain
where EFHD2 is located and which cell types it is associated with in the brain.
Figure 4.8: EFHD2 mRNA in murine brain.
152
CHAPTER 4. THE NOVEL CALCIUM-BINDING PROTEIN EFHD2 IS
ASSOCIATED WITH FRONTOTEMPORAL DEMENTIA
Figure 4.8: EFHD2 mRNA in murine brain (continued). RT-PCR on cDNA produced
from adult, ED14 and ED16 mouse brain tissue. Shown are PCR products for EFHD2
(top) and actin (bottom) as a house keeping gene. No-template controls were included
in the RT-step and the PCR reaction.
4.4.1 Purification of 6 × His-tagged EFHD2
His-tagged EFHD2 protein was expressed in BL21 E c.coli bacteria and purified
for experiments in which antibodies were pre-absorbed with the target protein as
a negative control. A bacterial expression vector for the expression of 6 × His-
tagged EFHD2 was kindly provided by Dr. Irving Vega (University of Puerto
Rico). The EFHD2 sequence and presence of the histidine tag were confirmed by
sequencing, which also revealed that the start codon was present in the EFHD2
cDNA sequence itself as well as the N-terminal His-tag. Like with the pHJ-EGFP-
Sw 1 plasmid, this could lead to the expression of untagged protein, although only
the AU-rich sequence of the N-terminal His-tag (codons CAT or CAG), bound
by the S1 ribosomal protein in gram-negative bacteria, but no Shine-dalgarno
sequence (AGGAGG) were present in the sequence.
Chemically competent BL21 bacteria were transformed with approximately
60 ng of the plasmid and plated on ampicillin containing LB-agar plates.
Overnight cultures from individual colonies were grown in ampicillin containing
LB-medium the following day, glycerol stocks were prepared from these cultures
and a small induction experiment was performed as described in Chapter 2.1.4
in order to verify successful induction of protein expression from the plasmid. A
fresh 10 mL overnight culture was prepared from the glycerol stock with best
expressing clone and expression of the protein in a 1 L culture at OD(600 nm) =
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0.6 and purification with Ni-NTA agarose were performed as described in Chapter
2.1.5. The only modifications to this protocol were that the lysis buffer (50 mM
Tris, pH 8.0, 0.5 M NaCl, 100 µg/mL DNase I, 100
mg/mL lysozyme, protease
inhibitors without EDTA), wash buffer (50 mM Tris, pH 8.0, 0.5 M NaCl, 10 mM
imidazol, protease inhibitors) and elution buffer (50 mM Tris, pH 8.0, 0.5 M
NaCl, 300 mM imidazol, protease inhibitors) did not contain any glycerol.
Figure 4.9(a) shows an image of a Coommassie stained gel containing all
fractions sampled during the purification process. A strong band corresponding
in size to His-EFHD2 could be detected in the 4 h induced sample but not in the
uninduced bacteria. This band was again present in the lysate but depleted in
the supernatant after incubation with the Ni-NTA agarose. The wash fractions
(W1–W5) also contained some of the protein alongside other proteins, which were
loosely attached to the beads. This indicates that a fraction of the His-EFHD2
bound only weakly to the Ni-NTA resin under these conditions, possibly due to
misfolding of the protein or expression of EFHD2 without the His-tag. However,
elution with 300 mM imidazol resulted in the retrieval of the majority of the
protein in the first elution step. In order to concentrate the samples and to reduce
the high NaCl concentration and imidazol from the elution buffer, the samples
with the highest protein concentration and purity were concentrated on a spin
column with a 10 kDa molecular weight cut-off (Amicon, Milipore) at 4000 × g
until the samples were 5–10 fold concentrated. The desalted column retention
was then mixed in a 1:1 ratio with a buffer containing 50 mM Tris, 350 mM NaCl
and 5% glycerol, so that the resulting samples contained 25 mM Tris, pH 8.0,
150 mM NaCl and 2.5% glycerol. The final protein concentration of the samples
was then measured with a Bradford microplate assay, and a 10 µl sample of
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the protein was separated on a 10% SDS-PAGE for an analytical staining. The
samples were finally snap frozen in liquid nitrogen and stored at -80 ◦C. Figure
4.9(b) shows a picture of the Coommassie stained gel after concentration of the
samples in comparison to a sample from the un-induced bacterial culture and
from the un-concentrated first eluate. It is apparent after the concentration of
the samples that all elution fractions also contained proteins other than His-
EFHD2. However, it was decided that the relative abundance of the protein was
sufficient for the purpose of this study (pre-absorption of an antibody) and that
further optimisation of the purification protocol was therefore not necessary at
this stage.
(a)
Figure 4.9: Purification 6 × His-tagged EFHD2.
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(b)
Figure 4.9: Purification 6 × His-tagged EFHD2 (continued). a) Fractions of the
purification process shown on a Coommassie stained gel. W1–W5: wash fractions 1–
5, E1–E5: elution fractions 1–5, beads: NiTA agarose after elution. b) Coommassie
stained gel of fractions W3, W4 and elution fractions E1–E3 after concentration on a
spin column with 10 kDa molecular weight cut off, compared to the uninduced sample
and fraction E1 before concentration on the spin column.
4.5 EFHD2 expression levels are increased in
human dementia
Following on from the findings by Vega et al. that EFHD2 associates more with
hyper-phosphorylated tau in the AD brain (Vega et al., 2008), I investigated if
total EFHD2 protein and mRNA levels were also changed in brains affected by
AD or by FTLD compared to age-matched control individuals. Samples from
the frontal cortices, hippocampi and cerebella from human brain with either a
diagnosis of AD, FTLD or no dementia were provided by the Manchester brain
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bank through Prof. David Mann. Table 3.1 gives histopathological scores for the
brain regions from each individual the samples were obtained from. Phospho-
rylated protein samples for western blotting analysis from four FTLD patients,
five AD patients and five age-matched control individuals were prepared by lysis
of approximately 300 mg of brain tissue in 1 mL of phospho-lysis buffer as de-
scribed in Chapter 2.1.1. Protein samples were diluted to a final concentration
of 1 mg/mL in 1 x protein sample buffer and 20 µl samples were separated on a
12.5% SDS-PAGE and subjected to western blotting and staining using the mouse
monoclonal anti-EFHD2 antibody and a HRP coupled goat anti-mouse secondary
antibody from Jackson Immunoresearch. Figure 4.10(a) shows the results of the
immunostaining and Figure 4.10(b) shows a bar chart representing the quan-
tification of the stained bands relative to actin of 3 repeats of the western blot
analysis. This quantification revealed that there was a tendency towards higher
levels of EFHD2 in all brain regions from FTLD sufferers and that EFHD2 levels
were increased significantly in the hippocampi compared to controls. However,
no changes in the levels of EFHD2 could be detected in AD cases.
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(a)
(b)
Figure 4.10: Levels of EFHD2 protein and mRNA in human tissue.
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(c)
Figure 4.10: Levels of EFHD2 protein and mRNA in human tissue (continued). Hu-
man tissue from frontal cortex (FCx), hippocampus (Hippo) or cerebellum (Cere) from
individuals with frontotemporal lobar degeneration (FTLD), Alzheimer’s disease (AD)
or age-matched non-demented individuals (Control) was analysed. a) Western blot
analysis of EFHD2 protein levels. Actin was used as a loading control. b) Quantifi-
cation of stained bands from 3 independent experiments by densitometry, normalised
to actin. Mean values were calculated for FTLD, AD and control and groups were
compared by 2-way ANOVA with Bonferroni post-hoc test. Error bars show SEM. n
= 4–5 c) Quantification of EFHD2 mRNA levels by quantitative real time PCR. Three
independent measurements were performed and each time expression levels were calcu-
lated relative to actin mRNA. Control = 1, n = 5–6. Error bars show SEM. Differences
were compared using 2-way ANOVA and Bonferroni post-hoc test.
I then also analysed EFHD2 mRNA levels in brains with dementia compared
to non-demented controls. In order to do this, I extracted total RNA from approx-
imately 100 mg of frozen human brain tissue from all brain regions provided by
the Manchester brain bank and removed potential DNA contamination by 45 min
DNase I digestion and produced cDNA with the Revert Aid reverse transcriptase
with reduced RNase H activity (Fermentas) as described in Chapter 2.2.2. For
this analysis, I analysed all six cases diagnosed with FTLD, five cases with AD
and five non-demented control cases. I then performed real-time qPCR analysis
as described in Chapter 2.2.3 using Brilliant II or Brilliant III SYBR Green kits
(Agilent) with 200 nM each of EFHD2-R-001 and EFHD2-Fwd primers (see Ta-
ble C.1). As a loading control, qRT-PCR for actin was performed with the same
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samples on the same PCR-plate and the analysis was repeated 3 times. The
calculation of expression levels of EFHD2 compared to actin was done according
to the ∆CC method (see formula described in Chapter 2.2.2). A bar chart il-
lustrating the collated results normalised to the non-demented control samples is
shown in Figure 4.10(c). The results are in line with the western blot analysis and
reveal a significant increase in the EFHD2 mRNA levels in the hippocampi from
FTLD cases but no changes in samples from AD cases compared to non-demented
controls.
These expression changes (up-regulation in the hippocampus but not the
frontal cortex of FTLD patients) might sound odd at first, given the name of
the disease which suggests a more frontal location of the pathology in the brain.
However, a biochemical marker for frontotemporal dementia does currently not
exist and it has not been possible to say, which neuronal cell populatoins are
affected by pathology in the FTLD brain and in fact how this exactly compares
between the various different types of FTLD. To this date, FTLD has mainly
been described as a spectrum of neurological symptoms characterised by atrophy
in certain brain regions and specific protein inclusions as described in Section 1.3.
As reviewed by Goedert et al. (2012), the hippocampus (in the temporal lobe)
and is function are also affected by these processes and it is conceivable, that
EFHD2 might mark a subset of neurons affected by FTLD in the hippocampus
as part of the disease process at a later stage. It will therefore be very important
to expand this study to more cases of different types of FTLD and to also include
immunohistochemical analysis of EFHD2 expression in the future.
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4.6 EFHD2 protein levels are increased in an
AD mouse model
The tight regulation of calcium levels and calcium mediated signalling processes,
partly through the mitochondrial permeability transition pore (mPTP), play a
crucial role for neuronal function. Cyclophilin D (CypD) is an important compo-
nent of the mPTP and ablation of the Ppif gene encoding CypD has been shown
to be protective against Aβ toxicity and neurodegeneration in AD mouse models
(Du et al., 2008, 2009, 2011). CypD has furthermore been shown to delay the
onset of pathology in motor neurons in a mouse model for amyotrophic lateral
sclerosis (ALS) (Martin et al., 2009), a disease which EFHD2 has been linked
to as well (Zhai et al., 2009). I therefore tested if deficiency in the CypD gene
has an influence on the protein levels of EFHD2. The CypD deficient mouse line
had been cross-bred with the Tg2572 mAPP mouse line, which is characterised
by amyloid pathology due to the overexpression of human APP695 harboring
the Swedish mutation (APPK595N/M596L). The pathology observed in the mAPP
transgenic animals includes reduction of the mitochondrial calcium buffering ca-
pacity and cognitive dysfunction at the age of 6–8 month, while tau-pathology
is absent. I analysed the levels of EFHD2 in protein samples from the brains
of wild-type and transgenic mouse brains, which are either deficient for the Ppif
gene (CypD−/−), overexpressing mAPP or both (mAPP/CypD−/−). To this aim,
protein samples were used which had been prepared by lysis of 1 hemisphere of
a mouse cortex in approximately 1 mL of protein lysis buffer as described in
Chapter 2.1.1. The protein concentration of the pre-diluted samples was mea-
sured using a Bradford assay and 30 µg of protein were separated on a 4–12%
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NuPAGE Bis-Tris acrylamide gel (Invitrogen).
In order to confirm the genetic background of the samples used in this study,
protein levels of APP and CypD were analysed by western blotting as shown in
Figure 4.11. Note the high levels of APP protein levels in one of the wild-type
control samples.
Figure 4.11: Cyclophilin D deficiency in a transgenic mouse model for AD. Western
blot analysis of APP (upper panel) and cyclophilin D (lower panel) in protein extracts
from whole mouse brains from wild-type (WT) animals or transgenic littermates as
indicated. Actin was used as a loading control.
I then performed western blot analysis of the same samples with a goat anti-
EFHD2 antibody and the results of the analysis are presented in Figure 4.12(a).
Actin staining was used as a loading control by re-probing the membranes after
removal of the first antigen as described in Chapter 2.1.3.
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(a)
(b)
Figure 4.12: EFHD2 in mAPP transgenic and CypD-deficient mouse models. Levels
of EFHD2 were measured in mouse brain tissue from wild-type (WT), mAPP overex-
pressing (mAPP), CypD-deficient (CypD -/-) and double transgenic (mAPP/CypD--/-)
animals;. (a) Western blot for EFHD2 using a goat anti-EFHD2 antibody. Actin was
used as loading control. (b) Quantification of stained bands by densitometry. WT = 1.
Error bars show SEM; n = 3. Significance was tested using 1-way ANOVA and Tukey’s
post-hoc test.
The western blot analysis on three brains from each genetic background was
repeated 3–5 times and the band intensities of the stained bands were quantified
by densitometry. A bar chart summarising the results is shown in Figure 4.12(b).
The results demonstrated that EFHD2 protein levels were not changed in brains
from CypD-deficient animals with or without expression of mAPP (compare WT
indicated by the horizontal bar to CypD−/− and mAPP to mAPP/CypD−/−).
This shows that the presence or absence of CypD and therefore regulation of
mitochondrial calcium release had no effect on EFHD2 protein levels in these
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mouse models. At the same time, quantification of the stained bands revealed that
EFHD2 protein levels were increased 1.2-fold in mAPP overexpressing animals
compared to their wild-type APP expressing littermates. This suggests that Aβ-
pathology or overexpression of human APP695 in the transgenic mouse model in
the absence of tau-pathology can affect EFHD2 protein levels.
The increase of EFHD2 in mAPP expressing animals is in line with previous
findings by our group from a proteomics study on mAPP overexpressing or wild-
type animals (Frank Gunn-Moore, unpublished data). Still, the increase was
unexpected in the light of the results obtained from the human AD brain, where
no such increase could be detected compared to non-demented controls. Because
the transgenic mouse model used in the above study had been engineered to
overexpress human APP protein, I tested if the up-regulation of EFHD2 protein
and mRNA levels in the human FTLD affected brain also correlates with higher
APP protein levels.
Western blot analysis and quantification of the stained bands of total APP
protein were performed on the human brain samples used to study the protein
and mRNA levels of EFHD2 (see Section 4.5). As shown in Figure 4.13, APP
protein levels were indeed elevated in the human hippocampus of FTLD cases
compared to non-demented controls but this up-regulation was not present in the
sporadic AD cases studied here. Due to the small number of cases studied and the
variable levels of APP within the groups, the increase was however only statisti-
cally significant when tested using a direct comparison to non-demented controls
by T-test (see Figure 4.13(c)) rather than 2-way ANOVA (Figure 4.13(b)).
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(a)
(b) (c)
Figure 4.13: APP protein levels in human dementia
165
CHAPTER 4. THE NOVEL CALCIUM-BINDING PROTEIN EFHD2 IS
ASSOCIATED WITH FRONTOTEMPORAL DEMENTIA
Figure 4.13: APP protein levels in human dementia (continued). Levels of APP in
different brain regions from human dementia sufferers (continued). (a) FCx: frontal
cortex, Hippo: hippocampus, Cere: cerebellum. Actin was used as a loading control.
(b) Quantification of stained bands by densitometry. APP bands were normalised to
actin and mean values were compared. Error bars show SEM. Control = 1. n =
5(c) Quantification of APP stained bands by densitometry. Bands were normalised to
actin as a loading control and mean values were compared. Significance was tested
using T-Test. Error bars show SEM. FTLD: Frontotemporal lobar degeneration, AD:
Alzheimer’s disease.
4.7 The cellular location of EFHD2
4.7.1 EGFP-EFHD2 in SK-N-SH neuroblastoma cells re-
veals a cytosolic location.
The function and location of EFHD2 have not been investigated in neurons and
neuronal cell lines so far. In order to get an insight into the location of EFHD2 in
these cell types, I transfected plasmids expressing either full length murine Flag-
tagged EFHD2 in a vector co-expressing EGFP controlled by an internal riboso-
mal entry site (pIRES-EGFP, see Figure B.4), or Flag-tagged EFHD2 lacking the
coiled coil domain (EFHD2∆CC) into SK-N-SH cells. Transfection was achieved
by lipofection of 2 µg of plasmid into approximately 85% confluent SK-N-SH cells,
which had been plated the day before in 35 mm Petri-dishes and expression of the
transgene was checked by fluorescence imaging of EGFP 48 h after transfection.
Cells grown on coverslips were then fixed with 4% PFA and permeabilised as
described in Chapter 2.4 and stained with the monoclonal mouse anti-EFhd2 an-
tibody or an M2 anti-Flag antibody (Sigma) overnight at 4◦C. The following day,
primary antibodies were detected with a goat anti-mouse IgG antibody coupled
to the Dylight 594 fluorescent marker (see Table A.1) and nuclei were counter-
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stained with DAPI. Figure 4.14 shows the result of the immunocytochemistry
after imaging with a Zeiss Axiostar epifluorescence microscope. Cells successfully
transfected by lipofection could be identified by their GFP-signal. Accordingly,
those cells also stained with a mouse anti-EFHD2 antibody (Figure 4.14 (a)) and
an anti-Flag antibody (Figure 4.14 (b)). At the same time no staining could be
observed with either antibody in non-transfected cells identified by the absence of
GFP-fluorescence, indicating that endogenous EFHD2 levels were too low for de-
tection by ICC using this antibody. This is in agreement with the findings from
the western blot analysis, where endogenous human EFHD2 could also not be
detected efficiently using this antibody (see Figure 4.6). Compared to the evenly
distributed cytosolic EGFP signal, staining of both the full length as well as the
EFHD2∆CC mutant appeared granular or punctate, which could be seen partic-
ularly well in cells with lower expression levels. This suggests an association with
intracellular membranes. However, the identity of these potential membranes
has not been investigated yet. Co-localisation studies with markers for intracel-
lular compartments such as the Golgi complex and the endoplasmic reticulum or
membrane domains such as lipid rafts will help to answer this question.
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(a)
(b)
Figure 4.14: Flag-EFHD2 in SK-N-SH cells. (a) Top: ICC against EFHD2 in SK-N-
SH cells 48 h after transfection with full length EFHD2 (left) or EFhd2∆CC (right).
Bottom: Imaging of EGFP co-expressed from the plasmid highlighting transfected cells.
(b) Fluorescence images of an ICC against the Flag-tag in SK-N-SH cells 48 h after
transfection with full length Flag-EFHD2 (left) or EFHD2∆CC (right). Images show
an overlay with DAPI. Scale bars = 10 µm.
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4.7.2 EFHD2 in primary neurons
I aimed to investigate the function of EFHD2 in a more physiologically relevant
system and therefore also studied the location of EFHD2 in mouse primary cor-
tical neurons. For this, ED14 primary neurons were grown on glass coverslips
and cultured for 72 h before fixation and staining of endogenous EFhd2 with ei-
ther of the available anti-EFhd2 antibodies. Unfortunately, immunocytochemical
staining with the goat anti-Efhd2 antibody could not be achieved. Immuno-
cytochemistry using the monoclonal mouse anti-EFhd2 antibody resulted in a
strong staining. However, it was realised that the staining pattern was signifi-
cantly different from the pattern seen in the transfected SK-N-SH cell line and
using a confocal microscope as well as a Deltavision deconvolution microscope
the same signal could also be seen in areas on the coverslips without any cells or
cell processes. It was therefore concluded that the staining pattern had derived
from an interaction of the primary antibody with the poly-D-lysine coating of
the coverslips used for the neuronal cultures.
In order to overcome this problem, I infected primary neurons with a lentivi-
ral vector for the expression of GFP-tagged EFHD2 (pHJ-Sw-1) as described
in Section 4.4. ED14 primary cortical neurons were infected 72 h after plating
on poly-D-lysine coated coverslips and cells were fixed with 4% PFA, mounted
in Prolong Gold mounting medium (Invitrogen) and imaged using a Deltavision
deconvolution microscope 48 h after infection. Figure 4.15 shows deconvolved
images of primary neurons expressing EGFP-EFHD2, one near the center of the
cell soma (left) and another image of the cell near the cell membrane on the
coverslip, where the cell processes can be seen as well (right). They illustrate
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the distribution of EFHD2 throughout the cytoplasm of the cell, including all
cell processes and sparing out the area of the cell nucleus. The pattern of the
GFP-signal appeared granular, and with accummulations in some areas of the
cell in a similar way to that detected in neuroblastoma cells (see Figure 4.14).
Figure 4.15: GFP-EFHD2 in primary cortical neurons. ED14 cortical neurons were
imaged after 5 days in vitro, 48 h after after infection with a lentiviral vector for the
expression of EGFP-EFHD2. Image stacks of 0.2 µm thickness were acquired with a
Deltavision deconvolution microscope. Left: Image slice close to the cell center. Right:
Image slice close to the cell membrane. Scale bar = 5 µm
Treatment of infected primary neurons before fixation with 22 µM Aβ(42),
which is known to affect cell stress signalling, mitochondrial function and calcium
signals in neurons, for 4 h, 12 h or 24 h did not affect this distribution of the
EFHD2 signal. Again, co-localisation studies of EFHD2 with markers for cellular
organelles and compartments will help to identify the exact location of EFHD2 in
the cytoplasm. Also, immunoelectron microscopy of EFHD2 in SK-N-SH cell cul-
tures or primary neurons will provide helpful information about the distribution
of EFHD2 throughout neuronal cells.
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4.8 The effect of EFHD2 overexpression in cell
lines and primary cortical neurons
4.8.1 Cell viability in EFHD2 overexpressing cultures
I investigated if overexpression of EFHD2 had an impact on the viability of
SK-N-SH cells or primary neurons. Constructs for the expression of full length
Flag-EFHD2 in the pIRES-EGFP expression vector, mutant Flag-EFHD2∆CC
or empty pIRES-EGFP vector were transfected into SK-N-SH cells plated in 8
wells of a 96-well plate with an equal number of cells for each condition. Cell
viability was assessed 48 h after transfection by MTT assay as described in chap-
ter 2.3.7.1. The average absorption of the formazan product at 570 nm in all 8
wells per condition was normalised to the average value obtained by the empty
pIRES-EGFP vector control. The results are presented in the bar chart in Fig-
ure 4.16(a). The MTT assay revealed no difference in cell viability between the
Flag-EFHD2 transfected cells and cells transfected with the control vector.
(a)
Figure 4.16: Cell viability in cells overexpressing EFHD2.
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(b) (c)
Figure 4.16: Cell viability in cells overexpressing EFHD2 (continued). (a) SK-N-
SH plated in a 96-well plate were transfected with a 0.2 µg per well of a pIRES-
EGFP expression vector for Flag-EFHD2, Flag-EFHD2∆CC mutant (EFhd2-dCC) or
an empty pIRES-EGFP vector. Cell viability of 8 wells per condition was measured
by MTT-assay and an average of absorbance at 570 nm was calculated (EGFP control
= 1). n = 3; error bars show SEM. (b) ED14 primary neurons were nucleofected with
a pcDNA3 expression vector for EFHD2 or an empty pcDNA3 vector at the time of
plating in a 96-well plate. Cell viability was measured by MTT-assay 3 days after
plating as in (a). n = 3; error bars show SEM. (c) Cell counts of primary neurons
transfected as in (b). Cell numbers in 5 fields of view of a 40× phase contrast objective
were counted 24 h after nucleofection and again 48 h after plating. The bar chart
presents the ratio of cell numbers at 48 h over cell numbers at 24 h. n = 3; error bars
show SEM.
I also explored the cell viability of primary neuronal cultures overexpressing
EFHD2. ED14 mouse primary cortical neurons were transfected by nucleofection
at the time of plating with full length EFHD2 in a pcDNA3 expression vector,
which was created in collaboration with Ms Zoe Allen. Neurons were cultured in
8 wells of a poly-D-lysine coated 96-well plate for each condition and after 3 days
in vitro the cell viability of the cultures was measured by MTT assay. Compared
to the empty pcDNA3 vector, overexpression of EFHD2 had no effect on the
reduction of MTT (Figure 4.16 (b)). Similarly, average cell counts on five phase
contrast images of nucleofected neurons after 24 h, 48 h or 72 h in culture did
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also not reveal any changes between EFHD2 expressing cells and empty vector
controls (Figure 4.16 (c)). It was therefore concluded that overexpression of
EFHD2 alone does not affect cell viability either in cell lines or primary neurons.
EFHD2 or its ∆CC mutant might still be able to modulate the activation of
pathways important for cell viability in response to extracellular signals.
A propidium iodide (PI) exclusion assay by FACS analysis of PI-fluorescence
did not show any changes in cell viability between SK-N-SH cells transfected
with either full length EFHD2, EFHD2∆CC or pIRES-EGFP. This might indi-
cate that the difference in MTT reduction measured previously did not represent
changes in cell viability but rather mitochondrial dehydrogenase activity in cells
transfected with the EFHD2∆CC mutant or that the PI-exclusion assay is not
sensitive enough to measure subtle changes of cell viability. In order to further
address the question of cell viability in cultures overexpressing EFHD2 or its mu-
tants, exposure of transfected cells to toxic agents or calcium modulators could
be helpful in elucidating a potential effect. Exposure of the cell cultures to Aβ
or the quinone-analogue and known oxidising agent menadione followed by mea-
surement of cell viability were tested but later abandoned because of technical
difficulties with the cell toxicity caused by the chemicals. An interesting alter-
native to this approach could be the measurement of intracellular calcium fluxes
with calcium-indicators such as Fura-2 or the assessment of other mitochondrial
properties such as the mitochondrial membrane potential with tetramethyl rho-
damine dyes in transfected cell cultures. This approach might be able to clarify
if EFHD2 or its ∆CC mutant are able to modulate intracellular calcium signals
in neuronal cells and indirectly influence cell viability, similar to its function in
B-lymphocytes described before (Avramidou et al., 2007; Kroczek et al., 2010).
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4.8.2 Analysis of the PI3-kinase pathway
Studies in mast cells have linked EFHD2 to the activation of the PI3-kinase
(PI3K)/Akt signalling pathway (Ramesh et al., 2009; Thylur et al., 2009). Be-
cause of the significance of this signalling pathway for cell survival as well as its
involvement in the control of GSK3 activity, which is one of the main tau-kinases
in the brain (see Chapter 1.2.3.2 and Hers et al. (2011)), I studied a potential in-
fluence of EFHD2 overexpression on the activation of PI3K signalling in neuronal
cells.
Activation of PI3K leads to the phosphorylation and activation of Akt (also
known as protein kinase B, PKB) by phosphorylation at Thr308 and Ser473 (facil-
itated by Thr308 phosphorylation) via 3-phosphoinositide-dependent protein ki-
nase 1 (PDK-1) and the mammalian target of rapamycin complex 2 (mTORC 2)
respectively. Active Akt then causes the phosphorylation and regulation of a
large number of substrates, including GSK3, PRAS 40 and pro-caspase 9 (Hers
et al., 2011). I investigated the activation of this pathway by western blotting
for phosphorylated Akt and its substrate GSK3. Because of the high transfec-
tion efficiency that can be achieved by lentiviral infection, I used this method
to deliver EGFP-EFHD2 (pHJ-SW1) or an empty EGFP vector (pHJ-EGFP)
into SK-N-SH cells plated, so the cells would reach different cell densities during
lentiviral infection and expression of the transgene (confluent, high cell density,
low cell density). Cells were infected 24 h after plating in a 6-well plate and
phosphorylated proteins from 3 wells per condition were extracted 48 h after in-
fection as described in Chapter 2.1.1 and subjected to SDS-PAGE and western
blotting. Figure 4.17 shows the results of the western blot analysis and bar charts
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presenting the quantification of total Akt as a ratio over actin, phosphorylated
Ser473-Akt and phosphorylated Thr308-Akt as ratios over the total amount of Akt.
(a)
(b) (c)
(d)
Figure 4.17: Akt signalling in SK-N-SH cells overexpressing EFHD2.
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Figure 4.17: Akt signalling in SK-N-SH cells overexpressing EFHD2 (continued). (a)
SK-N-SH cells were infected with lentiviruses delivering expression vectors for EGFP-
EFHD2 or EGFP alone. Cell were plated so that they reached confluency (left), high
cell density (middle) or low cell density (right) 48 h after infection. Western blot-
ting for Akt phosphorylated at Thr308 (pThr308-Akt), at Ser473 (pSer473-Akt), for
total Akt or actin was performed. (b)–(c) Quantification of phosphorylated Akt bands
by densitometry. The bar charts show ratios of Ser473-phosphorylated (b) or Thr308-
phosphorylated (c) Akt over total Akt protein (arbitrary units). (d) Quantification of
total Akt by densitometry. The bar chart presents ratios of total Akt protein over actin
stained bands. Significance was tested by 2-way ANOVA and Bonferroni post-hoc test.
Error bars show SD.
In agreement with the studies performed in immune cells, SK-N-SH cells in-
fected with full length EGFP-EFHD2 exhibited increased phosphorylation of
Akt compared to cells infected with the vector expressing EGFP alone (Fig-
ure 4.17(a)). However, this effect was strongly dependent on the cell density of
the infected cultures, so that phosphorylation of Akt could only be caused by
EFHD2 at high cell densities and was only significant for the Thr308 site in con-
fluent cultures, while in low density cultures, phosphorylated Akt levels tended
to be reduced, although this effect was not significant (see Figure 4.17(a)–(c)).
Interestingly, a similar reduction of phospho-Thr308 Akt and phospho-Ser473 Akt
levels could be observed in SK-N-SH cells transfected with EFHD2 by lipofection,
where the lower cell density was caused by toxicity of the lipofection reagent (not
shown). Quantification of total Akt levels in lentivirally infected SK-N-SH cells
revealed that EFHD2 also caused a reduction of total Akt protein compared to
EGFP expressing cells (Figure 4.17(d)).
It was noted that cell density alone also had an effect on the levels of total
and phosphorylated Akt protein. Total Akt protein levels increased significantly
in high density cultures (Figure 4.17(d)), whereas levels of Ser473 phosphorylation
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decreased (Figure 4.17(b)) and phosphorylation at the Thr308 site was not affected
at all in control infected cultures (Figure 4.17(c)). Meanwhile, a strong increase
of phosphorylation at Thr308 was seen the presence of EFHD2, indicating that
EFHD2 facilitates the activation of Akt via PDK, possibly upon stimulation of
cell adhesion molecules or neurotrophic factors in these cells.
Despite this effect on Akt phosphorylation, western blot analysis of GSK3α/β
phosphorylation in the same cultures as above did not reveal any effect of EFHD2
overexpression (Figure 4.18).
Figure 4.18: GSK3-phosphorylation in SK-N-SH cells overexpressing EFHD2. SK-N-
SH cells were infected with lentiviruses delivering expression vectors for EGFP-EFHD2
or EGFP alone. Cell were plated so that they reached confluency (left), high cell density
(middle) or low cell density (right) 48 h after infection. Western blotting for GSK3α/β
phosphorylated at Ser21/9, for total GSK3α/β or actin was performed
With the strong effect seen SK-N-SH cell line, the activation of the Akt-
signalling pathway in primary neuronal cultures from ED14 mouse cortex was
tested next. Primary neurons were plated on poly-D-lysine coated dishes and
infected with the same lentiviral expression vectors for EGFP-EFHD2 or the
EGFP control as used for the neuroblastoma cells. 72 h after infection, phospho-
rylated proteins were extracted from the neurons and SDS-PAGE and western
blot analysis were performed.
The results of the analysis of Ser473 phosphorylated Akt from two independent
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experiments are presented in Figure 4.19(a). As seen in lanes 1 and 3, overexpres-
sion of EGFP-EFHD2 did cause a significant reduction of Akt-phosphorylation
at Ser473 compared to the empty EGFP vector infected neurons. Quantification
of the stained bands of 5 repeats of the experiment revealed a 50% reduction of
Akt phosphorylation at this site. Notably, a smiliar albeit not statistically sig-
nificant effect had been detected in SK-N-SH cells overexpressing EFHD2 at low
cell density (Figure 4.17(b)–(c)). EFHD2 overexpression had however no effect
on the levels of total Akt in primary neurons compared to EGFP control infected
neurons.
(a) (b)
(c)
Figure 4.19: Akt signalling in primary neurons overexpressing EFHD2.
178
CHAPTER 4. THE NOVEL CALCIUM-BINDING PROTEIN EFHD2 IS
ASSOCIATED WITH FRONTOTEMPORAL DEMENTIA
Figure 4.19: Akt signalling in primary neurons overexpressing EFHD2 (continued).
(a) ED14 cortical neurons were infected with lentiviruses delivering expression vectors
for EGFP-EFHD2 or EGFP alone. Phosphorylated proteins were analysed 72 h after
infection by western blotting for Akt phosphorylated at Ser 473 (pSer473-Akt), total
Akt or actin. (b) Western blot analysis of the same samples as in (a) for GSK3α/β
phosphorylated at Ser 21/9 (p-GSK3α/β) or total GSK3α/β. (c) Quantification of
phosphorylated protein bands by densitometry. The bar chart presents ratios of pSer473-
Akt over total Akt protein. Error bars show SD. Significance was tested by T-Test.
I also analysed the phosphorylation of GSK3α/β in primary neurons overex-
pressing EFHD2 by western blot analysis (Figure 4.19(b)). In agreement with
the results obtained from the SK-N-SH cell line, I could not find any effect of
EFHD2 overexpression on GSK3α/β phosphorylation, indicating that EFHD2
acts in a different branch of the Akt-signalling cascade in both SK-N-SH cells
and embryonic primary neurons.
4.9 Discussion and outlook
4.9.1 EFHD2 in frontotemporal dementia and AD
With the work described in this chapter, I demonstrated that the EF-hand do-
main containing protein D2 (EFHD2) is linked to neurodegeneration and that
its function might be especially relevant in the pathogenesis of frontotemporal
dementia. I showed that protein and mRNA levels of EFHD2 are up-regulated
in frontotemporal dementia compared to non-demented age-matched controls but
unchanged in AD patient brains (Figure 4.10). These results fit together with the
results presented by Vega et al. (2008), who discovered an increased association of
EFHD2 with hyperphosphorylated (sarkosyl-insoluble) tau in a mouse model for
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frontotemporal dementia and also implied an increase in EFHD2 protein levels
in the temporal cortex from a human FTLD case, although no association with
tau could be observed in this case (Vega et al., 2008). Vega et al. did find an
increased association of EFHD2 with tau in a single human AD case, where in-
soluble tau-aggregates were present (Vega et al., 2008), however I could not find
an increase in EFHD2 expression levels in the AD cases studied in the course of
this project. In addition, I could also not find a correlation of EFHD2 protein
or individual mRNA expression levels with the levels of tau-pathology detected
in the individual human AD and FTLD brain samples (see Table 3.1) or with
the tau mutations present in the FTLD cases studied. However, an association
of EFHD2 with soluble or insoluble tau species by immunoprecipitation has not
been studied in the course of this work. It would therefore be valuable to find
out if the association of EFHD2 with tau in the AD brain is still maintained in
the samples studied here. Furthermore, analysing the expression levels and as-
sociation of EFHD2 with tau in more cases of FTLD with or without mutations
in tau would be an important piece of the puzzle, as it is the first time that a
protein has been linked to different variants of FTLD.
Together, the currently available data points towards a potential role for
EFHD2 in neurodegenerative diseases which are accompanied by distinct types
of tauopathy (like in FTLD compared to AD or the JNPL3 mouse model). As
mentioned in Chapter 1.2.3.2, some experimental results have already pointed
towards differences in the mechanism of tauopathy between these diseases, when
different tau-mutations and their ability to form tangles and promote Aβ-toxicity
were investigated (Tackenberg and Brandt, 2009). The question is therefore if
EFHD2 could be one of the molecules manifesting these differences in the human
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brain, possibly by changing tau-metabolism through its up-regulation in FTLD
but not AD. Investigating the location of tau and EFHD2 in neurons overex-
pressing EFHD2 would be helpful in clarifying this matter. With respect to the
findings from the JNPL3 mouse model expressing the more aggregation prone
P301L mutant version of human tau, it would also be of interest to explore if
mutant tau or hyperphosphorylated tau associated with late stage tau-pathology
in the human AD brain has an increased affinity for EFHD2. This might explain
why EFHD2 is not associated with tau in an FTDP17 brain not containing the
same species of aggregated tau protein (Vega et al., 2008).
I also presented evidence that the up-regulation of EFHD2 coincides with a
potential up-regulation of APP protein in the FTLD cases studied (Figure 4.13).
Similarly, analysis of EFHD2 expression levels in an mAPP transgenic mouse
model expressing mutant human APP695 revealed an up-regulation of EFHD2
in the mAPP transgenic mouse model. This hints at a potential role for an up-
regulation of APP levels in the regulation of EFHD2 expression levels (see chapter
6).
4.9.2 EFHD2 influences PI3K signalling
One of the most important tau-kinases involved in tau-pathology is GSK3. Be-
cause of its signalling properties in other cell systems and the new link between
EFHD2 and FTLD pathology, I investigated the phosphorylation of GSK3 and
the activation of its upstream regulator Akt in response to EFHD2 overexpression
in SK-N-SH cells and primary neuronal cultures (Figures 4.17, 4.18 and 4.19).
I could not find any effect of EFHD2 overexpression on the phosphorylation of
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GSK3α/β, indicating that EFHD2 is probably not involved in the regulation of
its function in cell lines or embryonic primary neurons.
However, EFHD2 did have an impact on the PI3K/Akt signalling pathway, as
the phosphorylation and therefore activation of Akt were increased in SK-N-SH
cells (see Figure 4.17). Of note, EFHD2 overexpression mainly affected Thr308
phosphorylation at high cell density in these cells, implying that EFHD2 activates
the pathway through PDK 1, which is the kinase responsible for phosphorylation
at this site (Hers et al., 2011), and that a cell adhesion molecule or neurotrophic
stimulation might be upstream of EFHD2. It will now be essential to decipher
the activators and targets of this EFHD2 containing signalling cascade. A screen
for interaction partners of EFHD2 is in progress in our lab and will be helpful in
defining candidate proteins in neuronal cells. Furthermore, western blot analysis
of known PI3K and Akt effectors other than GSK3 with a potential relevance for
neuronal functions such as PRAS40 and pro-caspase 9 or IRS 1 and regulators of
the actin cytoskeleton such as ARP 1/2, Rac or WASP will shed light on which
other branches of the PI3K/Akt pathway might be modulated.
The role of EFHD2 in primary neurons, where a marked reduction of Akt-
phosphorylation on Ser473 was detected, bears some similarity to the situation
in low density SK-N-SH cultures but is markedly different from high density
neuroblastoma cell cultures. These differences could be due to the trophic stim-
ulation received by high density cultures, where EFHD2 acts as a facilitator of
Akt signalling but the relative lack of such stimulation in low density cultures and
differentiated primary neurons, where it appears to have the opposite effect. As
mentioned in the introduction to this chapter, opposing effects of EFHD2 overex-
pression (on NFκB activation and Ca2+ signalling) have also been described for
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B-cells (Kroczek et al., 2010) compared to mast cells (Ramesh et al., 2009) and
between immature and mature B-cells (Avramidou et al., 2007). Future stud-
ies should therefore investigate a potential effect of EFHD2 overexpression on
the stimulation of PI3K/Akt signalling in neurons above baseline, for example
in response to exposure to neurotrophins. Additionally, determining the state of
Akt-phosphorylation in human brains affected by FTLD, where EFHD2 levels
are elevated and in non-demented control brains could provide some information
about which direction EFHD2 might be working in in the adult human brain.
In conclusion, Figure 4.20 illustrates how EFHD2 might act as a scaffold or
adaptor protein in the PI3K/Akt signalling pathway in a similar fashion to its
role at the B-cell receptor. It will be the task for future research to identify other
partners and upstream molecules of this potential scaffold.
Figure 4.20: EFHD2 in PI3K/Akt signalling.
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Figure 4.20: EFHD2 in PI3K/Akt signalling (continued). EFHD2 can lead to the
activation of Akt and might therefore act as an adaptor protein for PI3-kinase (PI3K) at
cell surface receptors or other membrane proteins, which then results in the production
of phosphoinositol-trisphosphate (PIP3) from phosphoinositol-bisphosphate (PIP2) and
the recruitment of PIP3-dependent kinase 1 (PDK 1), which phosphorylates Akt at
Thr308 in its activation loop. The Phosphatase and tensin homolog protein (PTEN),
can inactivate the pathway again by de-phosphorylating PIP3. The mammalian target
of rapamycin complex 2 (mTORC 2) phosphorylates Ser473 in Akt at a hydrophobic
motif, which facilitates Thr308 phosphorylation and might play a role in the regulation
of Akt-specificity. Modified with permission from Elsevier B.V. (Hers et al., 2011).
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5.1 Introduction
5.1.1 Peroxiredoxin-2 as an antioxidant and signalling
modulator
Peroxiredoxin-2 (Prx-2) is a 198 aa cytosolic protein belonging to a group of an-
tioxidant enzymes which possess peroxidase activity (ROOH + 2e → ROH +
H2O). Peroxiredoxins are a very abundant species in the cell and function to re-
duce hydrogen peroxide, organic peroxides and the very toxic peroxinitrite and
thereby represent an important defense against damaging oxidation of proteins
and lipids. In the case of Prx-2, which is a 2-Cys peroxiredoxin, the enzymatic
mechanism involves 2 cysteine residues, a peroxidatic cysteine and a resolving
cysteine, which react in two steps as depicted in Figure 5.1. The first step is
the reduction of the peroxide through a nucleophilic attack by the peroxidatic
cysteine residue, which leads to the formation of a cysteine sulfenic acid interme-
diate in Prx-2. The second step is the recovery of the Cys-sulfhydryl group. This
involves Prx-2 homodimerisation and formation of a disulfide bond between the
peroxidatic cysteine of one subunit with the resolving cysteine of the other sub-
unit, followed by the recovery of both cysteins with the help of disulfide reductase
together with thioredoxin. It has been proposed that redox-sensitive oligomeri-
sation/decamerisation of Prx-2 also forms part of its normal catalytic cycle and
enhances the catalytic activity of the subunits (Wood et al., 2003; Rhee et al.,
2005).
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Figure 5.1: Mechanisms of 2-Cys peroxiredoxins. (a) First step: reduction of the per-
oxide (in red), by the peroxidatic cysteine residue. The peroxidatic cysteine is de-ionised
by a catalytic base (B:) and stabilised by a conserved arginine residue. The outgoing
ROO− group is protonated by a catalytic acid (B:H). (b) Recovery of the oxidised
enzyme. Formation of a disulfide bond between the peroxidatic cysteine sulfenic acid
(black) and a resolving cysteine residue from another Prx-2 subunit (pink). Reduction
of the cysteine residues is achieved by a disulfide reductase together with thioredoxin
which is oxidized from a dithiol (2RSH) to a disulfide (RSSR). Reprinted with permis-
sion from Elsevier Science Ltd. (Wood et al., 2003).
High levels of ROS or low levels of Prx-2 have been shown to result in an
overoxidation of the catalytic cysteine residue to a non-reactive sulfinic acid (Cys-
SO2H) and the inactivation of the enzyme (Wood et al., 2003). With regard to
the rapid increase in ROS levels needed in order for H2O2 to act as a signalling
molecule, this inactivation of 2-Cys peroxiredoxins has been proposed to play an
important part in the facilitation of local H2O2 signalling events by delaying ROS
degradation (Rhee et al., 2005). Notably, the inactivation of 2-Cys peroxiredoxins
(but not other proteins containing cysteine residues which can be overoxidised)
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can eventually be reversed by the actions of sulfiredoxin (Srx), which reduces the
sulfinic acid back to the active thiol (Rhee et al., 2005).
An additional mechanism for regulating Prx-2 activity is its phosphorylation
at Thr89 by cyclin-dependent kinases, which has been shown to diminish its enzy-
matic activity by interfering with the homodimerisation required for the recovery
of the catalytic cysteine residues (Wood et al., 2003).
By controlling the diffusion of reactive oxygen species inside the cell, perox-
iredoxins have also been recognised as modulators of signalling events mediated
by H2O2. The main sources for reactive oxygen species in the cell are their leak-
age from the electron transport chain at complex I (NADH-oxidase) or NADPH
oxidase in the cytosol, both of which produce the reactive superoxide anion that
can then be converted to H2O2 by superoxide dismutase in the mitochondria and
the cytosol. It has been shown that production of ROS by NADPH-oxidases can
be enhanced for example in response PDGF- or TNFα exposure (Kang et al.,
1998) and also plays a part in other cellular processes such as the EGF-receptor
signalling, vascular endothelial growth factor (VEGF) and interleukin 1 (IL-1)
signalling as well as oxidative events in the ER (reviewed in Hall et al. (2009)).
Also, superoxide-flashes, caused by a transient opening of the mPTP in single
mitochondria of cells under normal conditions and cells under stress (hypoxia)
have been described (Wang et al., 2008) and could be an additional source for
localised peroxide signalling.
One of the most important signalling molecules activated by ROS is JNK and
intriguingly, Prx-2 has been given a role in the regulation of JNK activity in yeast
as well as in mammalian cells (Veal et al., 2004; Lee et al., 2011). In yeast, this
has been found to depend on the formation of a disulfide bond between Prx-2 and
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the yeast specific JNK-homolog Sty1 in response to peroxides, which promotes
its activation (Veal et al., 2004). In a human cancer cell line, Prx-2 has also been
identified as an activator of JNK/c-Jun-signalling in response to DNA damage
(Lee et al., 2011). Interestingly, this activation was found to be independent from
oxidative stress caused by the compounds studied, as Prx-2 expression efficiently
inactivated the oxidative species during exposure, but rather by a direct effect of
Prx-2 on JNK in the nucleus (Lee et al., 2011). However, this does not exclude
the possibility that peroxides are required to induce this interaction, as they
induce changes in Prx-2 conformation and quaternary structure (Wood et al.,
2003; Hall et al., 2009). Given this new function of Prx-2 in cellular signalling
events it is not surprising, that Prx-2 has been found to be associated with the
same pool of retrograde synaptic vesicles as Ep-1 and the JNK-interaction protein
JIP3 in the mouse brain cortex (Abe et al., 2009). This introduces the interesting
possibility that Prx-2 might be able to influence JNK-activation at the synapse
or at retrogradely transported synaptic vesicles.
5.1.2 Peroxiredoxin-2 in neurodegeneration
The role of Prx-2 has also been studied in model systems for neurodegeneration.
Like AD and FTLD, Parkinson’s disease is a disease associated with aging mani-
festing with a pronounced resting tremor, slowing of simple movements (bradyki-
nesia), an inability to move (akinesia) and rigid limbs, which can at a later stage
also be accompanied by personality changes and dementia. Underlying PD is the
degeneration of dopaminergic neurons in the substantia nigra of the brain and
the formation of toxic Lewy body inclusions made of α-synuclein. This is often
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associated with genetic mutations in the gene encoding for the ubiquitin-E3 ligase
Parkin, which is thought to interfere with protein (sich as α-synuclein) degrada-
tion and lead to cell death (Mayeux, 2003). It is noteworthy though that some
parallels between the pahtologies of AD and PD, especially with focus on mito-
chondrial dysfunction and oxidative stress have been identified (Beal, 1995) and
that APP as well as α-synuclein have been found to be able to be transported to
mitochondria causing their dysfunction (Devi and Anandatheerthavarada, 2010).
Unsurprisingly then, overexpression of Prx-2 has been shown to protect dopamin-
ergic neurons from oxidative stress induced by exposure to 6-hydroxydopamine
(6-OHDA) as a model for Parkinson’s disease in vitro and in vivo, where endoge-
nous Prx-2 becomes inactivated by overoxidation (Hu et al., 2011). It was also
revealed that the protection by Prx-2 was mediated by the inhibition of ASK-
activation and downstream activation of the JNK and p38 signalling cascades
(Hu et al., 2011) (see also Figure 3.1). Under normal conditions, ASK exists in
a complex with thioredoxin (Trx), termed ASK-signalosome, which dissociates
upon oxidation of Trx by cellular oxidants such as Prx-2 and leads to the release
of active ASK (Fujino et al., 2007). Accordingly, Hu et al. (2011) demonstrated,
that the oxidation of Trx was reduced and the association of ASK and Trx en-
hanced when the cells were exposed to 6-OHDA in the presence of surplus Prx-2,
thereby inhibiting ASK release and activation.
Qu et al. (2007) employed a different mouse model for PD, where neurodegen-
eration is induced by exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), which can also cause Parkinsonism in humans (Qu et al., 2007). It had
previously been shown, that activation of calpain and CDK5 are important me-
diators of MPTP induced toxicity on dopaminergic neurons (Smith et al., 2003).
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In the course of their study, Qu et al. identified Prx-2 as an interacting partner
of CDK5 through its activator p35, and showed that Prx-2 is phosphorylated by
CDK5/p35 at Thr89 in MPTP exposed neurons in vitro and in vivo, decreasing
its activity (Qu et al., 2007). In line with the study by Hu et al. (2011), wild-type
Prx-2 as well as a Prx-2T89A mutant, which can not be phosphorylated, both pro-
tected neurons against MPTP induced toxicity (Qu et al., 2007). In contrast, a
Prx-2T89E mutant mimicking constitutive phosphorylation of the protein, could
not provide this protection. The importance of this posttranslational modifica-
tion for the pathology of the human disease was demonstrated, when increased
levels of phosphorylated Prx-2 could also be detected in human brains affected
by PD (Qu et al., 2007).
This new link between calpain and CDK5 activation and the function of Prx-2
in neurons is particularly interesting as an increased activation of calpains and of
CDK5 has also been implicated in AD as mentioned in Chapter 1. The calcium
regulated protease calpain can regulate Aβ production via BACE1 activation
(Liang et al., 2010; Mathews et al., 2002) and its activity is increased in the AD
brain (Saito et al., 1993) as well as in APP overexpressing cell cultures (Kuwako
et al., 2002). CDK5 is also up-regulated in AD (Pei et al., 1998; Swatton et al.,
2004) and is one of the most important tau-kinases in the brain (see Chapter
1.2.3.2). Its activation has furthermore been linked to the production of intra-
neuronal Aβ (Cruz et al., 2006) and to the signalling events mediating amyloid
toxicity (Wei et al., 2002; Zempel et al., 2010). At the same time, Prx-2 protein
levels have been shown to be elevated in the AD brain (Krapfenbauer et al., 2003;
Yao et al., 2007) and in the mAPP transgenic as well as the ABAD/mAPP dou-
ble transgenic mouse models as a result of the ABAD–Aβ interaction (Yao et al.,
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2007). This increase in Prx-2 expression could be due to the aggravated mito-
chondrial dysfunction and cellular stress seen in these mouse models (Takuma
et al., 2005). However, the processes leading to this up-regulation have not been
explained yet. The new findings in the mouse models for PD described above
also beg the question, if the up-regulation of Prx-2 and the activation of the cal-
pain/CDK5 system are linked in AD and if a phosphorylation of Prx-2 also plays
a role in AD pathology.
5.2 Aims of this chapter
The aim of the work presented in this chapter was to further elucidate the role of
Prx-2 in neurodegeneration. Hence, protein and mRNA expression levels of Prx-
2 were analysed in human brain samples from patients with dementia (AD and
FTLD) and compared to the levels found in non-demented controls. Taking their
relationship in the mAPP/ABAD double transgenic mouse model into account,
the expression levels of ABAD and Ep-1 were also analysed in human brains
with dementia. Other mouse models for neurodegeneration were analysed in
order to broaden the picture of how the expression of these proteins is linked to
neurodegenerative disorders in general.
Finally, the the effect of Prx-2 on neuronal cell survival and the activation
of the JNK-signalling cascade were studied in an in vitro model for AD. Mouse
embryonic primary neurons were transfected with Prx-2 or its mutants and cell
survival and the phosphorylation of components of the JNK-signalling cascade in
response to exposure to amyloid were analysed.
It was anticipated that these studies would shed more light on the functions
193
CHAPTER 5. PEROXIREDOXIN-2 IN DEMENTIA AND IN VITRO
MODELS FOR NEURODEGENERATION
of Prx-2 and also of ABAD and Ep-1 in different settings of neurodegeneration.
A deeper understanding of their roles in the brain will also be necessary in order
to validate ABAD as a potential drug-target for the treatment of Alzheimer’s
disease.
5.3 Expression levels of Prx-2 in human AD and
AD mouse models
5.3.1 Analysis of Prx-2 protein levels in brains from hu-
man dementia sufferers
Protein and mRNA expression levels of Prx-2 were analysed in brain tissue sam-
ples from human dementia sufferers as described before in Chapters 3.3 and 4.5.
Tissue samples from 4 patients diagnosed with FTLD, 5 cases diagnosed with AD
and 5 non-demented control subjects were used for the analysis. For real-time
PCR analysis 6 FTLD cases were analysed. Figure 5.2 shows the results of the
western blot and qPCR analyses of Prx-2 expression. The western blot images
5.2(a) together with quantification of the western blots by densitometry shown in
Figure 5.2(b) revealed that while there was a tendency towards higher levels of
Prx-2 in the hippocampus of both, AD affected brains and the frontal cortex from
FTLD cases, only the levels of Prx-2 in the hippocampus from FTLD patients
were increased significantly compared to non-demented controls. No changes of
Prx-2 expression could be measured by qRT-PCR (Figure 5.2(c)).
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(a)
(b)
Figure 5.2: Prx-2 protein levels in human dementia.
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(c)
Figure 5.2: Prx-2 protein levels in human dementia (continued). Levels of Prx-2
in different brain regions from human dementia sufferers. (a) FCx: frontal cortex,
Hippo: hippocampus, Cere: cerebellum. Actin was used as a loading control. (b)
Quantification of stained bands by densitometry. Prx-2 bands were normalised to
total actin and mean values were compared. Error bars show SEM. Control = 1, n =
5. Groups were compared using 2-way ANOVA and Bonferroni post-hoc test. FTLD:
Fronto-temporal lobar degeneration, AD: Alzheimer’s disease (c) Quantification of Prx-
2 mRNA levels by quantitative real time PCR. 3 independent measurements were
performed and each time expression levels relative to actin mRNA were calculated.
Control = 1. Error bars show SEM. n = 5. Groups were compared using 2-way
ANOVA and Bonferroni post-hoc test.
It was noted that this increase of Prx-2 expression correlated with the in-
creased APP and EFHD2 expression (see Figures 4.10 and 4.13) detected in the
hippocampus of FTLD cases, all of which have been linked to calcium controlled
processes in the cell either directly or via calpain/CDK5. It was unexpected not
to find increased expression of Prx-2 in the brain samples from human AD suf-
ferers in this this study, as an increased expression of Prx-2 had been shown in
AD previously (Ren et al., 2008; Krapfenbauer et al., 2003). This underlines the
large amount of variability that is inherent in studies on the post mortem human
brain and the need for sufficiently large samples sizes in order to detect more
subtle changes in protein or mRNA expression. It might also reflect differences in
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the cohorts studied by Yao et al. (Columbia Alzheimers Disease Research Center
brain banks) and in this study (Manchester brain bank).
5.3.1.1 Analysis of ABAD, Ep-1 and protein and mRNA expression.
In their studies on the cellular effects of the interaction of ABAD and Aβ on
neurons in the brain, Yao et al. and Ren et al. revealed that the increases in
Prx-2 expression (Yao et al., 2007) and Ep-1 levels (Ren et al., 2008) were caused
by the ABAD–Aβ interaction. Because of this link, I also analysed the mRNA
and protein expression levels of ABAD and Ep-1 the same samples from human
dementia patients. Figures 5.3(a) and (b) present the results of the analysis
of ABAD protein expression, which did not reveal differences in ABAD protein
levels between the different cases studied here. However, the analysis of ABAD
mRNA levels shown in Figure 5.3(c) demonstrated an increase in ABAD mRNA
expression in the hippocampi from AD and FTLD patients.
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(a)
(b)
Figure 5.3: Levels of ABAD protein and mRNA in brain tissue from human dementia
sufferers.
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(c)
Figure 5.3: Levels of ABAD protein and mRNA in brain tissue from human de-
mentia sufferers (continued). Human tissue from frontal cortex (FCx), hippocampus
(Hippo) and cerebellum (Cere) from individuals with frontotemporal lobar degeneration
(FTLD), Alzheimer’s disease (AD) or non-demented control individuals was analysed.
Analysis was performed as for Figure 5.2. (a) Representative images of ABAD western
blots. (b) Quantification of stained bands normalised to actin by densitometry. Control
= 1; n = 5 (c) Quantification of ABAD mRNA levels by quantitative real time PCR.
Control = 1; n = 5
In the same way, Figure 5.4 shows the results of the analysis of Ep-1 expres-
sion in these brain samples. Surprisingly, despite the increased expression levels
of ABAD mRNA and Prx-2 protein seen in the FTLD and AD affected hip-
pocampi (Figures 5.2 and 5.3), no differences in the protein or mRNA levels of
Ep-1 could be measured between the human AD, FTLD or non-demented control
cases analysed in this study.
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(a)
(b)
Figure 5.4: Endophilin-1 protein and mRNA in brain tissue from human dementia
sufferers.
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(c)
Figure 5.4: Endophilin-1 protein and mRNA in brain tissue from human dementia suf-
ferers (continued). Human tissue from frontal cortex (FCx), hippocampus (Hippo) and
cerebellum (Cere) from individuals with frontotemporal lobar degeneration (FTLD),
Alzheimer’s disease (AD) or non-demented control individuals was analysed. Analysis
was performed as for Figure 5.2. (a) Representative images of Ep-1 western blots. (b)
Quantification of stained bands by densitometry. Control = 1; n = 5. (c) Quantification
of Ep-1 mRNA levels by quantitative real time PCR. Control = 1; n = 5
In summary, these results show an increase of Prx-2 protein and ABAD mRNA
levels in the hippocampus from brains affected by FTLD, which has not been
noted before.
Meanwhile, this analysis could not confirm previous findings by Ren et al. and
Yao et al. , who had identified a link between the up-regulation of Ep-1 and Prx-2
in the AD brain and that of ABAD (Ren et al., 2008; Yao et al., 2007). Instead,
the analysis shown in Figures 5.2–5.4 revealed no changes in the protein levels
of Prx-2, ABAD or Ep-1 in the AD brain compared to non-demented controls,
although an increase in ABAD mRNA levels was measured.
As mentioned before, the discrepancies to the previous findings might reflect
inherent differences in the cohorts of donors studied or in the techniques used dur-
ing tissue sampling and preparation for western blotting and qRT-PCR. They do
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therefore point towards the high level of variability often seen when studying the
aging human brain, especially when investigating dementia. Furthermore, the ex-
pression levels of these proteins have not been studied by immunohistochemistry
during this study, which had been done by Yao et al. and Ren et al. to confirm
their western blotting results (Yao et al., 2007; Ren et al., 2008). Information
about the localisation and expression levels of these proteins in individual cells
could provide important information about their relative expression levels on the
cellular level which might be able to confirm a link between their expression levels
which the biochemical analysis could not reveal.
Also, a link between the expression levels of ABAD and Ep-1 could still
be found, even though it did not correlate with AD in the case of this study.
Analysing the western blot results for the individual samples, it was noted that
high levels of ABAD strongly correlated with high levels of Ep-1 protein, espe-
cially in samples from the frontal cortex and hippocampus. The findings of this
experiment do therefore not undermine the role for the Ep-1, Prx-2 or ABAD in
dementia pathology.
5.3.2 Prx-2 in a CypD-deficient mouse model for AD
The CypD deficient mouse model, crossed with mice overexpressing human mu-
tant APP has proven to be a valuable model to study the effects of increased
APP or Aβ levels and the impact of mPTP formation and mitochondrial calcium-
homeostasis (see also chapter 4.6). I therefore also analysed the protein levels of
Prx-2 in this mouse model by western blotting. Figure 5.5(a) shows the results
of the western blot analysis. Quantification of the stained bands by densitometry
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as shown in Figure 5.5(b) revealed that there was a significant increase in Prx-
2 protein levels in those animals overexpressing mAPP compared to wild-type
APP expressing mice. The reduction of oxidative stress in the CypD-deficient
animals was however not sufficient to reduce Prx-2 levels back to the levels seen
in wild-type animals (Figure 5.5(b)).
(a)
(b)
Figure 5.5: Peroxiredoxin-2 in the CypD-KO/mAPP transgenic mouse model. (a)
Western blot analysis of Prx-2 in protein extracts from whole mouse brains from 3
Wild-type (WT), CypD-deficient (CypD-/-) or mAPP or mAPP transgenic (mAPP)
littermates. (b) Densitometry of stained bands from 3 independent experiments. WT
= 1, n = 3. Error bars show SEM. Groups were compared using 1-way ANOVA and
Tukey’s post-hoc test. Actin was used as a loading control.
In keeping with the logic applied when the EFHD2 expression levels were
analysed (see chapter 4.6), up-regulation of Prx-2 levels could be detected in the
mAPP overexpressing mouse model but not in the human AD brain. Amyloid
pathology is an important feature of the human AD brain and its presence in
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the mAPP transgenic mouse brain has been confirmed by numerous independent
studies. This indicates that amyloid pathology does not correlate with increased
expression levels of Prx-2 in the samples studied here. At the same time total APP
protein levels have been found to be elevated in the FTLD-cases (see Figure 4.13)
and are by definition increased in the mAPP transgenic mouse model (see Figure
4.11). It therefore appears that Prx-2 expression correlates with an increase in
total APP protein levels, similar to what had been found for EFHD2 (see chapter
4.6).
5.3.2.1 JNK-activation in the CypD−/−/mAPP transgenic mouse
model
The human hippocampal tissue samples from FTLD-affected brains studied also
harbored significantly increased levels of phosphorylated JNK. I therefore anal-
ysed the phosphorylation of JNK in the brains from littermates of the wild-type,
CypD−/−, mAPP/CypD−/− and mAPP transgenic mice. To do this, phosphory-
lated proteins from the brain of one animal per genotype were extracted in 1 ml
of phospho-lysis buffer per cortical hemisphere as described in Chapter 2.1.1. Di-
luted protein samples were subjected to SDS-PAGE and western blot analysis
for total and Thr183/Tyr185 phosphorylated JNK. The results of the western blot
analysis presented in Figure 5.6 and suggest an increase in phosphorylated JNK
levels in the mAPP overexpressing animals (with or without CypD-deficiency)
compared to their wild-type APP transgenic by visual insepction of the staining
result. Activation of JNK in mAPP transgenic mouse models carrying the APP
swedish mutation has been described before (Hwang et al., 2004) and supports
the idea that JNK could be phosphorylated in the mouse model studied. How-
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ever, quantification of phosphorylated JNK was not possible due to the shortage
of brain samples from these transgenic animals.
Figure 5.6: Phosphorylated JNK in the CypD−/−/mAPP transgenic mouse model.
Western blot analysis of JNK phosphorylated at Thr183/Tyr185 (top) or total JNK
(bottom) in protein extracts from whole mouse brain from a wild-type (WT), CypD-
deficient (CypD−/−), mAPP transgenic (mAPP) or double transgenic littermates
(mAPP/CypD−/−).
This demonstrates again a co-occurrence of Prx-2 up-regulation and the pres-
ence of active JNK in tissue overexpressing APP. However, it has to be taken
into account that the animals studied here express the Swedish mutant of APP,
which also causes excessive Aβ pathology that also leads to JNK-activation (Mar-
ques et al., 2003; Minogue et al., 2003; Morishima et al., 2001). Therefore the
individual effects of APP and Aβ can not be dissected in this mouse model.
5.3.2.2 ABAD and Ep-1 in the CypD−/−/mAPP transgenic mouse
model
In line with the hypothesis that there is a link between increased levels of ABAD,
Ep-1 and Prx-2, I next analysed the protein expression levels of ABAD and Ep-
1, the in the CypD−/−/mAPP transgenic mouse model. Figures 5.7 and 5.8
show the results of the western blot analysis of 3 brains from each genotype and
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the quantification of the stained bands by densitometry. It is apparent that in
contrast to its effect on Prx-2 expression, CypD deficiency has no effect on the
expression levels of ABAD and Ep-1. Also, no changes in their expression could
be detected in the mAPP transgenic animals compared to their wild-type APP
expressing littermates.
(a)
(b)
Figure 5.7: ABAD protein levels in the CypD−/−/mAPP transgenic mouse model.
Western blot analysis of ABAD in protein extracts from whole mouse brains from 3
wild-type (WT), CypD-deficient (CypD -/-) or mAPP or mAPP transgenic (mAPP)
littermates. (a) Representative western blot images. (b) Densitometry of stained bands
from 3 independent experiments. WT = 1, n = 3. Error bars show SEM. Actin was
used as a loading control.
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(a)
(b)
Figure 5.8: Ep-1 protein levels in the CypD−/−/mAPP transgenic mouse model.
Western blot analysis of endophilin-1 (Ep-1) in protein extracts from whole mouse
brains from 3 wild-type (WT), CypD-deficient (CypD -/-) or mAPP or mAPP trans-
genic (mAPP) littermates. (a) Representative western blot images. (b) Densitometry
of stained bands from 3 independent experiments. WT = 1, n = 3. Error bars show
SEM. Actin was used as a loading control.
Previous studies had provided evidence that ABAD protein levels are in-
creased in the brains of AD patients (Yan et al., 1997; Lustbader et al., 2004)
and in a triple transgenic mouse model for AD, overexpressing mutant human
APP, presenilin and tau, which leads to excessive amyloid pathology in these
animals (Yao et al., 2009). However, no published study has investigated ABAD
protein levels in the mAPP single transgenic mouse model. Ren et al. (2008) did
also not reveal an up-regulation of Ep-1 in the mAPP transgenic mice but only
in the mAPP/ABAD double transgenic animals. It appears therefore, that over-
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expression of mAPP alone is not sufficient to cause the up-regulation of ABAD
and Ep-1.
5.4 Peroxiredoxin-2 protects primary neurons
in vitro
5.4.1 Prx-2 overexpression protects against Aβ toxicity
Prx-2 is an antioxidant protein and a such is expected to have protective effects
on cells exposed to toxic agents. This has been demonstrated for cells exposed
to 6OHDA (Hu et al., 2007) and to MPTP (Qu et al., 2007) and in an AD
specific setting, Yao et al. (2007) demonstrated that overexpression of Prx-2 can
protect primary neurons from cytotoxicity caused by Aβ exposure. In order to
further investigate the protective function of Prx-2, I tested the effect of the
overexpression of wild-type Prx-2 but also its phosphorylation mutant Prx-2T89E
in primary neurons exposed to Aβ. For these experiments, I chose to use the
same method of Aβ preparation employed in the study by Yao et al. (2007), who
used an aqueous solution of Aβ(25–35) aggregated at 37◦C over 3 days at a final
concentration of 50 µM (Yao et al., 2007) (see chapter 2.3.6).
At the time of plating, primary neurons were transfected by nucleofection
with 2 µg of wild-type Flag-Prx-2, a mutant version, Flag-Prx-2T89E (see Figure
B.4 for a plasmid map) or the empty pcDNA3 vector and plateD in 2 wells of
a ply-D-lysine coated 24 well plate (for cell counts) or 8 wells of a 96-well plate
(for MTT-assays). 72 h after plating, cells were treated with 50 µM Aβ(25-35) or
PBS as a control for 24 h and cell survival was assessed by counting cell numbers
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in 5 fields of view at the start and the end of the incubation period for each
condition or by MTT-assay. Figure 5.9 shows the results of the cell viability
tests. The bar chart in Figure 5.9(a) reveals that transfection of primary neurons
with wild-type Prx-2 prior to exposure to Aβ could provide a significantly higher
level of protection against amyloid toxicity compared to the empty vector control.
However, the Prx-2T89E mutant did not have the same effect. Similar results were
obtained when the cells were analysed by MTT assay as shown in Figure 5.9(b).
(a) (b)
Figure 5.9: Cell survival of primary neurons transfected with either wild-type Prx-2
(WT), mutant Prx-2T89E or an empty pcDNA3 vector control. 72 h after nucleofection
and plating, cells were treated with 50 µM Aβ(25-35) or PBS as a control for 24 h. (a)
Analysis of cell viability by cell counts in 5 fields of view per time point. The bar chart
presents the ratio of cell counts at the start over counts at the end of the incubation
period; pcDNA3 = 1. Error bars show SEM. n = 5. (b) MTT-assay of 8 wells per
transfection condition after exposure to 50 µM Aβ(25-35) or PBS for 24 h; PBS control
= 1. Error bars show SEM. n = 5. Significance between groups was tested using 1-
way ANOVA and Tukey’s post-hoc test. Differences towards the pcNDA3 control were
tested using T-Test.
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5.4.2 Overexpression of Prx-2 modulates JNK-signalling
in neurons.
As mentioned in section 5.1.1, Prx-2 has been linked to the activation of the
JNK signalling cascade by direct interaction with JNK (Veal et al., 2004) and by
indirect facilitation of ASK 1 activity through the oxidation of Trx (Hu et al.,
2011). Hence, I asked if overexpression of Prx-2, in addition to improving the cell
viability, also affected the activation of the JNK-signalling cascade in primary
neurons at baseline levels or in response to Aβ exposure.
Primary neurons in were prepared as described in chapter 2.3.2 and nucle-
ofected with Flag-tagged wild-type Prx-2, mutant Prx-2T89E, mutant Prx-2T89A
or an empty pcDNA3 vector as control. 72 h after transfection and plating, the
phosphorylation of JNK as well as of c-Jun were analysed by western blotting in
protein extracts from 3 combined 25 mm dishes of transfected cells. As shown
in Figure 5.10(a), staining for the Flag-tag expressed with Prx-2 confirmed suc-
cessful transfection of the neurons with the plasmids, while no Flag antigen could
be detected in the (pcDNA3) vector transfected cells. The figure also shows,
that transfection with Prx-2 or its mutants had no effect on the amount of phos-
phorylated JNK detected (Figure 5.10(a)) and quantification of stained bands in
(c)). However, a marked decrease in the levels of total and phosphorylated c-Jun
was found in neurons overexpressing Prx-2 or its mutants (Figure 5.10(a)) and
quantification of stained bands in (d)). This demonstrates a significant nega-
tive effect of Prx-2 overexpression directly c-Jun as a downstream effector of the
JNK-signalling cascade, but not on the phosphorylation and activation of JNK
itself.
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(a)
(b) (c)
Figure 5.10: Prx-2 effect on baseline JNK-signalling in neurons (continued). ED14
primary neurons were transfected by nucleofection with with 2 µg Flag-WT-Prx-2, Flag-
Prx-2T89E , Flag-Prx-2T89A or an empty pcDNA3 vector (Ve) at the time of plating.
(a) Western blot analysis of phosphorylated JNK, total JNK, phosphorylated c-Jun
and total c-Jun 72 h after plating. Actin was used as a loading control. Anti-Flag
staining was used to verify transfection. (b) Quantification of phosphorylated JNK
by densitometry. The bar chart presents the ratio of p-JNK over total JNK. pcDNA
control vector = 1 (dotted line), n = 4. Error bars show SD. (c) Quantification of
phosphorylated c-Jun by densitometry. The bar chart presents the ratio of p-c-Jun
over actin. pcDNA control vector = 1 (dotted line), n = 4. Error bars show SD.
Significance was tested using T-test against the control.
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Following from this result, I tested if Prx-2 overexpression could also interfere
with the phosphorylation of c-Jun seen after exposure of the cells to Aβ. In line
with the cell survival studies presented in Figure 5.9, Aβ(25–35) was again used
in this experimental setup. It could be shown that exposure of primary neurons
for 12 h to 25 µM of Aβ(25–35) caused the phosphorylation of JNK (Figure
5.11(a)) and the phosphorylation and up-regulation of c-Jun (Figure 5.11(b) and
quantification in (c)). Note the lower levels of total JNK compared to the control
in Figure 5.11(a), indicating a higher level of phosphorylated JNK relative to
total JNK. These results are in agreement with what had been shown for Aβ42
and Aβ40 (see Figure 3.6), where activation of c-Jun, probably through JNK,
could also be demonstrated.
(a) (b)
Figure 5.11: Activation of JNK by Aβ(25–35).
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(c) (d)
Figure 5.11: Activation of JNK by Aβ(25–35) (continued). ED14 primary neurons
were treated with 25 µM Aβ(25–35) or PBS as a control at 72 h in vitro. Phos-
phorylated proteins were analysed after 12 h exposure. (a) Western blot analysis of
phosphorylated JNK and total JNK. Actin was used as a loading control. (b) Quan-
tification of phosphorylated JNK by densitometry. The bar chart presents the ratio of
pJNK over total JNK. PBS = 1, n = 3. Error bars show SD. (c) Western blot analysis
of phosphorylated c-Jun and total c-Jun. Actin was used as a loading control. (b)
Quantification of phosphorylated c-Jun (left) and total c-Jun (right) by densitometry.
The bar charts present the ratio of pc-Jun over actin (left) or total c-Jun over actin
(right). PBS = 1, n = 3. Error bars show SD. Significance was tested using T-test.
Primary neurons were then transfected as before with 2 µg of wild-type Flag-
Prx-2, mutant Flag-Prx-2T89E or mutant Flag-Prx-2T89A and plated on 3 35 mm
dishes per condition. 72 h after plating neurons were exposed for 12 h to either
25 µM Aβ(25-35), aggregated for 3 days at 37 ◦C in PBS or PBS only as a control.
Phosphorylated proteins were extracted at the end of this incubation period and
subjected to SDS-PAGE and western blotting without delay. Figure 5.12 shows
the western blot images of c-Jun phosphorylation in the Prx-2 transfected and
amyloid-treated neurons. Staining of the Flag-tag expressed with Prx-2 was again
used to verify transfection. While virtually no phosphorylated c-Jun and only low
levels of total c-Jun could be detected in wild-type or mutant Prx-2 transfected
neurons exposed to the PBS control, overexpression of Prx-2 could not prevent
the up-regulation of total c-Jun and phosphorylated c-Jun levels in response to Aβ
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(Figure 5.12), which were up-regulated by visual inspection to the same extend
as seen in Figure 5.11(c).
Figure 5.12: Activation of c-Jun in Prx-2 overexpressing neurons. ED14 primary
neurons were transfected by nucleofection with with 2 µg Flag-WT-Prx-2 (WT), Flag-
Prx-2T89E (T89E), Flag-Prx-2T89A (T89A) at the time of plating. 25 µM Aβ(25–35) or
PBS as a control were added to the culture medium at 72 h in vitro for 12 h and total
c-Jun levels and phosphorylated c-Jun were analysed by western blotting. Staining
against β-actin was used as loading control. Anti-Flag staining was used to verify
transfection.
The differential effects of wild-type Prx-2 and its mutants on cell viability
(Figure 5.9) and on c-Jun phosphorylation (Figures 5.10 and 5.12), suggests that
different molecular processes were at play in both experimental setups. A strong
component of oxidative stress might lead to cell death in neurons exposed to
amyloid, which could be counteracted by Prx-2 overexpression but not by over-
expression of its T89E mutant. Meanwhile, no difference could be measured
between neurons nucleofected with wild-type Prx-2 or its mutants on c-Jun phos-
phorylation at baseline or after exposure to amyloid. This indicates that Prx-2
enzymatic function was not needed for its negative effect on c-Jun activity, which
appeared to be independent from JNK-phosphorylation (see Figure 5.10). In con-
trast, Aβ(25–35) exposure most likely caused c-Jun activation through JNK by
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other means (see Figure 5.11) and was therefore still able to activate this tran-
scription factor in Prx-2 overexpressing neurons. This also implies that Prx-2 was
not able to act as a strong enough antioxidant in nucleofected primary neurons,
which appeared to be more susceptible to the activation of the JNK-signalling
pathway (see Chapter 3.5.2). It would be possible to answer if this is the case by
measuring the amount of overoxidised Prx-2 in these cells, a method which has
been used by Hu et al. (2011). Importantly, it will also be necessary to test if the
same effects occur in cells infected with lentiviruses for Prx-2 expression, which
is a more gentle and efficient way of gene delivery.
5.5 Prx-2, ABAD and Ep-1 in a mouse model
for ALS
As mentioned in chapter 1.4.4, the Cu/Zn-dependent superoxide dismutase 1
(SOD1) has been identified as an amyloid binding molecule in cells (Yoon et al.,
2009). SOD1 has also been found to be up-regulated in AD and PD brain tissue
compared to non-demented controls and oxidation and aggregation of SOD 1
have been linked to senile plaques and neurofibrillary tangles in these brains
(Choi et al., 2005). Yoon et al. (2009) also pointed out that the G93A mutant
of SOD1 (SODG93A) which is linked to a familial form of amyotrophic lateral
sclerosis (ALS), has a greater affinity to Aβ than wild-type SOD 1. Bosco et al.
(2010) described that this SODG93A mutant shares conformational similarities
with oxidised wild-type SOD1, which can be detected in the spinal cord of human
sporadic ALS cases (Bosco et al., 2010). Of note, their investigation also revealed
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that oxidatively modified SOD but not normal SOD 1 could inhibit kinesin-
mediated fast axonal transport through an activation of p38-kinase. It is therefore
possible that a similar mechanisms underlie the modification and aggregation of
SOD1 seen in the AD and PD brain (Choi et al., 2005).
With this interesting link between AD and ALS in mind, I investigated
whether proteins known to be affected in the AD brain are also affected in a
mouse model for ALS expressing SODG93A. To this aim, cortices from 2 adult
SODG93A transgenic mice and 2 wild-type SOD1 littermates were dissected and
one hemisphere of each brain was lysed in 1 ml of protein lysis buffer as described
in Chapter 2.1.1. The protein concentration of the lysates was determined and
30 µg of total protein was subjected to SDS-PAGE and western blotting. Figure
5.13 shows representative images of the western blot analysis. It revealed, that
neither ABAD, Ep-1 or Prx-2 protein levels were altered in the SODG93A trans-
genic brains compared those from their wild-type SOD1 littermates. These results
indicate that defects in axonal transport and cytosolic oxidative stress caused by
overexpression of the mutant SOD1 in this mouse model are not sufficient to
cause alterations in ABAD, Ep-1 or Prx-2 as seen in human AD.
(a) (b)
Figure 5.13: Protein levels of ABAD, Ep-1 and Prx-2 in a mouse model for ALS.
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(c)
Figure 5.13: Protein levels of ABAD, Ep-1 and Prx-2 in a mouse model for ALS.
Western blot analysis for (a) ABAD, (b) Ep-1 and (c) Prx-2 in brain cortex protein
extracts from mutant SOD 1 (mSOD) overexpressing or wild-type control mice. Actin
staining was used as a loading control.
5.6 Prx-2 in neurodegeneration. Discussion and
outlook
The aim of the work presented in this chapter was to shed new light on the role of
Prx-2 in neurodegeneration with special focus on AD, where Prx-2 had previously
been found to be up-regulated (Yao et al., 2007).
5.6.1 Prx-2 in the human brain and transgenic mouse
models
With the analysis of protein and mRNA expression levels of Prx-2 in human
brain samples from patients with dementia (AD and FTLD) and non-demented
controls, I could for the first time reveal an up-regulation of Prx-2 protein levels
in the hippocampus from patients diagnosed with FTLD compared to the non-
demented individuals (Figure 5.2).
In the course of this study, I did not find the previously reported up-regulation
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of Prx-2 in the brains from AD patients and could also not measure increased
protein levels of ABAD and Ep-1, as reported previously (Yan et al., 1997; Yao
et al., 2007; Ren et al., 2008). This might be caused by technical differences
in the sampling of the tissue, variations in the execution of the experiments
and/or inherent differences in the cohorts studied (UK versus USA). Furthermore
a large degree of variation of expression levels was observed within the different
groups and this might have been possible to overcome with larger sample numbers
and the use of immunohistochemistry, revealing potential changes at the cellular
level. Especially the samples from FTLD patients represented a wide variety
of underlying diagnoses which might have been a confounding aspect (see Table
3.1). Finally, it had been hypothesised that the levels of ABAD, Prx-2 and Ep-1
become up-regulated during the early stages of pathology, possibly due to synaptic
failure, which implies that their elevated expression might not be detectable any
longer in the post-mortem tissue studied here. Information regarding disease
progression and length as well as the genetic background of the cases studied
here been gathered but could not be compared to the data from previous studies
which was not available.
5.6.2 The link to ABAD for Prx-2 and Ep-1
Despite the above described deviations, I could still observe a link between el-
evated levels of ABAD and higher levels of Ep-1, as individual samples with
increased ABAD protein levels also exhibited high levels of Ep-1. This verifies
the connection between these proteins as proposed by Ren et al. (2008). In con-
trast, I could not detect a similar correlation between ABAD protein levels and
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Prx-2 expression, that had been predicted by its additional up-regulation in the
mAPP/ABAD double transgenic mouse model compared to the mAPP trans-
genic animals (Yao et al., 2007). However, unlike Ep-1, Prdx-2 was also elevated
in the mAPP transgenic animals alone, a finding, which I verified with the work
described in this chapter (Figures 5.5 and 5.8). This suggests, that the addi-
tional mitochondrial and oxidative stress experienced in the double transgenic
mouse model (Takuma et al., 2005) might have prompted the increase in Prx-2
expression.
Different mechanisms appear to be involved in the up-regulation of Ep-1 and
its link to ABAD, as overexpression of mAPP alone was not sufficient to cause
the up-regulation of ABAD and Ep-1 in the mAPP transgenic animals (Figures
5.7 and 5.8). This is even though Aβ pathology can be observed in these an-
imals like in the human AD brain and it could be due to a potential effect of
the overexpressed APP protein itself (that is the AICD) acting as a signalling
molecule or transcriptional regulator (see Chapter 1.2.1.3). This effect might be
outweighed by the exacerbated production of Aβ in the triple transgenic mouse
model, where increased ABAD expression has been reported (Yao et al., 2009),
so it would be interesting to see if Ep-1 levels are also elevated in these animals.
Deciphering the mechanisms that underlie the link between ABAD and Ep-1 will
be important for explaining the diverse roles of ABAD in neuronal networks and
for synaptic function specifically.
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5.6.3 Prx-2 in the JNK-signalling cascade
Finally, the the effect of Prx-2 on neuronal cell survival and the activation of the
JNK-signalling cascade were studied in vitro. In agreement with earlier studies
demonstrating a protective role for Prx-2 in neurons (Yao et al., 2007; Hu et al.,
2011; Qu et al., 2007), I showed that overexpression of Prx-2 protected primary
neurons form amyloid toxicity (Figure 5.9). The finding that an inactive mutant
of Prx-2 (Prx-2T89E) could not provide protection against Aβ(25–35) pointed
towards oxidative stress as the main cause of cell death in Aβ exposed neurons.
Reactive oxygen species provoke an array of cellular responses and one of
the main mediators of this reaction is JNK (see Chapter 3). I therefore studied
the activation of the JNK-signalling cascade in Prx-2 overexpressing neurons and
found that Prx-2 overexpression could in fact suppress the phosphorylation and
activation of the JNK-target c-Jun (Figure 5.10). Surprisingly, no reduction of
JNK-phosphorylation in response to Prx-2 overexpression was observed in these
cell cultures and the Prx-2T89E as well as the Prx-2T89A mutants acted indistin-
guishable from wild-type Prx-2. This indicates that Prx-2 interferes with c-Jun
activation without affecting ROS levels and either exerts a direct effect on c-Jun
or modifies JNK activity without inhibiting its phosphorylation. Such a result
could be achieved by direct interaction or Prx-2 with either of these proteins.
Notably, Prx-2 has already been found to directly bind to a JNK homologue
in yeast through the formation of a disulfide bond between Prx-2 and Sty1 in
response to peroxides (Veal et al., 2004). In addition, Prx-2 has been identified
as an activator of JNK/c-Jun-signalling in human cancer cell lines (Lee et al.,
2011). Although these studies describe activation of JNK-signalling rather than
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its suppression, they demonstrate a direct interaction of Prx-2 and JNK which
could have cell specific effects in neuronal cells.
In conclusion, the current experimental data strongly suggests a protective role
for Prx-2 in neurons exposed to different types of cell stress. Also, up-regulation of
Prx-2 in mouse models for neurodegeneration and in the human brain affected by
dementia points towards a compensatory up-regulation of Prx-2 in order to cope
with oxidative stress caused by neurodegenerative processes. At the same time,
experimental evidence presented in this chapter points towards a more complex
role for Prx-2 in the regulation of JNK-signalling in neurons, which goes beyond
just the degradation of ROS and might involve direct interaction with JNK.
Figure 5.14 summarises the findings of this chapter in the light of other recent
advances. It illustrates the current understanding of the function of Prx-2 in the
defence against oxidative stress and JNK-signalling which are important factors
in neurodegeneration.
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Figure 5.14: Prx-2 in oxidative stress defence and JNK-signalling.
Figure 5.14: Prx-2 in oxidative stress defence and JNK-signalling. Cell stress such
as exposure to Aβ or 6OHDA can lead to the formation of peroxides (ROOH). Prx-2
degrades these to ROH and H2O, whereby a disulfide bond is formed between two
Prx-2 monomers. Thioredoxin (Trx) together with disulfide-reductase restores active
Prx-2. Excessive oxidative stress can lead to the activation of JNK by releasing ASK
(a MAP3K) from inhibition by Trx (Hu et al., 2011). Overexpression of Prx-2 or Prx-
2T89A can reduce JNK activation by increasing the antioxidant capacity and reducing
the need for Prx-2 recycling and engagement of Trx. Prx-2 (as well as Prx-2T89A and
Prx-2T89E) can also directly bind JNK and modulate its function, especially in times
of reduced oxidative stress.
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6.1 The idea
Endophilin-1 (Ep-1), amyloid-binding alcohol dehydrogenase (ABAD), peroxiredoxin-
2 (Prx-2) and the EF-hand domain family, member D2 (EFHD2) have all previ-
ously been found to be elevated in the human brain with dementia or in mouse
models for frontotemporal lobar degeneration or Alzheimer’s disease. With the
work described in this thesis, I aimed to extend the current knowledge by investi-
gating the expression of all of these proteins in human brains from AD or FTLD
patients and by studying the cellular effects of the overexpression of Ep-1, Prx-2
or EFHD2.
6.2 Endophilin-A1: the key to synaptic function
In addition to its up-regulation in the human AD brain, elevated levels of Ep-
1 have specifically been found in the mAPP/ABAD double transgenic mouse
model as a result of the ABAD–Aβ interaction and so a link between ABAD
expression or activity and Ep-1 expression has been suggested (Ren et al., 2008).
As described in Chapter 5, I could also observe a link between high expression
levels of ABAD and that of Ep-1 protein levels in the aged human brain. However,
I could not verify the up-regulation of either protein in the human AD brain.
This might be due to various effects caused by technical differences between the
studies and importantly, the different number of cases studied as discussed in
Chapter 5. This might have confounded the detection of potential expression
changes detected by Lustbader et al. (2004) Ren et al. (2008). The detected
changes of ABAD mRNA expression levels described in chapter 5 also indicate
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that expression levels might in fact have been affected.
Ep-1 is a synaptic protein which functions in synaptic vesicle recycling
(Ringstad et al., 1999), influences neurotransmitter release (Weston et al., 2011)
and has also been given new roles in signalling processes associated with dendri-
togenesis (Fu et al., 2011) and JNK-activation (Ramjaun et al., 2001). ABAD
is also important for synaptic function as it helps to supply energy through mi-
tochondrial metabolism but can also interact with Aβ inside mitochondria when
Aβ levels rise (Lustbader et al., 2004) and thereby cause extensive mitochon-
drial dysfunction, which synaptic mitochondria are exceptionally susceptible to
(Takuma et al., 2005; Du et al., 2011). The synaptic dysfunction observed in the
mAPP transgenic animals and in the AD brain is usually characterised by the
loss of synaptic markers such as synaptophysin (Dodart et al., 2000; Heffernan
et al., 1998; Reddy et al., 2005). Instead, Ep-1 levels increase in AD and the
mAPP/ABAD double transgenic mouse model, suggesting that Ep-1 acts as a
key multifunctional modulator of synaptic activity and that its up-regulation is
a compensatory response to synaptic deficiency, Ca2+-dysregulation or changes
in lipid metabolism due to an altered ABAD activity. Direct proof for this se-
quence of events in AD has not been produced so far, however, it would be
possible to address this question by investigating Ep-1 expression levels and its
precise location (pre-synaptic or post-synaptic) for example by immunoelectron
microscopy in brain tissue from Aβ overproducing mouse models challenged with
metabolic/nutritional stress (known to increase ABAD levels (Yan et al., 2000))
compared to tissue from control animals. A similar approach could be taken in
in vitro models using media deprived of glucose and exposure of primary neurons
to Aβ with or without the increased expression of ABAD.
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The fact that Ep-1 can also lead to JNK-activation and neuronal death in
vitro (Ramjaun et al., 2001; Ren et al., 2008) seems at odds with the idea of its
synaptic function at first. However, as shown in Chapter 3, I demonstrated that
although Ep-1 is in principle capable of activating the JNK-signalling cascade,
this signalling function is conditional in that it requires other insults. In line
with this hypothesis, preliminary data has shown that lentivirus mediated over-
expression of Ep-1, but not its SH3-domain deficient mutant is able to boost the
activation of JNK and c-Jun in primary neurons exposed to Aβ. It remains to be
seen what the consequences of this are for the synapse where c-Jun is absent. Are
there local effects of this activation in the synapse or does the activated JNK-
signal only get transmitted back to the neuronal cell body? This question could
be addressed in the recently created mAPP/Ep-1 double transgenic mouse line,
where the localisation of activated JNK could be determined at high resolution
and electrophysiological measurements could answer if increased Ep-1 levels can
positively influence synaptic strength in these animals. Furthermore, the effect
of increased Ep-1 on TrkB-signalling and dendritogenesis, which are known to
be dysregulated in AD (Schindowski et al., 2008) and mAPP transgenic animals
(Wu et al., 2006), could also be investigated in these animals. The results of
these studies will be important steps towards a better understanding of how the
neuronal network reacts to the challenges its faces in AD and other neurodegen-
erative conditions and how modulating the activity of ABAD as a potential drug
target (and therefore Ep-1) might change these processes.
Figure 6.1 summarises the proposed pathological link between the accumu-
lation of Aβ inside synaptic mitochondria and the altered activity of ABAD,
leading to the up-regulation of Ep-1, Prx-2 and synaptic dysfunction.
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Figure 6.1: Effects of the ABAD–Aβ interaction in AD. APP can be transported
to mitochondria, where it interacts with TOM/TIM (translocase of the outer/inner
membrane), disturbing mitochondrial protein import. Aβ can be imported into mito-
chondria via TIM and TOM and is found associated with the inner mitochondrial mem-
brane, disrupting mitochondrial respiration and leading to excess production of ROS.
Aβ has been found to interact with ABAD in the mitochondrial matrix, inhibiting or
altering the enzyme activity. The ABAD–Aβ interaction leads to the up-regulation of
Ep-1 and Prx-2. At the inner mitochondrial membrane, Aβ can bind to CypD, which
is involved in the formation of the mPTP and Ca2+-release from mitochondria. In the
cytosol, Aβ can disturb cell signalling, protein degradation and cause ROS production,
also leading to an increase in cytosolic Ca2+. Ca2+ mediated Cdk5 activation has been
found to inhibit Prx-2 function and Ca2+ levels also influence in targeting and function
of Ep-1. Modified with permission from Portland Press Ltd (Borger et al., 2011).
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6.3 EFHD2, Prx-2 and APP and tau in fron-
totemporal dementia
The increased expression of Prx-2, ABAD and EFHD2 protein or mRNA levels
in the hippocampus of FTLD affected brains is paralleled by changes in the
levels of total APP protein supporting the possibility that their up-regulation
in FTLD might be linked to common mechanisms involving calcium-homeostasis
and mitochondrial function.
Notably, the increase of Prx-2 and EFHD2 protein levels in the mAPP trans-
genic mice overexpressing human mutant APP, together with the results from the
human FTLD cases lends support to the hypothesis that up-regulation of APP
itself (being a common factor between the mAPP transgenic mouse model and
the FTLD-affected brain) could cause the increased expression of these proteins
independent from amyloid pathology, possibly through actions of its intracellular
domain (see Chapter 1.2.1.3). Increased levels of Aβ production in the secretory
pathway (Khvotchev and Sudhof, 2004) in cells overexpressing wild-type APP
have been observed, however, amyloid-pathology has not been reported as one
of the main features in the FTLD brain. Instead, it is known that APP protein
expression can be enhanced in situations of cellular stress in cell cultures and me-
diate ER-stress induced cell death via the AICD (Keita et al., 2009). Increased
expression of APP has also been found in the human brain after head injury
(Gentleman et al., 1993). Hence, increased levels of APP caused by metabolic
dysfunction or ER-stress could be a crucial factor in the up-regulation of Prx-2,
EFHD2 and ABAD in the mAPP transgenic mice and the FTLD affected brain.
This hypothesis could be tested in cell culture models, for example using SK-N-
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SH cells or primary neurons with stable or transient overexpression of wild-type
APP or the ACID alone and could reveal a new cellular function of APP with
relevance for FTLD and the analysis of mAPP transgenic mouse models.
Some experimental evidence also exists for a potential mechanism of this pro-
posed APP mediated pathology. In primary neurons deprived of neurotrophic
factors as well as in the mAPP transgenic mouse model, a complex comprised of
of APP, JIP1, ASK and JNK1 has been found (Galvan et al., 2007). This might
promote both, amyloidogenic cleavage of APP (Colombo et al., 2009) as well as
downstream signaling and gene transcription by the AICD (Mueller et al., 2008).
However, earlier work points towards AICD signaling as a potential mediator of
this response, as it has already been implicated directly in neuronal cell death
via ASK1 and JNK activation in neuronal cells (Hashimoto et al., 2003).
The JNK-signaling pathway is crucially important in regulating cell stress re-
lated protein transcription and function and has been analysed in the course of
this study (see Chapter 3). It is noteworthy that increased levels of phospho-
rylated JNK (Figure 3.3) were indeed found in the hippocampus samples from
FTLD patients compared to non-demented controls but were not accompanied
by an increase in phosphorylated or total c-Jun (Figure 3.4), which were predom-
inantly found elevated in the frontal cortices of FTLD patients. This might mean
that the JNK/c-Jun signalling cascade is not involved in pathologically relevant
transcriptional regulation in neurons in the hippocampus. However, as mentioned
in Chapter 1.1.1, it is known that disease symptoms often spread along anatomi-
cal tracts in the brain. This therefore leaves the possibility that a phosphorylated
JNK-signal, originating from nerve terminals in the hippocampus is retrogradely
transported to neuronal cell bodies in the frontal cortex, where it activates c-Jun.
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In line with this idea is the study by Abe et al. who found JIP3 in association
with retrograde synaptic vesicles (Abe et al., 2009).
A similar dissociation of the phosphorylated JNK and c-Jun signals, has been
found in the AD brains studied in the course of this work. Amyloid and tau
pathologies are known to spread from the hippocampus to the frontal cortex
during disease progression (Duyckaerts et al., 2009). Fittingly, it has also been
reported that activated JNK associates more with neurofibrillary structures in
neuronal processes in more advanced cases of AD in the human brain, rather
than the cell nuclei, where it can be found in earlier stages (Zhu et al., 2001).
Hence, it is possible, that JNK-mediated signalling events play a major role in
disease progression in both AD and FTLD.
Figure 6.3 illustrates where the proteins studied here have been found up-
regulated in the human brain affected by FTLD and AD on protein or mRNA
level.
(a) (b)
Figure 6.2: Proteins and mRNA levels up-regulated in the human dementia brain.
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Figure 6.3: Proteins and mRNA levels up-regulated in the human dementia brain
(continued). Increased expression of proteins found in the course of this work are
mapped onto the human brain structure. (a) Frontotemporal dementia (b) Alzheimer’s
disease. Increased mRNA expression is indicated in grey, increased protein expression
in black writing. The double arrows denote anatomical tracts between the temporal
lobe/hippocampal formation and the frontal cortex.
In the course of this project, I confirmed that an up-regulation of Prx-2 has
beneficial effects on neuronal survival, when cells are exposed to toxic agents
inducing ROS production such as Aβ and that it can also suppress the effects of
JNK activity in these cells. At this point, it is not clear how this relates to the
situation in the FTLD brain. However, in keeping with the idea that APP up-
regulation might be at least partly responsible for the activation of JNK in this
situation, this could be investigated further in cell culture models of wild-type
APP or AICD overexpression and resolve if Prx-2 up-regulation, knock-down
or inhibition (using Conoidin A (Haraldsen et al., 2009)) could modulate the
activation of JNK-signalling in these cultures.
As mentioned in Chapter 4, I did not find a correlation between the presence of
tau-pathology in the human FTLD or AD cases and the up-regulation of EFHD2
protein or mRNA levels. Notably, all AD cases presented with high scores for
tau-pathology, when the immunoreactivity for phosphorylated tau was assessed
(see Table 3.1), but did not have increased levels of EFHD2. The report first
linking EFHD2 to neurodegenerative processes in dementia did also not describe
an association of EFHD2 with tau in a case of FTD and Parkinsonism linked to
chromosome 17 (FTDP17) but only in a single AD case and in the JNPL3 mouse
model, where sarkosyl insoluble tau species were detectable (Vega et al., 2008).
Differences in the nature of tau-aggregates found in the brains of FTLD patients
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and those patients with AD have be recognised before (van Eersel et al., 2009)
and could be behind the difference in the association of EFHD2 with tau in these
diseases implicated by the study by Vega et al. (2008). Together with the finding
that EFHD2 overexpression did not affect the regulation of the important tau-
kinase GSK3 (see Chapter 4.8.2), the current data contradicts a role for EFHD2
in the pathologically relevant processing of tau in the human brain. However, this
does not rule out a potential function of EFHD2 in physiological tau-metabolism,
which might in fact prevent tau from forming sarkosyl-insoluble aggregates in the
case of its up-regulation in FTLD. Further deciphering the signalling pathways
modulated by EFHD2 in cell cultures and correlating those with their activity in
the FTLD brain and effect on tau-phosphorylation/cleavage of the different tau
isoforms will be invaluable for answering this question.
6.4 From mouse to man
The current work has highlighted new intracellular mechanisms, which are linked
to dementia and might contribute to the development of new diagnostic tools and
treatments. Many aspects described in this thesis would however not have been
recognised without the careful and open-minded comparison of cell culture and
animals models used in this study to the situation in the human brain.
The high level complexity of the processes that feature in the human brain
during neurodegeneration and aging, in particular, results in a large degree of
variability between individuals and in fact whole study groups. It is therefore
challenging to mimic all aspects of these processes in the mouse and in vitro
models widely used to represent these neurodegenerative diseases. The use of
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mouse models gives precious insights into the activity of the brain under physio-
logical and pathological conditions, which would remain undetectable otherwise
but there are limitations to their applicability to humans which are of particular
importance for the aspects which ave been studied here.
Firstly, the mouse genome only encodes for one single confirmed isoform of
tau with 4 microtubule binding domains (4R tau), whereas the human tau gene
produces at least 6 isoforms as shown in Figure 1.9 by alternative splicing, so
that an equal amount of 3R and 4R tau proteins is produced. As mentioned in
Chapter 1.2.3.1, this ratio of tau isoforms is important for neuronal function and
affects its interactions with other proteins. It is therefore easy to understand that
the endogenous murine tau protein, will not be able contribute to the pathological
processes in the same way as it happens in the human brain. This potentially
explains, why single mAPP transgenic mice do not develop the same tauopathy
that is seen in human AD. Double and triple transgenic mouse models which
express mutant human P301L tau protein, do produce neurofibrillary tangles
(LaFerla and Oddo, 2005) and Vega et al. could show that JNPL3 mice expressing
this version of human tau produce sarkosyl-insoluble tau, which is similar to the
tau-aggregate found in human AD (Vega et al., 2008). However mutations in the
tau gene are genetically linked to frontotemporal lobar degeneration and not AD
(Crawford et al., 1999; Goedert et al., 2012). Differences in the behaviour of tau
during tauopathy in AD and FTLD (with Pick’s disease) have been described (van
Eersel et al., 2009) and are further exposed by the finding that the aggregation
prone P301L mutant tau version is not able to promote amyloid-pathology in
neurons (Tackenberg and Brandt, 2009). As another example, Vega et al. (2008)
demonstrated association of EFHD2 with tau in a post mortem human AD brain
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but not in a brain from an FTLD case linked to tau (FTDP17).
Secondly, overexpression of AD related proteins in these animal and cell cul-
ture models might itself pose a problem as mentioned in Section 6.3. Although,
mAPP mice have synaptic dysfunction (Chapman et al., 1999) and the mutant
APP is known to increase the amount of amyloid peptide produced (Haass et al.,
1995; Citron et al., 1992), human AD is not normally characterised by a signif-
icant up-regulation of APP (or tau) protein levels but rather by their aberrant
processing and targeting. Therefore, mouse models that better represent the
genetic background of human AD sufferers for example by genetic-targeting of
the endogenous mouse APP gene (Reaume et al., 1996), should be the preferred
system to study.
Finally, cell culture models using human or murine cell lines or mouse pri-
mary neurons are a good system for studying cellular signaling pathways and the
effects of the amyloid peptide in detail. However, limitations apply here as well.
For example, the primary neurons used extensively in the current work derive
from embryonic mouse cortices which potentially have a different biochemical
setup from neurons in later embryonic stages, as has previously been reported
for cerebellar granule cells (Oldreive et al., 2008). Similarly, I showed that ex-
pression levels of EFHD2 also vary between the embryonic and the postnatal
mouse brain (see Figure 4.7(b)) and an effect of cellular maturation on the func-
tion of EFHD2 has been reported in B-cells (Avramidou et al., 2007). Recently
refined culture systems for neurons derived from induced pluripotent stem cells
(Shi et al., 2012b,a) could be an advance into the right direction for overcoming
these potential problems.
The result of maturation on neurons in particular is an extreme level of com-
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partmentalisation of the cell between the cell body and the synapse, where APP is
located and Aβ peptides of varying length are secreted. Therefore, an additional
problem is that topical administration of Aβ peptides to cell cultures might evoke
responses, which do not naturally occur in the brain, especially when applied at
supranatural concentrations and when only one type of peptide is used.
In conclusion, the increasing knowledge about the above mentioned caveats
should result the development of according experimental paradigms and results
obtained from transgenic animal models and cell culture systems should be anal-
ysed with caution and compared to other in vivo and in vitro models as well as
to the human condition.
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APPENDIX A
ANTIBODY DILUTIONS AND SOURCES
A.1 Primary antibodies
Antigen Supplier Host Dilution Dilution
(product code) (WB) (IF)
ABAD Abcam rabbit 1:7500 NA
(] ab52243)
Akt (pan) (C67E7) Cell Signalling rabbit 1:2000 NA
(] 4691)
phospho-(Ser473)-Akt Cell Signalling mouse 1:1000 NA
(587F11) (] 4051)
phospho-(Thr308)-Akt Cell Signalling rabbit 1:1000 NA
(] 9275)
Amyloid Precursor Sigma rabbit 1:10,000 NA
Protein (APP) (] A8967)
β-Actin Sigma mouse 1:10,000 NA
(] A1978)
CD95 Abcam rabbit 1:5000 NA
(] ab82419)
c-Jun (60A8) Cell Signalling rabbit 1:1000 NA
(] 9165)
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phospho- Cell signalling rabbit 1:1000 1:100
(Ser63)-c-Jun (] 9261)
CypD Abcam mouse 1:10,000 NA
(] ab54496)
Ep-1 Invitrogen rabbit 1:2500 1:100
(] 36-3000)
Ep-1 Abcam mouse 1:1000 NA
(] ab55702)
EFHD2 kind gift from mouse 1:1000 1:100
Dr. Irving Vega
EFHD2 Abcam goat 1:1000 NA
(] ab24368)
Enoyl-CoA- Aviva rabbit 1:1000 NA
hydratase (ECHS) (] ARP45699)
Flag Sigma mosue 1:1000 NA
(] F1804)
GSK3α/β Upstate rabbit 1:1000 NA
(] 05-903)
phospho-(Ser21/9)- Cell Signalling rabbit 1:1000 NA
GSK3α/β (] 9331)
SAPK/JNK Cell Signalling rabbit 1:1000 NA
(] 9252)
phospho-(Y83/T89) Cell Signalling mouse 1:2000 1:100
-SPK/JNK (] 9251)
Prx-2 Abcam rabbit 1:3000 NA
(] ab71533)
β3-tubulin Promega mouse NA 1:7,500
(] G7121)
Table A.1: Primary antibody dilutions for western blotting (WB) and immunofluo-
rescence (IF)
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A.2 Secondary antibodies
Antigen Supplier Host Dilution Dilution
(WB) (IF)
rabbit IgG -HRP Abcam goat 1:50,000 NA
(] ab97051)
mouse IgG -HRP Abcam rabbit 1:20,000 NA
(] ab6709)
mouse IgG -HRP Jackson rabbit 1:10,000 NA
Immunoresearch
(] 115-035-062)
goat IgG -HRP Sigma rabbit 1:20,000 NA
rabbit IgG -FITC Vector goat NA 1:1000
Laboratories
mouse IgG Vector goat NA 1:2000
- Texas-Red Laboratories
mouse IgG Jackson goat NA 1:500
-DylLight 594 Immunoresearch
(] 115-515-062)
mouse IgG Jackson goat NA 1:500
-DylLight 488 Immunoresearch
(] 115-486-003)
rabbit IgG Jackson goat NA 1:500
-DyLight 488 Immunoresearch
(] 111-486-003)
goat IgG Jackson goat NA 1:500
-DyLight 594 Immunoresearch
(] 205-515-108)
Table A.2: Secondary antibody dilutions for immuno-western blotting (WB) and
immuno-fluorescence (IF)
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GENE SEQUENCES AND PLASMIDS
B.1 Mouse Endophilin A1
Accession number: NM 019535.2
Coding sequence: bp 122–1180
0001 GCGCCGCGCC CCCGCGCCAG CAGCTCCCGC GGTCGCACGA CCAGCGGCGG CCCGGCGACC
0061 CCAGCCGCCT CTCCGCATCT GCATCTGCAT CTGCCGGCCG CGCAGCCTCC CGCATCCCAT
0121 CATGTCGGTG GCAGGGCTGA AGAAGCAGTT CCACAAAGCC ACTCAGAAAG TGAGTGAGAA
0181 GGTGGGAGGA GCGGAAGGCA CCAAGCTCGA TGATGACTTC AAAGAGATGG AGAGGAAAGT
0241 GGATGTCACC AGCAGGGCTG TGATGGAGAT AATGACAAAA ACGATTGAAT ACCTCCAACC
0301 CAATCCAGCT TCCAGGGCTA AGCTCAGTAT GATCAACACC ATGTCGAAAA TCCGCGGCCA
0361 AGAGAAGGGG CCAGGCTACC CTCAGGCGGA AGCACTGCTG GCAGAGGCCA TGCTCAAGTT
0421 CGGCAGGGAG CTGGGTGATG ATTGCAACTT TGGTCCTGCT CTCGGTGAGG TGGGAGAAGC
0481 CATGAGGGAG CTCTCGGAGG TCAAGGACTC ATTGGACATG GAAGTGAAGC AGAATTTCAT
0541 CGACCCCCTT CAGAATCTTC ATGACAAGGA TCTGAGGGAG ATTCAGCATC ATCTGAAAAA
0601 GCTGGAAGGC CGACGCTTAG ACTTTGATTA TAAGAAGAAG CGACAAGGCA AGATTCCAGA
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0661 TGAAGAACTC CGCCAAGCTC TGGAGAAATT CGATGAGTCT AAAGAAATCG CCGAGTCGAG
0721 CATGTTCAAC CTCTTGGAGA TGGATATAGA ACAGGTGAGC CAGCTCTCCG CACTTGTTCA
0781 GGCTCAGCTG GAGTACCACA AGCAGGCAGT GCAGATCCTG CAGCAGGTCA CTGTCAGACT
0841 GGAAGAAAGA ATAAGACAAG CTTCATCTCA GCCAAGAAGG GAATATCAGC CCAAACCACG
0901 GATGAGCCTA GAGTTTGCCA CTGGAGACAG TACTCAGCCC AACGGGGGTC TCTCCCACAC
0961 AGGCACACCC AAACCTCCAG GTGTCCAAAT GGATCAGCCC TGCTGCCGAG CTCTGTATGA
1021 CTTTGAACCT GAAAATGAAG GGGAATTGGG TTTTAAAGAG GGCGATATCA TCACACTCAC
1081 TAATCAGATT GACGAGAACT GGTATGAGGG GATGCTTCAT GGCCAGTCTG GCTTTTTCCC
1141 CATCAACTAT GTAGAAATTC TGGTTGCTCT GCCCCATTAG GATCCTGTGC TGGCTGGCTC
1201 ACCTCCTTCT GACCCAGATA GTTAAGTTTA ACCACTGCTT TGGTAATGCT GCTTCCAATA
1261 CATCACGAAT GCAGGCCGCA GTGGATGAGT CACCAAGCCC ACACGTGCCC TGGGTTGACC
1321 CGTGTGCTCC TCCAGGAGAC GCGGTGATAG ATGGTATCTT CCAAGGCCAG TGGGCCTGGT
1381 ACATGCTTTA AAACACCATC TGAGACTAGC CAGGAGTCCC AGAACTGGCT TCACAGTTCT
1441 CAGGAGGCTG TGGTTCCTGG TAACATGCCT GTGAACCACA TGGCAGAAAA ACTCTCCTCA
1501 CTGAAGATAT TGTCTCTCAC CCAGGGGCCA TCTCAAGGTC TCCAGTTCTC CATTTACAGA
1561 GGAGAAAGTC CTTTTTGTTG CACTTTCCCT TCCTAAATAT GTGAGTCACA GAATTGTTGG
1621 CAAAAACATC CCCTCACCAG CAAGATGTCT GCTGGTTTAA GCAACTTGGT CTCTTGATGC
1681 CATTAGCAAA AGTATTAATT GTCCAAAGCA CCTTTGTTCA CTAATATCTA TCTATCTATC
1741 TATCTATCTA TCTATCTATC TATCTATCTA TCTATCTATC TATCATCTAT CTACCTACCT
1801 ATCTACCTAT CATCTATCTA TCTATCATCT ATTATCTATC TATCTATCTA TCTATCTATC
1861 TATCTATCTA TCTATCCATC TATCTATCCA TCATCTATCT ACCTACCTAT CTACTATCCA
1921 TCTATCTATC TATCCATCAT CTATCTACCT ACCTATCTAC TATCCATCCA TTTATCTATC
1981 TATCTATCTA TCTATCTATC TATCTATCTC CCTCATACTT CTGAGACATG GCCAGTTTTC
2041 TTCCCTCCCT GCTGTTAAGC ACTTGGCAGA TGAGGGGGGG GGTCCCATTT ATTTCTGAGT
2101 GAGATGGTGA GCAATCTGTA TGTTGGCTGA AAAGAAAAAA AAATCTCCAG TCTGAATTGG
2161 GAAGAAATCT GGTCTCTAAG CTCAGATTCC TTGCTGTACA GAAGCTGTGT ATATACGTAG
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2221 CCCGTTTCTG AAGGGTACAG GAAGGGGGCA CGGCTGTCTT CCCTTCTCTG TTTACTTACC
2281 CAGGAATCAG TCCATTCCCT GAGTCCCTTT ACCACAAAGA CGTAGGAGAG AAACACTAGT
2341 AAGCATTTCC CACTCCATAG AACAAGACAG TGAGCATCGC TCCTTCCCAC GTTTACTTGT
2401 TTGTGTTCCT TGAACATCAT TTGTGCATAT TCTGCCCTCA ATGAGGACCA AATAAAGATG
2461 ATTTTTGTGC TTAGCAGTTT AAGGTATGTG GCTGCATATG CAAACCCCTT TTCCACTCCA
2521 GTCATTACTT TGAACGCCTC CCTTCCTCAT TTTGTGTGTA CAGTGCTGTG TACGCTGATC
2581 AGTGTTGGGT TTTCGTTTTG TTCTCCTTTC AGTTATGGAA GTCCCGATAG GCACCCAGAG
2641 TTCTATTTAT CTAGCTGTAC AGGCTCCTTC AGAGGTTTAG CGTGCTGCTT CCGATATGCC
2701 ACTTGCGGTA GTGGATCGTG TGGAGTGAAA GGCAAATCTT CCTGCTTAAT GTATAAACTC
2761 ACCACGGGAA GCACTGCTGT TTCCAATAAA CATTGCTGAA GACGAAAAAA AAAAAAA
Wild-type and mutated endophilin A1 constructs (Figure B.1) in pcDNA3 vectors
were kindly provided by Dr. Peter McPherson. Deletion of the SH3 domain of en-
dophilin A1 (bp 885–1038) was accomplished by introducing the mutation C869T and
therefore creating a stop codon (TAG) after amino acid 291 (Micheva et al., 1997).
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Figure B.1: Plasmid map of Endophilin A1 in the pcDNA3 vector.
Wild-type and mutated endophilin A1 lentiviral constructs with red fluroescent
protein (RFP) (Figure B.2) co-expression were kindly provided by Prof. Matthias
Rosenmund (Weston et al., 2011).
Wild-type endophilin A1 was cloned into the pSX69 lentiviral destination vector by
recombination using the Gateway R© cloning system in collarboration with Mr. Christo-
pher Owen (Figure B.3).
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Figure B.2: Plasmid map of Endophilin A1 lentiviral constructs with RFP co-
expression.
(a) Ep-1 psX69 lentiviral constructs (b) VSV-G envelope protein expression plas-
mid
Figure B.3: Ep-1 lentiviral expression constructs and lentiviral production vectors.
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(c) Gag, pol, Rev, expression plasmid
Figure B.3: Plasmid maps of Endophilin A1 lentiviral psX69-constructs (continued).
B.2 Human Peroxiredoxin-2
Accession number: NM 005809
Coding sequence: bp 151–747
0001 GCTCGTCCGC TCCCTCCCCC GCGCCGTGCA CGTCTTGGTT CGGGCCGGGC ATAAAAGGCT
0061 TCGCGGCCCA GGGCTCACTT GGCGCTGAGA ACGCGGGTCC ACGCGTGTGA TCGTCCGTGC
0121 GTCTAGCCTT TGCCCACGCA GCTTTCAGTC ATGGCCTCCG GTAACGCGCG CATCGGAAAG
0181 CCAGCCCCTG ACTTCAAGGC CACAGCGGTG GTTGATGGCG CCTTCAAAGA GGTGAAGCTG
0241 TCGGACTACA AAGGGAAGTA CGTGGTCCTC TTTTTCTACC CTCTGGACTT CACTTTTGTG
0301 TGCCCCACCG AGATCATCGC GTTCAGCAAC CGTGCAGAGG ACTTCCGCAA GCTGGGCTGT
0361 GAAGTGCTGG GCGTCTCGGT GGACTCTCAG TTCACCCACC TGGCTTGGAT CAACACCCCC
0421 CGGAAAGAGG GAGGCTTGGG CCCCCTGAAC ATCCCCCTGC TTGCTGACGT GACCAGACGC
0481 TTGTCTGAGG ATTACGGCGT GCTGAAAACA GATGAGGGCA TTGCCTACAG GGGCCTCTTT
0541 ATCATCGATG GCAAGGGTGT CCTTCGCCAG ATCACTGTTA ATGATTTGCC TGTGGGACGC
0601 TCCGTGGATG AGGCTCTGCG GCTGGTCCAG GCCTTCCAGT ACACAGACGA GCATGGGGAA
0661 GTTTGTCCCG CTGGCTGGAA GCCTGGCAGT GACACGATTA AGCCCAACGT GGATGACAGC
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0721 AAGGAATATT TCTCCAAACA CAATTAGGCT GGCTAACGGA TAGTGAGCTT GTGCCCCTGC
0781 CTAGGTGCCT GTGCTGGGTG TCCACCTGTG CCCCCACCTG GGTGCCCTAT GCTGACCCAG
0841 GAAAGGCCAG ACCTGCCCCT CCAAACTCCA CAGTATGGGA CCCTGGAGGG CTAGGCCAAG
0901 GCCTTCTCAT GCCTCCACCT AGAAGCTGAA TAGTGACGCC CTCCCCCAAG CCCACCCAGC
0961 CGCACACAGG CCTAGAGGTA ACCAATAAAG TATTAGGGAA AGGTGTGAAA AAAAAAAAAA
1021 AAAAAAAAAA AAAAAAAAA
Wild-type and mutated human Peroxiredoxin-2 constructs (Figure B.4) were kindly
provided by Prof. David Park. The mutation A415G was introduced to produce the
T89A mutant of peroxiredoxin-2. A mutation of bp 415–417 (ACC) to GAG accordingly
lead to the production of the T89E mutant of peroxiredoxin-2 (Qu et al., 2007).
Figure B.4: Plasmid map of Prx-2 in the N-terminal p3xFlag-CMV vector.
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B.3 Human EFHD2
Accession number: NM 024329
Coding sequence: 78–800
0001 AGGAAGAGGA AGAGCGCGGC CGGCGGCGCT GCGCTGAGAG CAGGGGCCCG GCCAAGGCGA
0061 GTGCCGCGCG GGCCACCATG GCCACGGACG AGCTGGCCAC CAAGCTGAGC CGGCGGCTGC
0121 AGATGGAGGG CGAGGGCGGC GGCGAGACCC CGGAGCAGCC CGGGCTGAAC GGGGCAGCGG
0181 CGGCGGCGGC GGGGGCACCC GACGAGGCGG CCGAGGCGCT GGGCAGCGCG GACTGCGAGC
0241 TGAGCGCCAA GCTGCTGCGG CGCGCAGACC TCAACCAGGG CATCGGCGAG CCCCAGTCGC
0301 CCAGCCGCCG CGTCTTCAAC CCCTACACCG AGTTCAAGGA GTTCTCCAGG AAGCAGATCA
0361 AGGACATGGA GAAGATGTTC AAGCAGTATG ATGCCGGGCG GGACGGCTTC ATCGACCTGA
0421 TGGAGCTAAA ACTCATGATG GAGAAACTTG GGGCCCCTCA GACCCACCTG GGCCTGAAAA
0481 ACATGATCAA GGAGGTGGAT GAGGACTTTG ACAGCAAGCT GAGCTTCCGG GAGTTCCTCC
0541 TGATCTTCCG CAAGGCGGCG GCCGGGGAGC TTCAGGAGGA CAGCGGGCTG TGCGTGCTGG
0601 CCCGCCTCTC TGAGATCGAC GTCTCCAGTG AGGGTGTCAA GGGGGCCAAG AGCTTCTTTG
0661 AGGCCAAGGT CCAGGCCATC AACGTGTCCA GCCGCTTCGA GGAGGAGATC AAGGCAGAGC
0721 AGGAGGAAAG GAAGAAGCAG GCGGAGGAGA TGAAGCAGCG GAAAGCGGCC TTCAAGGAGC
0781 TGCAGTCCAC CTTTAAGTAG CGGGGGCTGC AGCCGACCGC CCTGCTCCGG CCCCAGTGTG
0841 GTGGGCGAGG GTGGCGCATG GGAGGCCGAG CCTGAATCCT TGCCTGTGTC TGACGGGACC
0901 ACTACTAAAA ACCTAAAAAT ATCTGTGAAT GGAGCAAGTT CAGGGGTCTT ATGGAGGTGG
0961 CCCGGCCCCT CCCCGCTCCC TTCCACTCTG CACGAGGCCG CCACACCGGC GCTGGCTCCC
1021 TGCCCGGCCC GGCCCTCCCT GGCAATCCCT GGGCTCTCTT GCACCCCTAA CTGCCCCCTG
1081 CCTGCTCCGG CACTGCCCCA GGCCCAGCTC CTGGCCCTAG GTCCCTCCCA GCCCCATGTG
1141 CCTGCCGCCT GCCCTCCACA CATCCCTGTC CCCCCAACCC GGGAACCCCT GCCCTCCTCC
1201 AGCAGGCCGC ACCGCCCCTG GGGCCCCCTG CCAGCCCCTT CCCAGGCTGG GAGACGGCAG
1261 AAGAGATAGA ATCAGGGCTG CCCCCACAGA GTGGGACCCA AGGGGCTAAT TGGAGGCACG
1321 AGGGGACCCC TCCCCAGGGC CTTTTCCTCC TCTGCGTCTT CCATCTACTG AAATGGGAGA
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1381 GGGGGTGGGG AGCTTCTGTT CTGGTGAAGG GACCCGGGCA GGCCCCCAGC ACCCCATGCT
1441 GACTTGGAGA ACCCCAGATC TCTGGGGCCC AGCCAGGCAG GGTGTGGGGG CAGCTGTGCC
1501 AATCTACCTC ACAGGCCCAC CCCCTGCCGG GCATGCCGTG GGATCATGGG CAGGGAAGGC
1561 TCTGGGGGTC GGAGACACCG CTGCTTAGCA CCCCCAGCCA GAACACCCTG AGGGTCTCGG
1621 GGCTCTGGAG AGAGTGGGGC GGGAGGAAGA ATTGGCACCT TCCTAGGGAA GGAGACGAGC
1681 GCTTCGCCTT GATTCTCCGA GAAGCCTCCG AGAAGTGCTT TAAGTGTGTT TGCATGCGCC
1741 AGGCGGTGGG CAGCGGGGGC CTGTCCAGCC CTCTCCCGCC ATCCTTCCCC AAGTGACGTC
1801 CACTGCCTTG TCACCAGCGA CCTGCCTGTC ATGCCCACCC CCTGAGGAAG CATGGGGACC
1861 CTAACACCCT GGTGCCCTGC ACCAGACAGG CCGTGGTCAG GCCCAGGCCA CCGGCCGGGT
1921 TCTGCCACAG CTTCCCACGT GCTTGCTGAC ATGCGTGTGC CTGTGTGTGG TGTCTGTTGC
1981 TGTGTCGTGA AACTGTGACC ATCACTCAGT CCAAACAAGT GAGTGGCCCT CGAGGCCACA
2041 GTTATGCAAC TTTCAGTGTG TGTCATAACG ACGTCACTGC TTTTTAAACT CGATAACTCT
2101 TTATTTTAGT AAAATGCCCA GGAGTCCTGG AAGCTACGCG GACTTGCAGA GGTTTTATTT
2161 TTTGGCCTTA GAATCTGCAG AAATTAGGAG GCACCGAGCC CAGCGCAGCA GCCTCGGACC
2221 CGGATTGCGT TTGCCTTAGC GGATATGTTT ATACAGATGA ATATAAAATG TTTTTTTCTT
2281 TGGGCTTTTT GCTTCTTTTT TCCCCCCCTT CTCACCTTCC CTTCTCCCCG ACCCCACCCC
2341 CCAAAAAAGC TACTTCTTCA TTCCGTGGTA CGATTATTTT TTTTAACTAA AGGAAGATAA
2401 AATTCTATAT TCTTATGTGA AAAA
Wild-type GFP-tagged human EFHD2 in a lentiviral expression vector and a
lentiviral for GFP expression only were kind gifts from Prof. Chang-Duk Jun (GIST,
Gwangju, South Korea) (Thylur et al., 2009) (Figure B.3).
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(a) pHJ-EGFP
(b) pHJ-EFHD2
Figure B.5: EFHD2 lentiviral expression constructs. The pHJ-EGFP lentiviral vector
is 7162 bp (a) and pHJ-EFHD2 based on the same vector and including the mouse
EFHD2 coding sequence fused to GFP (b). The vector includes the CMV IE promoter
(98bp), ampicillin resistance and the EGFP gene (2938bp–3657bp) and has no multiple
cloning site.
B.4 Mouse EFHD2
Accession number: NM 025994
Coding sequence: 54–776
0001 GGGAGCGCGG CGCAGAGCAG GGGCCCGGCC GAGGCAGCGC TGCGCGGGCC ACCATGGCCA
0061 CGGACGAGTT GGCCAGCAAG CTGAGCCGGA GGCTGCAGAT GGAGGGCGAA GGCGGCGAGG
0121 CGACGGAGCA GCCGGGGCTC AACGGGGCGG CGGCGGCGGC GGCGGCCGAG GCTCCCGACG
0181 AGACTGCCCA GGCGTTGGGC AGCGCGGACG ACGAGCTGAG CGCCAAGCTG CTGCGGCGCG
0241 CGGACCTCAA CCAGGGCATC GGCGAGCCAC AGTCGCCCAG CCGCCGCGTC TTCAACCCCT
0301 ACACCGAGTT CAAGGAGTTC TCCAGGAAGC AGATCAAAGA CATGGAGAAG ATGTTCAAGC
0361 AGTATGATGC CGGCAGGGAT GGCTTCATCG ACCTGATGGA GCTGAAACTC ATGATGGAGA
0421 AGCTGGGGGC CCCCCAGACA CACTTGGGCC TCAAGAGTAT GATCCAGGAG GTGGACGAGG
0481 ATTTCGACAG CAAACTCAGC TTCCGGGAGT TCCTTCTGAT CTTCCGCAAG GCAGCAGCAG
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0541 GGGAGTTGCA GGAAGACAGC GGCTTGCACG TCCTGGCCCG CCTGTCCGAG ATCGATGTCT
0601 CCACAGAGGG CGTTAAGGGT GCCAAGAACT TCTTCGAGGC CAAGGTACAG GCCATCAACG
0661 TGTCCAGCCG CTTTGAGGAA GAGATCAAAG CTGAGCAAGA GGAAAGGAAG AAGCAGGCTG
0721 AGGAGGTGAA GCAGCGGAAA GCGGCCTTTA AGGAGCTGCA GTCCACGTTC AAGTAGCCAG
0781 AGCCAAGGCC GAGACCTGGC CCTGCCCCGT GTGCGGTCTG GGGGCACGGG TGGGTACAGG
0841 GGATCTGTGG GAGACTAGCT CCCAGGTCCT GCTCTCTGTG CCCGGACCAC TACTAAAAAC
0901 CGCAAACGAT ATGTGACCCG ATCTCATTCA GGAGTCTCCT CGGTGGTTGG TCCCTGCCCT
0961 GCCCTCTCCT GCGGTTCATG CGGCTGTGAT GCCAGCCAGC AGCATCCTCT CTGGCCATCC
1021 CTACGTGTCT TGTTCTCTGG CCACCTTGCT GCCTGCTCTA GCCCAACTTC AGCCCATTCA
1081 CGCCCCTGCC TTTGGTACCA GCTACTTTCT CCACCCACCC AACTCCCCTT AACTATAGGC
1141 CGCCCTGCCA TGGTCCAGCA GAGAGTGAGA CCCTCCCCAG GACGCTTCCT TTCAGATCAG
1201 GCCCCATCTC TGATGGAAGT GGAGAGACTC TTCTATTAGT GAGGAGATCC GGGGACTCCT
1261 ACATTAGTGA GGAGATCCAG GCCCTAGCAC TCTAAGCTGA TTTCAATGGG GCCCAGCCAG
1321 GCAGGGTGAA GGCCACTGTG CGAATCTACC TCACAGGCTA CACTCTGCCA GGCATGCCTT
1381 GGGGATGTGA GTGATAGGGT TCCGAGGGGA GGGGCAGAAA TGTCACCCTC TGACAGCCTA
1441 CCCCCGCAGC AAGCTGAGGG TCCCAAGGGG CTGTGGAGAG AGGGGTGGGG TCCCTAAGGG
1501 ATTGGCCTTT TCAGGGTGGA CCTCAGCACT CTGCCTTGAC TCCCCAAGGA GTGCCTGACG
1561 TGTTTATGTT CACTGGCAGT AGGACTCGGG GCCGGCACCC CTTTCACACT CTCCTTCCTT
1621 GGGTTTGTCA CCCGTGATGG CACCAGCCTG TCGTGCCCAC CCGTAGACTC GCATGGGGAC
1681 TCCCCAGGCC ACAGTGAAAC CCGTGCCGTT CCTCTATAGC TCCATGTGCT TGCTCACGTG
1741 TGTGTATGTG CGTGTCCGTT GCTGTGTTGT GAAACTGTGA CGTCACCCAG TCTAAGTGAA
1801 TGGCCACCGG GGCCACCGTT ATGCAATGTT CAGCGTGTCA CTGCTTGTGA AGCTCGATAA
1861 CTCTTTATTT TACTACAATG TCCCCAGAGT CCCTGGGACC CCTGTGGGAC TTGCAAAGGT
1921 TTTATTTTTT CGGTCTTAGA ACCTATGAGA ATCGGAGGGG CCGAGCCAAG CCCAGCCCAG
1981 CCCAGCTGCC GTGGCCTTGG CTTGCGTTTG CCTCAGCGGA TATGTTTATA CAGATGAATA
2041 TAAATTCTCT TTACTTTTGG CTGTTTGCAT TTTATTTTTG GTTCCCCCTC TCAGTACCTC
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2101 CCAAAAAAAG AAAAAAAGAA AAAAACTACT TCTTCATTCG GTGGTACGAT TATTTTTTTT
2161 AACTAAAATG AGATAAAATT CTATATTCTT ATGTGTGTGT GGTTTTTGAT GACTAACTAG
2221 AAACAAAGGT GGACAGGATC AGGATGAGGT CGCTGGATCT GGGCCGTCAC ATCAGGAGCC
2281 TGGGGAGGAA GGCACTCCTG CTGGAGAGCT CTGTCCCTTA GCATCTACAA ACACTCCTGA
2341 TCTAAGCACT ACCTGTATTA AACTCATTTC ATCCTTAAAG G
Wild-type and mutated EFHD2 constructs were kindly provided by Dr. Irving Vega
(University of Puerto Rico) (Vega et al., 2008). Deletion of the c-terminal coiled coil
domain of EFhD2cing was accomplished by introducing the mutation C648T, thereby
producing a a stop codon in the EFHD2 coding sequence.
(a)
Figure B.6: EFHD2 expression construct in pIRES-EGFP.
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(b)
Figure B.6: EFHD2 expression construct in pIRES-EGFP (continued).
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APPENDIX C
PRIMER SEQUENCES FOR PCR AND MOLECULAR
CLONING
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Name Acc. No Target Sequence(5’→3’) Product
ABAD-fwd NM004493 308–328 GGCATCGCG... 321 bp
GTGGCTAGCAAG
ABAD-rev NM004493 628–606 ACCTGGGGCA.. AT:60◦C
ATGGTCATCACCC
Actin-fwd NM007393.3 526–545 AGGCATTGTGATGGACTCCG 301 bp
Actin-rev NM007393.3 826–807 AGTGATGACCTGGCCGTCAG AT:56◦C
EFHD2-Fwd NM025994.3 335–358 TCGACCTGATG... 276 bp
NM024329.5 412–435 AGCTGAAACTCA AT:56◦C
EFHD2-Rev NM025994.3 610–589 CACGTTGATG...
NM024329.5 687–666 GCCTGTACCTT
EFHD2-001R NM024329.5 680–656 GATGGCCTGGACCTTGGCC... 269 bp
NM025994.3 TCAAAGCTTGGCCTCAAAG AT:58◦C
EFHD2-002R NM024329.5 526-508 GCAAAGCAAGGGCGCTCGA 351 bp
Ep-1-fwd NM019535.2 287–308 GAATACCTTCA... 107 bp
NM003026.2 454–475 ACCCAATCCAG AT:60◦C
Ep-1-rev NM019535.2 393–375 GCCTCTGCCT...
NM003026.2 560–542 GAGGATAGC
Ep-1-fwd NM019535.2 269–318 GCCTCTGC... 141 bp
(mouse) CTGAGGATAGC AT:60◦C
Ep-1-rev NM019535.2 393–375 GCCTCTGC...
(mouse) NM019535.2 437–418 CTGAGGATAGC
Prx-2 fwd NM005809 418–439 CCCCGGAAAGA... 200 bp
GGGAGGCTTGG
Prx-2 rev NM005809 617–597 AGAGCCTCAT... AT:60◦C
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CCACGGAGCGT
pSX69-fwd – – CTGTGACCGAATCAC seq
pSX69-rev – – GCGTAAAAGGAGCAACATAG
Syn-fwd – – GCTGCCTCAGTCTGCGGTGG seq
Ubi-rev – – CCCTTCGTCT... seq
Ubi-rev GACGTGGCAGCG
Table C.1: Nucleotide primers used for molecular cloning, RT-PCR and sequencing.
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